
<html lang="en"     class="pb-page"  data-request-id="1cd0d944-f2cd-436d-be56-3cd806d213f8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-23;article:article:10.1021/jm501578n;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation" /></meta><meta name="dc.Creator" content="Emily J.  Hanan" /></meta><meta name="dc.Creator" content="Charles  Eigenbrot" /></meta><meta name="dc.Creator" content="Marian C.  Bryan" /></meta><meta name="dc.Creator" content="Daniel J.  Burdick" /></meta><meta name="dc.Creator" content="Bryan K.  Chan" /></meta><meta name="dc.Creator" content="Yuan  Chen" /></meta><meta name="dc.Creator" content="Jennafer  Dotson" /></meta><meta name="dc.Creator" content="Robert A.  Heald" /></meta><meta name="dc.Creator" content="Philip S.  Jackson" /></meta><meta name="dc.Creator" content="Hank  La" /></meta><meta name="dc.Creator" content="Michael D.  Lainchbury" /></meta><meta name="dc.Creator" content="Shiva  Malek" /></meta><meta name="dc.Creator" content="Hans E.  Purkey" /></meta><meta name="dc.Creator" content="Gabriele  Schaefer" /></meta><meta name="dc.Creator" content="Stephen  Schmidt" /></meta><meta name="dc.Creator" content="Eileen M.  Seward" /></meta><meta name="dc.Creator" content="Steve  Sideris" /></meta><meta name="dc.Creator" content="Christine  Tam" /></meta><meta name="dc.Creator" content="Shumei  Wang" /></meta><meta name="dc.Creator" content="Siew Kuen  Yeap" /></meta><meta name="dc.Creator" content="Ivana  Yen" /></meta><meta name="dc.Creator" content="Jianping  Yin" /></meta><meta name="dc.Creator" content="Christine  Yu" /></meta><meta name="dc.Creator" content="Inna  Zilberleyb" /></meta><meta name="dc.Creator" content="Timothy P.  Heffron" /></meta><meta name="dc.Description" content="Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are corre..." /></meta><meta name="Description" content="Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are corre..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 20, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm501578n" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2014 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm501578n" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm501578n" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm501578n" /></link>
        
    
    

<title>Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm501578n" /></meta><meta property="og:title" content="Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0013.jpeg" /></meta><meta property="og:description" content="Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients. Approximately 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M). Due to dose-limiting toxicities associated with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-containing EGFR mutants with selectivity over wtEGFR. We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors. X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-containing mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochemical properties." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm501578n"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm501578n">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm501578n&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm501578n&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm501578n&amp;href=/doi/10.1021/jm501578n" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10176-10191</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm501568b" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm501375c" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emily+J.++Hanan">Emily J. Hanan</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Charles++Eigenbrot">Charles Eigenbrot</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marian+C.++Bryan">Marian C. Bryan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+J.++Burdick">Daniel J. Burdick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bryan+K.++Chan">Bryan K. Chan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuan++Chen">Yuan Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennafer++Dotson">Jennafer Dotson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Heald">Robert A. Heald</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip+S.++Jackson">Philip S. Jackson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hank++La">Hank La</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Lainchbury">Michael D. Lainchbury</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shiva++Malek">Shiva Malek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hans+E.++Purkey">Hans E. Purkey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gabriele++Schaefer">Gabriele Schaefer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Schmidt">Stephen Schmidt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eileen+M.++Seward">Eileen M. Seward</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Sideris">Steve Sideris</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Tam">Christine Tam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shumei++Wang">Shumei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Siew+Kuen++Yeap">Siew Kuen Yeap</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ivana++Yen">Ivana Yen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianping++Yin">Jianping Yin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Yu">Christine Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Inna++Zilberleyb">Inna Zilberleyb</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+P.++Heffron">Timothy P. Heffron</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Departments of <sup>â </sup>Discovery Chemistry, <sup>â¡</sup>Structural Biology, <sup>Â§</sup>Drug Metabolism and Pharmacokinetics, <sup>â¥</sup>Biochemical and Cellular Pharmacology, <sup>â¥</sup>Molecular Oncology, and <sup>#</sup>Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">â</span> <span class="aff-text">Argenta, Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-225-4577. E-mail: <a href="/cdn-cgi/l/email-protection#3c545d525d521259515550457c5b595259125f5351"><span class="__cf_email__" data-cfemail="690108070807470c04000510290e0c070c470a0604">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm501578n&amp;href=/doi/10.1021%2Fjm501578n" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10176â10191</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 10, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 October 2014</li><li><span class="item_label"><b>Published</b> online</span>20 November 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 December 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm501578n" title="DOI URL">https://doi.org/10.1021/jm501578n</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm501578n"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5043</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">35</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm501578n" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;J. Hanan&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;Eigenbrot&quot;},{&quot;first_name&quot;:&quot;Marian&quot;,&quot;last_name&quot;:&quot;C. Bryan&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;J. Burdick&quot;},{&quot;first_name&quot;:&quot;Bryan&quot;,&quot;last_name&quot;:&quot;K. Chan&quot;},{&quot;first_name&quot;:&quot;Yuan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jennafer&quot;,&quot;last_name&quot;:&quot;Dotson&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Heald&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;S. Jackson&quot;},{&quot;first_name&quot;:&quot;Hank&quot;,&quot;last_name&quot;:&quot;La&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Lainchbury&quot;},{&quot;first_name&quot;:&quot;Shiva&quot;,&quot;last_name&quot;:&quot;Malek&quot;},{&quot;first_name&quot;:&quot;Hans&quot;,&quot;last_name&quot;:&quot;E. Purkey&quot;},{&quot;first_name&quot;:&quot;Gabriele&quot;,&quot;last_name&quot;:&quot;Schaefer&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Schmidt&quot;},{&quot;first_name&quot;:&quot;Eileen&quot;,&quot;last_name&quot;:&quot;M. Seward&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Sideris&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Tam&quot;},{&quot;first_name&quot;:&quot;Shumei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Siew&quot;,&quot;last_name&quot;:&quot;Kuen Yeap&quot;},{&quot;first_name&quot;:&quot;Ivana&quot;,&quot;last_name&quot;:&quot;Yen&quot;},{&quot;first_name&quot;:&quot;Jianping&quot;,&quot;last_name&quot;:&quot;Yin&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Inna&quot;,&quot;last_name&quot;:&quot;Zilberleyb&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;P. Heffron&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;10176-10191&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm501578n&quot;},&quot;abstract&quot;:&quot;Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients. Approximately 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M). Due to dose-limiting toxicities associated with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-containing EGFR mutants with selectivity over wtEGFR. We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors. X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-containing mutants of EGFR, high&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501578n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501578n" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501578n&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501578n" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501578n&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501578n" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm501578n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501578n&amp;href=/doi/10.1021/jm501578n" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm501578n" /></input><a href="/doi/pdf/10.1021/jm501578n" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26pmid%3D25383627%26genre%3Darticle%26aulast%3DHanan%26date%3D2014%26atitle%3DDiscovery%2Bof%2BSelective%2Band%2BNoncovalent%2BDiaminopyrimidine-Based%2BInhibitors%2Bof%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BContaining%2Bthe%2BT790M%2BResistance%2BMutation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D23%26spage%3D10176%26epage%3D10191%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292017" title="Solvents">Solvents</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jmcmar.2014.57.issue-23/20141211/jmcmar.2014.57.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients. Approximately 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M). Due to dose-limiting toxicities associated with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-containing EGFR mutants with selectivity over wtEGFR. We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors. X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-containing mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochemical properties.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47360" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47360" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nonsmall cell lung cancers (NSCLC) harboring mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) are well-studied examples of oncogene addiction.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Activating mutations, most commonly the point mutation L858R or deletions within exon 19 (e.g., residues 746â750), increase EGFR-driven cell proliferation and survival.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5">(2-5)</a> The first-generation EGFR inhibitors erlotinib and gefitinib have had remarkable success for the treatment of EGFR-mutated NSCLC.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10">(6-10)</a> However, the dramatic initial clinical responses to these agents are always followed by an acquired resistance.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a> Approximately 60% of this acquired resistance arises from a particular secondary mutation within the EGFR kinase domain, leading to the substitution of the gatekeeper residue threonine-790 with methionine (T790M).<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16">(12-16)</a> This mutation maintains the catalytic function of the enzyme but reduces the activity of gefitinib and erlotinib through two mechanisms. The bulkier side chain of the methionine residue occludes part of the binding site utilized by both quinazoline-based inhibitors and reduces their binding affinity. This is similar to the resistance mechanism observed for Abl tyrosine-kinase inhibitors (TKIs) in CML, which is also the result of a gatekeeper residue substitution (T315I).<a onclick="showRef(event, 'ref12 ref13 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref17 ref18 ref19 ref20">(12, 13, 17-20)</a> A 2008 report proposed a second contributing mechanism, in which the T790M-containing mutants have an increased affinity for ATP, resulting in reduced cellular potency for the ATP-competitive inhibitors.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">Several second-generation EGFR inhibitors form a covalent bond with Cys-797 within the EGFR active site and have shown preclinical activity against T790M-containing mutants of EGFR. However, their clinical efficacy has been limited by associated skin rash and gastrointestinal toxicity, possibly because of their potency against wild-type EGFR (wtEGFR).<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Additionally, there have been reports of acquired resistance to one such covalent inhibitor via the T790M mutation, and it is questionable if drug levels can be achieved to sufficiently inhibit T790M mutant forms of EGFR.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> It is therefore desirable to develop a potent inhibitor of T790M-containing EGFR mutants with reduced activity against wtEGFR. Recently, third-generation covalent inhibitors including AZD9291 and CO-1686 have been generated that demonstrate selectivity for T790M-containing EGFR mutants over wtEGFR, and early phase I data indicate promising efficacy and tolerability with this approach.<a onclick="showRef(event, 'ref26 ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29 ref30">(26-30)</a></div><div class="NLM_p last">The compelling nature of T790M EGFR mutants as a drug target and an understanding of the relationship between wtEGFR inhibition and dose-limiting toxicities led us to initiate an effort to identify inhibitors of the major resistance mutations of EGFR, the T790M/L858R mutation (TMLR), and the T790M/del746â750 mutation (TMdel), with selectivity over wtEGFR. It is worth noting that second- and third-generation EGFR inhibitors described to date have been almost exclusively covalent in nature. Due to the low TMLR and TMdel <i>K</i><sub>m</sub> for ATP (â¼1â2 Î¼M),<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> it was expected that exquisite biochemical potency (<i>K</i><sub>i</sub> < 1 nM) against both T790M-containing mutants of EGFR would be required for a robust cellular effect. While covalent inhibitors cannot be displaced by ATP and are able to circumvent this issue, concerns about possible toxicity with covalent inhibitors, both off-target and resulting from time-dependent inhibition of wtEGFR, led us to pursue a noncovalent strategy.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35">(32-35)</a> Herein we describe our efforts to identify reversible inhibitors of T790M mutant forms of EGFR beginning with a potent inhibitor of Jak2/Tyk2. X-ray crystal structures revealed two distinct binding modes of these early inhibitors that enabled design of subsequent T790M EGFR inhibitors with high levels of selectivity over wtEGFR, broad kinase selectivity, and with desirable physicochemical properties that render them appealing for further optimization.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27784" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27784" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A high-throughput biochemical screen identified compounds <b>1</b>â<b>3</b> as moderately potent inhibitors of both T790M-containing mutant forms of EGFR (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Interestingly, the acyclic amine <b>1</b> has only marginal selectivity for TMLR and TMdel over wtEGFR (5â10 times), whereas piperidine-containing <b>2</b> and <b>3</b> have a higher level of selectivity (11â53 times). In order to advance these initial hits into a viable lead series, a number of parameters required optimization. First, these compounds were originally identified as potent inhibitors of Jak2 and Tyk2 with <i>K</i><sub>i</sub> values between 1 and 16 nM, and it was desirable to minimize the inhibition of Jak family kinases (see Table S1 of the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for the Jak family activity of <b>1</b>â<b>3</b>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Broader kinase selectivity was promising: when tested at 1 Î¼M against a panel of 296 kinases, <b>3</b> inhibited only 5 other kinases at >80%.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Second, compounds <b>1</b>â<b>3</b> are highly lipophilic, resulting in both poor solubility and rapid turnover in liver microsomes (Cl<sub>hep</sub> > 15 mL/min/kg determined in human liver microsomes). With the dual goals of increasing potency and decreasing lipophilicity, the lipophilic ligand efficiency (LLE) was a useful parameter for measuring progress during compound optimization.<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38-40)</a> A low lipophilicity starting point was desired to enhance the likelihood of identifying molecules with high LLE during lead optimization. For advancement of the series, we sought a combined target profile with TMLR and TMdel biochemical potency <10 nM, wtEGFR selectivity >20 times, LogD < 2.5, and kinetic solubility >50 Î¼M.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Hits</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">LLE is calculated using cLogD at pH 7.4.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last"><i>K</i><sub>i</sub> data are an average of at least two independent experiments.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Ratio of wtEGFR <i>K</i><sub>i</sub><sub>app</sub> over EGFR(TMLR) <i>K</i><sub>i</sub><sub>app</sub>.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Ratio of wtEGFR <i>K</i><sub>i</sub><sub>app</sub> over EGFR(TMdel) <i>K</i><sub>i</sub><sub>app</sub>.</p></div></div><div></div></div><div class="NLM_p">An X-ray crystal structure of compound <b>1</b> with the TMLR kinase domain revealed a binding mode analogous with those seen for similar compounds in the active site of Tyk2 (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The aminopyridine functionality forms hydrogen bonds with the backbone carbonyl and NH of the hinge residue Met793. The hydroxyethyl group extends into the ribose pocket and the oxygen makes an intramolecular hydrogen bond with the amide NH. The carbonyl of the amide group is directed toward the gatekeeper residue Met790, in close proximity (3.2 Ã) to the terminal methyl of the methionine side chain. When modeled into the structure of the wtEGFR kinase domain complexed with erlotinib,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> the pyridyl ring of <b>1</b> overlays with the quinazoline portion of erlotinib (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b). The quinazoline N3 of erlotinib is observed to make a water-mediated hydrogen bond with the gatekeeper Thr790 side chain, and we anticipated that the carbonyl of <b>1</b> could make a similar water-bridged interaction with the Thr790 of wtEGFR.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> Compounds <b>2</b> and <b>3</b> would not be conformationally restricted by the same intramolecular hydrogen bond, and the observed reduction in potency for these compounds against wtEGFR may be a result of the additional rotational degrees of freedom around the amide bond, with a corresponding increase in population of non-Thr790-interacting conformations.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0015.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) X-ray structure of compound <b>1</b> complexed with TMLR and (b) overlay of <b>1</b> (green) and erlotinib (magenta) complexed with wtEGFR (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>)<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We attempted to modify the dihaloaryl motif found in compounds <b>1</b>â<b>3</b>, as this group is a significant contributor to the high lipophilicity and poor solubility of these molecules. However, modification of the dihalophenyl group was not productive (see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table S2). Nonaromatic amides do improve solubility but lack the potency required for further consideration. Polar substituents on the phenyl ring, as well as heteroaryl replacements, provide no improvement in solubility or potency compared with compounds <b>1</b>â<b>3</b>.</div><div class="NLM_p">We next turned our attention to replacement of the amide functionality common to compounds <b>1</b>â<b>3</b>. Conversion of the amide into a fused heterocyclic ring reduces the degrees of rotational freedom and could therefore improve potency. Furthermore, the crystal structure of <b>1</b> suggests additional space in the binding site adjacent to the gatekeeper residue that could accommodate a fused five-membered heterocyclic ring. A series of bicyclic compounds were therefore designed with the general substructure shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. Depending on the choice of heterocycle, this additional ring provides alternative substitution vectors: into the ribose pocket (R<sup>1</sup>), toward the catalytic lysine (R<sup>2</sup>), and toward the gatekeeper side chain (R<sup>3</sup>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0016.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of the bicyclic motif.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>4</b> and <b>5</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) were synthesized as proof of concept molecules for this design, with the inclusion of a pyrazole substituent at R<sup>2</sup> (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) designed to interact with catalytic Lys745. We were gratified to see that while there is a slight decrease in potency for <b>4</b> and <b>5</b> compared to <b>3</b>, replacement of the dihalophenyl amide results in a significant reduction in lipophilicity and a net increase in LLE. X-ray crystal structures of both compounds <b>4</b> and <b>5</b> with the TMLR kinase domain revealed that the compounds bind in the active site as designed, with the pendant pyrazole ring interacting with the side chains of both Lys745 and Glu762 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). However, the complete loss of selectivity for both compounds against wtEGFR is difficult to rationalize. While the imidazo compound <b>4</b> could engage in a water-mediated hydrogen bond with the wtEGFR gatekeeper Thr790 side chain, as described above, and might be expected to have similar TMLR and wtEGFR activity, the pyrrolo compound <b>5</b> positions a hydrophobic face toward the gatekeeper residue and could make no such hydrogen-bonding interaction. However, the alternative rotamer of the Thr790 side chain could provide positive lipophilic interactions similar to the lipophilic Met790 side chain.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Bicyclic Amide Replacements</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0009.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0010.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">LLE is calculated using LogD measured at pH 7.4.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last"><i>K</i><sub>i</sub> data are an average of at least two independent experiments.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Ratio of wtEGFR <i>K</i><sub>i</sub><sub>app</sub> over EGFR(TMLR) <i>K</i><sub>i</sub><sub>app</sub>.</p></div></div><div></div></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0017.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structures of <b>4</b> (green) and <b>5</b> (magenta) complexed with TMLR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While selectivity was not optimized with bicyclic compounds <b>4</b> and <b>5</b>, the structures with TMLR suggest that the unsubstituted N1 of both compounds could provide a useful vector toward the ribose pocket in the center of the binding site (vector R<sup>1</sup> in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). We hypothesized that additional potency for EGFR could be gained by occupying the ribose pocket with lipophilic groups, as this pocket is particularly lipophilic in EGFR with Cys797 forming the floor of the binding site. The addition of an isopropyl substituent to the N1 position (compound <b>6</b>) does provide an improvement in biochemical potency when compared to the N1-unsubstituted <b>5</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Interestingly, <b>6</b> also regains selectivity (22-fold) for TMLR over wtEGFR. We sought a TMLR crystal structure with compound <b>6</b> in order to rationalize this selectivity and were surprised to discover that the ligand adopts a different binding mode than previous inhibitors.</div><div class="NLM_p">As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>a, relative to compounds <b>4</b> and <b>5</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) or <b>1</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a), <b>6</b> has flipped 180Â° horizontally and is positioned deeper within the binding site, with the pyridine nitrogen still maintaining a hydrogen bond with the backbone NH of Met793. However, the NH of the aminopyrimidine in the ligand now forms a hydrogen bond with the backbone carbonyl of Gln791. The pyrimidine ring is positioned underneath the gatekeeper Met790 side chain, providing substantial hydrophobic contact, and the pyrimidine N1 nitrogen achieves a hydrogen bond with the side chain hydroxyl of Thr854. Adding to the back pocket interactions, the oxygen of the methoxypiperidine group is within hydrogen-bonding distance of Lys745. The <i>N</i>-isopropyl group does occupy the ribose pocket as designed, although it approaches from the opposite direction than originally anticipated. In light of what appear to be favorable hydrophobic contacts between the ligand and the Met790 side chain, and the lack of possible hydrogen bonding interactions with Thr790, the enhanced potency of <b>6</b> against T790M mutants relative to wtEGFR is understandable.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> While it appears that the original binding mode should be accessible by <b>6</b>, the isopropyl group may achieve more favorable hydrophobic contacts in the flipped binding mode, serving as the driving force for that conformation. An overlay of the bound conformations of <b>5</b> and <b>6</b> highlights the dramatic difference in binding mode that is possible with a very minor structural change (NH vs N-iPr) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0018.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. a) X-ray structure of <b>6</b> complexed with TMLR and (b) overlay of ligands <b>5</b> (magenta) and <b>6</b> (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Methionineâaryl interactions are frequently found in protein structures, and the coplanar interaction of Met790 with the pyrimidine of <b>6</b> is similar to the arrangement often observed in the binding sites of adenine rings.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> However, in both the CSD and the PDB, Bissantz et al. have determined that thioether sulfur atoms are preferentially found in the plane of a phenyl ring and not in a coplanar arrangement (see Figure S-8 of ref <a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">46</a>). The Ï systemÂ·Â·Â·thioether interaction observed in the <b>6</b>/TMLR structure, as depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a, is outside of that preferred geometry. To better understand the kinase selectivity of these inhibitors, we were interested in applying a distribution analysis more specifically to kinases. Within the PDB, we found 58 unique examples of methionine-gatekeeper kinases where the sulfur atom of the gatekeeper side chain is within 7 Ã of an aromatic ring in the ligand.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Following the methodology of Bissantz, we plotted the distribution of interaction geometries between ligand aromatic rings and methionine sulfur atoms within these structures (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>b). Interestingly, the methionine interaction geometry observed in the <b>6</b>/TMLR complex lies in a relatively unpopulated area of the plot. Additional refinement of this analysis to examine phenyl vs heteroaryl ring systems does not change the distribution; the small number of structures in the PDB with a ligand heteroaryl ring in close proximity to a kinase methionine gatekeeper side chain (only 10 structures) further supports the uncommon nature of this binding mode in a kinase active site. Finally, while methionine-gatekeeper residues are common, the combination with a threonine residue (or other hydrogen-bond donor) in a comparable position to Thr854 is relatively unusual.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Therefore, we believe that the combination of a coplanar pyrimidine interaction with the Met790 side chain and a hydrogen-bonding interaction with Thr854 might provide an opportunity for achieving broader kinase selectivity in this binding mode.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0019.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. The centroid shift describes the distance within the plane of a sulfur atom from the center of the aromatic ring. (a) PyrimidineÂ·Â·Â·Met790 geometry observed in the <b>6</b>/TMLR complex: centroid shift â 1.375 Ã, height â 3.34 Ã measured roughly perpendicular to the plane at 92.9Â°. (b) Distribution of gatekeeper methionine sulfur in the proximity of a ligand aromatic ring for methionine-gatekeeper kinases in the PDB.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The appealing LLE and selectivity over wtEGFR led us to use this new, T790M-selective binding mode as a starting point for structure-based design, and we constructed a series of bicyclic inhibitors, as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. The crystal structure of <b>6</b> suggests that the pendant pyrazole ring is pointed toward solvent and is likely not providing additional potency (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>a). Compound <b>7</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) seemingly confirms this hypothesis, in which a hydrogen replaces the pyrazole ring and provides a compound of comparable potency for both TMLR and TMdel, as well as similar LLE and selectivity over wtEGFR. Furthermore, a crystal structure of <b>7</b> with TMLR recapitulates the binding mode observed with <b>6</b>, with ligands closely overlapping (data not shown).</div><div class="NLM_p">A significant benefit in removing this pyrazole was realized with respect to general selectivity over other kinases. Pyrazole-containing compounds <b>4</b>â<b>6</b> exhibit undesirable activity against CDK2, with <b>6</b> also showing decreased selectivity against Aurora B and KDR as compared to <b>3</b>â<b>5</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Interestingly, while the imidazopyridine compound <b>4</b> ablates the Jak2 and Tyk2 activity exhibited by original hits <b>1</b>â<b>3</b> (<50% inhibition of Jak2 or Tyk2 activity observed at 1 Î¼M), both pyrrolopyridine compounds <b>5</b> and <b>6</b> retain significant Jak family activity. NH-pyrrolopyridine <b>5</b> is equipotent against TMLR and Jak2/Tyk2, while <i>N</i>-isopropyl <b>6</b> exhibits approximately 10-fold selectivity for TMLR over Jak2. The differential activity against Jak2 for <b>4</b> relative to <b>5</b> and <b>6</b> may be understood using a model of all three compounds bound in the Jak2 active site in the orientation observed for <b>4</b> and <b>5</b> in TMLR (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). In this orientation, the five-membered heterocycle is adjacent to the gatekeeper residue and the hydrophobic side chain of Jak2âs Met929 gatekeeper can be expected to preferentially interact with the pyrrolo C3 methines of <b>5</b> and <b>6</b>, while the imidazo N2 of <b>4</b> introduces unfavorable polarity in this hydrophobic region. The selectivity of compound <b>6</b> can be improved with removal of the terminal pyrazole moiety; as compared to <b>6</b>, compound <b>7</b> exhibits minimal activity against the off-targets Aurora B, KDR, and Jak2 (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). This improvement in broader kinase selectivity is perhaps unsurprising given the alternative hinge-binding motif provided by the unsubstituted pyrazole.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0001.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Models of <b>4</b> (a, green), <b>5</b> (b, magenta) and <b>6</b> (b, blue) in the Jak2 active site (PBD ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4hge">4hge</a>), with the protein surface colored according to lipophilicity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Heterocycle Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0011.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0012.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">LLE is calculated using LogD measured at pH 7.4.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last"><i>K</i><sub>i</sub> data are an average of at least two independent experiments.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Ratio of wtEGFR <i>K</i><sub>i</sub><sub>app</sub> over EGFR(TMLR) <i>K</i><sub>i</sub><sub>app</sub>.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Ratio of wtEGFR <i>K</i><sub>i</sub><sub>app</sub> over EGFR(TMdel) <i>K</i><sub>i</sub><sub>app</sub>.</p></div></div><div></div></div><div class="NLM_p">While <b>7</b> has >20-fold selectivity over Aurora B, KDR, and Jak2, we sought to improve its selectivity over CDK2 in order to drive an EGFR-dependent antiproliferative effect. Modification of the ribose-pocket group from an isopropyl to the slightly larger cyclopentyl (compound <b>8</b>) to fill a greater portion of the lipophilic ribose pocket does improve potency against TMLR and TMdel slightly (â¼2-fold). However, this change from isopropyl to cyclopentyl increases lipophilicity and does not substantially affect kinase selectivity. A comparison of X-ray crystal structures of <b>8</b> with TMLR and CDK2 (Figures <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>a,b) suggested an opportunity to enhance selectivity in subsequent designs. The binding mode of <b>8</b> in TMLR is consistent with that observed for <b>6</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>a), while in CDK2, the binding mode corresponds to the original binding mode observed for compounds <b>2</b>, <b>4</b>, and <b>5</b>.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The gatekeeper residue in CDK2 is a phenylalanine (Phe80), and this bulky side chain precludes binding of the ligand in the orientation observed in TMLR. Noting that the phenyl group of the Phe80 side chain provides hydrophobic contacts with the aromatic methines of the pyrrole ring, we hypothesized that introducing polarity in this region would disfavor interactions with CDK2 Phe80 and improve selectivity, similar to the selectivity benefit seen with <b>4</b> as compared with <b>5</b>. Indeed, the addition of an extra ring nitrogen in imidazopyridine compound <b>9</b> provides an improvement in selectivity over all key off-targets as compared to <b>7</b> and <b>8</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>), with a 24-fold reduction in activity against CDK2. Aurora B, KDR, and Jak2 also have lipophilic gatekeeper residues (Aurora B = Leu170, KDR = Val914, Jak2 = Met929), and the concurrent reduction in all of these off-target activities suggests that the binding mode observed for <b>8</b> in CDK2 may be shared among these other off-targets, consistent with the Jak2 model described in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. When tested at 1 Î¼M in a broader panel of 219 kinases, <b>9</b> inhibits only 5 kinases at >80%.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50, 51)</a> Compared with <b>7</b>, compound <b>9</b> also has reduced lipophilicity while potency is maintained and thus provides an increased LLE. The improvement in physicochemical properties also results in a significant increase in kinetic aqueous solubility (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0002.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of <b>8</b> complexed with (a) TMLR and (b) CDK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both pyrazolopyridine compounds <b>10</b> and <b>11</b> were expected to result in a similar polarity mismatch with the CDK2 binding site, and as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, both of these compounds have good selectivity against all tested off-targets. Additionally, the 3-aminopyrazolopyridine compound <b>10</b> is 3â8-fold more potent than <b>9</b> with a TMLR <i>K</i><sub>i</sub> of 12 nM and TMdel <i>K</i><sub>i</sub> of 37 nM. This compound reached our initial objective of simultaneously achieving good potency with selectivity against wtEGFR (8â26 times) and with acceptable physicochemical properties that are substantially improved over those of compounds <b>1</b>â<b>3</b> (LogD < 2.5, kinetic solubility >50 Î¼M). Critically, <b>10</b> has good selectivity over a broad panel of kinases, inhibiting only 5 out of 219 at >80% when tested at 1 Î¼M.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51, 52)</a></div><div class="NLM_p">Other bicyclic systems were tested but did not result in further improvement over <b>10</b> (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). 2-Oxoimidazole <b>12</b> was similarly anticipated to insult the CDK2 and Jak2 active sites and provide good kinase selectivity; however, compared with <b>10</b>, this compound has decreased activity against TMLR and was therefore not pursued. The dihydropyrrolo <b>13</b> was designed to increase the percentage of sp<sup>3</sup> centers in an attempt to improve the solubility of pyrrolopyridine <b>7</b>. This compound does exhibit an improvement in kinetic aqueous solubility (increased from 8 to 69 Î¼M), but it has significantly reduced TMLR potency. While the structure of <b>8</b> with TMLR suggests that the sp<sup>3</sup> carbons of <b>13</b> should be accommodated sterically, a greater energetic benefit may be provided by the aliphaticâaromatic contacts of pyrroles <b>7</b> and <b>8</b> sandwiched between Leu718 and Gly796 as compared to the aliphaticâaliphatic contacts afforded by the dihydropyrrole of <b>13</b>.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Finally, pyridone <b>14</b> was synthesized to evaluate 6â6 bicyclic systems, but the lack of potency and poor solubility led to no additional pursuit.</div><div class="NLM_p">Further characterization of compounds in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> indicated only modest cellular activity in a pEGFR assay in H1975 cells, an EGFR(TMLR)-driven cell line (<b>8</b> IC<sub>50</sub> = 1.2 Î¼M, <b>10</b> IC<sub>50</sub> = 1.3 Î¼M). Additionally, the in vitro metabolic stability of all compounds in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> is less than desirable with Cl<sub>hep</sub> determined in human liver microsomes ranging from 11 to 19 mL/min/kg, suggesting directions for further optimization.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Kinase Selectivity Profiles</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">Aurora B<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">KDR<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CDK2<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Jak2<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Tyk2 <i>K</i><sub>i</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">3290</td><td class="colsep0 rowsep0" align="left">503</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">3260</td><td class="colsep0 rowsep0" align="left">1360</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">3100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">1770</td><td class="colsep0 rowsep0" align="left">219</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="left">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">107</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">154</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">6190</td><td class="colsep0 rowsep0" align="left">1990</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">718</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">4030</td><td class="colsep0 rowsep0" align="left">2270</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">225</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">2220</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">1660</td><td class="colsep0 rowsep0" align="left">530</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">2240</td><td class="colsep0 rowsep0" align="left">476</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Aurora B, KDR, and CDK2 IC<sub>50</sub> values determined at Invitrogen.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Jak2 IC<sub>50</sub> and Tyk2 <i>K</i><sub>i</sub> values determined using an assay method previously described.<a onclick="showRef(event, 'ref36 ref53'); return false;" href="javascript:void(0);" class="ref ref36 ref53">(36, 53)</a></p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last"><20% inhibition observed at 1000 nM.</p></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, beginning with potent inhibitors of Jak2/Tyk2, we identified a novel series of noncovalent diaminopyrimidine-based T790M EGFR inhibitors. Replacement of the biarylamide motif with bicyclic substructures provided a significant reduction in lipophilicity. X-ray crystal structures revealed two distinct binding modes that enabled design of T790M EGFR inhibitors with high levels of selectivity over wtEGFR and with favorable physicochemical properties that provide a desirable starting point for further optimization. The unusual binding mode utilizing interactions with both the gatekeeper Met790 and Thr854 side chains provides a framework for broad kinase selectivity. The bicyclic scaffolds identified in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> (<b>7</b>, <b>9</b>, and <b>10</b>) enable a substantial improvement in LLE compared to the initial HTS hits (<b>1</b>â<b>3</b>) and are promising leads in the search for selective and noncovalent inhibitors of T790M-containing EGFR mutants. Further optimization of this scaffold to achieve improved cellular potency and metabolic stability will be the focus of future publications.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52022" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52022" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>1</b>â<b>3</b> were prepared as generally described by Liang et al.<a onclick="showRef(event, 'ref36 ref54'); return false;" href="javascript:void(0);" class="ref ref36 ref54">(36, 54)</a> Compounds <b>4</b>â<b>6</b> were prepared as described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. 2-Bromo-4,5-diaminopyridine and pyrazole 4-carboxylate were converted to imidazopyridine <b>15</b> via a polyphosphoric acid-mediated cyclization. Subsequent bis-SEM protection afforded intermediate <b>16</b>. The corresponding pyrrolopyridine intermediates were prepared by starting with 2-bromo-4-aminopyridine <b>17</b>, which was iodinated and N-sulfonylated to provide <b>18</b>. Annulation with optionally SEM-protected 4-alkynylpyrazoles provided the pyrrolopyridines <b>19a</b> and <b>19b</b>. N1 alkylation or SEM protection of <b>19a,</b><b>b</b> provided the key intermediates <b>20a,</b><b>b</b>. S<sub>N</sub>Ar reaction of 4-methoxypiperidine with 2-chloro-4-aminopyrimidine <b>21</b> afforded intermediate <b>22</b>. Finally, palladium-catalyzed coupling of intermediates <b>16</b> or <b>20a,</b><b>b</b> with <b>22</b> yielded compounds <b>4</b>â<b>6</b>.</div><div class="NLM_p">Schemes <a class="ref internalNav" href="#sch2" aria-label="2">2</a>â<a class="ref internalNav" href="#sch4" aria-label="4">4</a> describe preparation of additional bicyclic pyridine analogs. Pyrrolopyridines <b>7</b> and <b>8</b> were readily prepared as shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Alkylation of commercially available 6-chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine to give <b>23a,</b><b>b</b> followed by palladium-catalyzed coupling to aminopyrimidine <b>22</b> provided compounds <b>7</b> and <b>8</b>. As described in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>, a nucleophilic displacement reaction with isopropylamine and 2,4-dichloro-5-nitropyridine provided chloropyridine <b>24</b>, which was coupled with the aminopyrimidine fragment <b>22</b> followed by reduction of the nitro group to provide <b>25</b>. Closure of the imidazo ring with trimethyl orthoformate yielded <b>9</b>. Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a> describes the synthesis of 3-aminopyrazolopyridine <b>10</b>, beginning with compound 2-bromo-5-iodopyridin-4-amine. A Sandmeyer reaction converted the 4-amino functionality to a 4-chloro group (<b>26</b>). Conversion of the 3-iodo group to a methyl ester proceeded via palladium-catalyzed carbonylation. Subsequent reduction to the aldehyde with diisobutylaluminum hydride afforded compound <b>27</b>. Treatment with hydrazine effected the ring closure to pyrazolopyridine <b>28</b>. Iodination at the 3-position to <b>29</b> followed by N-alkylation provided key intermediate <b>30</b>. Sequential palladium-catalyzed couplings first at the iodo position and then at the bromo position, followed by deprotection, provided compound <b>10</b>.</div><div class="NLM_p">The preparation of compounds <b>11</b>â<b>14</b> is described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>4</b>â<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) polyphosphoric acid, 200 Â°C, 18 h, quant.; (b) sodium hydride, SEM-Cl, THF, DMF, rt, 2 h, 81%; (c) iodine monochloride, NaOAc, HOAc, 70 Â°C, 18 h, 34%; (d) methanesulfonyl chloride, triethylamine, DCM, 0 Â°C to rt, 2 h, 46%; (e) 4-ethynyl-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, triethylamine, DMF, 50â100 Â°C, 33%; (f) 4-ethynyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, triethylamine, DMF, 50â100 Â°C, 34%; (g) NaH, SEM-Cl, THF, 0 Â°C to rt, 5 h, 36%; (h) 2-iodopropane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 Â°C, 48 h, 40%; (i) 4-methoxypiperidine hydrochloride, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 120 Â°C, 18 h, 87%; (j) <b>16</b>, <b>20a</b>, or <b>20b</b>, Pd<sub>2</sub>dba<sub>3</sub>, X-Phos or Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 120 Â°C, 28â81%; (k) HCl, MeOH, rt to 50 Â°C, 22â76%.</p></p></figure><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>7</b> and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-iodopropane or iodocyclopentane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 Â°C, 18â20 h, 56â90%; (b) <b>22</b>, chloro[[BrettPhos][2-(2-aminoethylphenyl)palladium(II)]]/[BrettPhos], NaOtBu, tBuOH, 90 Â°C, 5 h, 33â49%.</p></p></figure><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compound <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) isopropylamine, triethylamine, THF, rt, 3 h, quant.; (b) <b>22</b>, Pd<sub>2</sub>dba<sub>3</sub>, X-Phos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, reflux, 3 h, 72%; (c) Pd/C, EtOAc, MeOH, H<sub>2</sub>, rt, 18 h, 92%; (d) trimethyl orthoformate, formic acid, 100 Â°C, 1 h, 27%.</p></p></figure><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CuCl, <i>tert</i>-butyl nitrite, acetonitrile, 50 Â°C to reflux, 1 h, 72%; (b) palladium(II) acetate, triethylamine, MeOH, CO, 60 Â°C, 18 h, 47%; (c) diisobutylaluminum hydride, DCM, â78 Â°C, 1 h, 55%; (d) hydrazine hydrate, triethylamine, dioxane, reflux, 3 d, 34%; (e) iodine, potassium hydroxide, DMF, 40 C, 16 h; (f) 2-iodopropane, sodium hydride, DMF, rt, 16 h, 44% over two steps; (g) diphenylmethanimine, Pd<sub>2</sub>dba<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 90 Â°C, 3 h, 58%; (h) <b>22</b>, Pd<sub>2</sub>dba<sub>3</sub>, X-Phos or Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 Â°C, 2 h, 57%; (i) HCl, dioxane, rt, 0.5 h, 60%.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62833" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62833" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> General</h3><div class="NLM_p last">Unless otherwise indicated, all reagents and solvents were purchased from commercial sources and used without further purification. Moisture or oxygen sensitive reactions were conducted under an atmosphere nitrogen gas. Unless otherwise stated, <sup>1</sup>H NMR spectra were recorded at room temperature using Varian Unity Inova Bruker AVANCE III UltraShield-Plus Digital NMR spectrometer at indicated frequencies. Chemical shifts are expressed in ppm relative to an internal standard, tetramethylsilane (=0.00 ppm). The following abbreviations are used: br = broad signal, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. Purification by silica gel chromatography was carried out using a CombiFlash by Teledyne ISCO system with prepacked cartridges. Purification by reverse-phase high-performance liquid chromatography (HPLC) and supercritical fluid chromatography (SFC) was also used. All final compounds were purified to â¥95% chemical purity as determined by HPLC with UV detection at 254 nm. Further details on the analytical conditions used for individual compounds may be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 6-Bromo-2-(1<i>H</i>-pyrazol-4-yl)-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (<b>15</b>)</h3><div class="NLM_p last">A mixture of 6-bromopyridine-3,4-diamine (100 mg, 0.53 mmol) and 1<i>H</i>-pyrazole-4-carboxylic acid (60 mg, 0.53 mmol) in polyphosphoric acid (1 g) was heated in a sealed vial at 200 Â°C for 18 h. The reaction mixture was diluted with water and made basic by addition of NaOH (50% aq) and a white precipitate formed. The solid thus formed was collected by filtration and washed with water to afford the title compound (150 mg, quant.). LCMS (ESI): [M + H]<sup>+</sup> 264.1.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 6-Bromo-3-(2-trimethylsilanylethoxymethyl)-2-[1-(2-trimethylsilanylethoxymethyl)-1<i>H</i>-pyrazol-4-yl]-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (<b>16</b>)</h3><div class="NLM_p last">To a suspension of 6-bromo-2-(1<i>H</i>-pyrazol-4-yl)-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (150 mg, 0.53 mmol) in THF (2 mL) under a nitrogen atmosphere was added NaH (60% dispersion in mineral oil, 63 mg, 1.6 mmol). DMF (2 mL) was added to facilitate dissolution. After effervescence had ceased, 2-(trimethylsilyl)ethoxymethyl chloride (265 mg, 1.6 mmol) was added and stirring was continued for 2 h. The reaction mixture was partitioned between water and EtOAc. The aqueous phase was further extracted with EtOAc (3Ã), and the combined organic phases were dried (MgSO<sub>4</sub>) and concentrated in vacuo. The resulting residue was purified by chromatography on silica (solvent gradient of 0â40% EtOAc in cyclohexane) to afford the title compound (a mixture of two regioisomers) as a yellow oil that solidified on standing (224 mg 81%). LCMS (ESI): [M + H]<sup>+</sup> 524.2.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 2-Bromo-5-iodopyridin-4-amine (<b>18a</b>)</h3><div class="NLM_p last">To a solution of 2-bromopyridin-4-amine (15.0 g, 86.7 mmol) and sodium acetate (14.2 g, 173.4 mmol) in glacial acetic acid (150 mL) was added a solution of iodine monochloride (4.9 mL, 95.4 mmol) in glacial acetic acid (70 mL). After heating for 18 h at 70 Â°C, the reaction was cooled to room temperature and poured into water (800 mL). The aqueous solution was partitioned twice with EtOAc. The combined organic layers were washed with saturated aqueous Na<sub>2</sub>CO<sub>3</sub>, saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, and brine and dried over MgSO<sub>4</sub>. The organic layer was filtered and concentrated in vacuo, and the resulting residue was purified by silica gel chromatography (solvent gradient of 10â60% EtOAc in heptane) to afford the title compound (8.9 g, 34%). LCMS (ESI): [M + H]<sup>+</sup> = 300.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.16 (s, 1H), 6.77 (s, 1H), 6.50 (s, 2H).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>N</i>-(2-Bromo-5-iodopyridin-4-yl)methanesulfonamide (<b>18</b>)</h3><div class="NLM_p last">Methanesulfonyl chloride (2.15 mL, 27.3 mmol) in DCM (8 mL) was added dropwise to a cold (0 Â°C) solution of 2-bromo-5-iodopyridin-4-amine (1.63 g, 5.45 mmol) and triethylamine (3.84 mL, 27.3 mmol) in DCM (20 mL). The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The solvent was removed in vacuo and the resulting residue was purified by silica gel chromatography (solvent gradient of 5â100% EtOAc in heptane) to afford <i>N</i>-(2-bromo-5-iodopyridin-4-yl)-<i>N</i>-(methylsulfonyl)methanesulfonamide (1.1 g, 44% yield) as an off-white solid that was dissolved in aqueous NaOH solution (10%, 15 mL) in THF (15 mL) and stirred at room temperature for 16 h. The reaction mixture was concentrated. Water was added and then the mixture was acidified to pH 4 using an aqueous citric acid solution. The resulting solid was filtered and dried to afford the title compound (0.950 g, 46%). LCMS (ESI): [M + H] = 379.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.62 (s, 1H), 7.52 (s, 1H), 3.26 (s, 3H).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 6-Bromo-2-(1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (<b>19a</b>)</h3><div class="NLM_p">To a solution of 4-iodo-1<i>H</i>-pyrazole (11.0 g, 56.7 mmol) and ethynyl(trimethyl)silane (22.3 g, 227 mmol) in THF (80 mL) were added diethylamine (80 mL, 758 mmol), bis(triphenylphosphine)palladium(II) dichloride (6.03 g, 8.51 mmol), and copper(I) iodide (1.62 g, 8.51 mmol), and the reaction mixture was stirred at room temperature for 18 h. The solvent was removed in vacuo and the resulting residue was dissolved in Et<sub>2</sub>O (400 mL) and filtered. The filtrate was concentrated and the residue was purified by silica gel chromatography (solvent gradient of 0â100% Et<sub>2</sub>O in heptane) to afford 4-((trimethylsilyl)ethynyl)-1<i>H</i>-pyrazole (5.1 g, 55%) as a brown oil. LCMS (ESI): [M + H]<sup>+</sup> = 165.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 12.92 (s, 1H), 7.87 (s, 1H), 7.46 (s, 1H), 0.01 (d, <i>J</i> = 6.4 Hz, 9H).</div><div class="NLM_p">To a solution of 4-((trimethylsilyl)ethynyl)-1<i>H</i>-pyrazole (5.0 g, 30 mmol) in THF (50 mL) was added a solution of lithium hydroxide hydrate (1.9 g, 46 mmol) in water (10 mL). After stirring for 18 h at room temperature, the reaction mixture was neutralized with acetic acid and concentrated. The residue was partitioned between 1-butanol and water, and the combined organic layers were concentrated to yield 4-ethynyl-1<i>H</i>-pyrazole (2.8 g, quantitative). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 13.08 (s, 1H), 7.84 (s, 2H), 3.93 (s, 1H).</div><div class="NLM_p last">A mixture of <i>N</i>-(2-bromo-5-iodopyridin-4-yl)methanesulfonamide (1500 mg, 4.0 mmol), 4-ethynyl-1<i>H</i>-pyrazole (440 mg, 4.8 mmol), bis(triphenylphosphine)palladium(II) dichloride (140 mg, 0.20 mmol), copper(I) iodide (38 mg, 0.20 mmol), and triethylamine (2.5 mL, 18 mmol) in DMF (35 mL) was heated at 100 Â°C for 3 h and then cooled to 50 Â°C. DBU (1.8 mL) was added and stirring continued at 50 Â°C for 30 min. After cooling to room temperature, the solution was diluted with saturated NH<sub>4</sub>Cl and extracted twice with EtOAc. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (solvent gradient of 5â100% EtOAc in heptane) to afford the title compound (350 mg, 33%). LCMS (ESI): [M + H]<sup>+</sup> = 263.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 13.13 (s, 1H), 11.92 (s, 1H), 8.51 (s, 1H), 8.26 (s, 1H), 8.01 (s, 1H), 7.48 (s, 1H), 6.72 (s, 1H).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 6-Bromo-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (<b>19b</b>)</h3><div class="NLM_p">Into a 1 L three-necked round-bottom flask purged and maintained with nitrogen were added 4-iodo-1<i>H</i>-pyrazole (45.0 g, 232 mmol, 1.00 equiv) and <i>N</i>,<i>N</i>-dimethylformamide (500 mL). This was followed by addition of sodium hydride (60% dispersion in mineral oil, 10.2 g, 2.55 mmol) in several batches at 0 Â°C. The reaction mixture was stirred for 30 min at 0 Â°C in an ice/salt water bath. To the reaction mixture was added [2-(chloromethoxy)ethyl]trimethylsilane (42.3 g, 254 mmol) dropwise with stirring. The resulting solution was stirred for an additional 3 h at room temperature. The reaction mixture was quenched by addition of water/ice (250 mL) and extracted with EtOAc (2 Ã 500 mL), and the organic layers were separated and combined. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum to afford 4-iodo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1<i>H</i>-pyrazole (80.0 g) as light yellow oil without further purification.</div><div class="NLM_p">Into a 1 L three-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen were added 4-iodo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1<i>H</i>-pyrazole (75.0 g, 231 mmol), CuI (880 mg, 4.62 mmol), dichlorobis(triphenylphosphine)palladium(II) (3.25 g, 4.63 mmol), triethylamine (93.5 g, 926 mmol), (trimethylsilyl)acetylene (56.7 g, 578 mmol), and THF (500 mL). After being stirred for 5 h at room temperature, the reaction mixture was diluted with water (300 mL) and EtOAc (1000 mL), filtered, washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum to afford 1-[[2-(trimethylsilyl)ethoxy]methyl]-4-[2-(trimethylsilyl)ethynyl]-1<i>H</i>-pyrazole (80.0 g) as brown oil. LCMS (ESI): [M + H]<sup>+</sup> = 295.</div><div class="NLM_p">Into a 100 mL three-necked round-bottom flask purged and maintained with nitrogen were added 1-[[2-(trimethylsilyl)ethoxy]methyl]-4-[2-(trimethylsilyl)ethynyl]-1<i>H</i>-pyrazole (80.0 g, 272 mmol, 1.00 equiv) and THF (100 mL). This was followed by addition of tetrabutylammonium fluoride (1 N solution in THF, 300 mL) dropwise with stirring at room temperature. After being stirred for 4 h at room temperature, the reaction mixture was diluted with EtOAc (300 mL), washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was purified by chromatography with EtOAc/petroleum ether (1:50) to afford 4-ethynyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazole (30.0 g, 50.0%) as yellow oil. LCMS (ESI): [M + H]<sup>+</sup> = 223. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.68 (s, 1H), 7.59 (s, 1H), 5.34 (s, 2H), 3.50 (m, 2H), 2.99 (s, 1H), 0.85 (m, 2H), 0.03 (s, 9H).</div><div class="NLM_p last">A mixture of <i>N</i>-(2-bromo-5-iodopyridin-4-yl)methanesulfonamide (5.9 g, 16.0 mmol), 4-ethynyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazole (4.5 g, 20.0 mmol), bis(triphenylphosphine)palladium(II) dichloride (550 mg, 0.78 mmol), copper(I) iodide (150 mg, 0.78 mmol), and triethylamine (6.6 mL, 47.0 mmol) in DMF (50 mL) was heated at 100 Â°C for 3 h and then cooled to 50 Â°C. DBU (7.1 mL) was added and stirring continued for an additional 30 min at 50 Â°C. After stirring at room temperature for 18 h, the mixture was diluted with NH<sub>4</sub>Cl aqueous solution and extracted twice with EtOAc. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (gradient of 0â100% EtOAc in heptane) to afford the title compound (2.1 g, 34%). LCMS (ESI): [M + H]<sup>+</sup> = 395.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.57 (s, 1H), 8.41 (s, 1H), 8.09 (s, 1H), 7.53 (s, 1H), 6.80 (s, 1H), 5.51 (s, 2H), 3.67â3.55 (m, 2H), 0.97â0.74 (m, 2H), 0.00 (s, 9H).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 6-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (<b>20a</b>)</h3><div class="NLM_p last">Sodium hydride (60% dispersion in mineral oil, 270 mg, 6.7 mmol) was added slowly to a solution of 6-bromo-2-(1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (350 mg, 1.3 mmol) in THF (10 mL) at 0 Â°C and stirred for 30 min followed by addition of 2-(chloromethoxy)ethyltrimethylsilane (0.94 mL, 5.3 mmol). The reaction mixture was allowed to warm to room temperature and stirred for an additional 5 h. The reaction was quenched with water (50 mL), and the aqueous layer was extracted twice with EtOAc. The combined organic layers were concentrated in vacuo, and the resulting residue was purified by silica gel chromatography (solvent gradient of 0â50% EtOAc in heptane) to afford the title compound (250 mg, 36%). LCMS (ESI): [M + H]<sup>+</sup> = 524.0. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.60 (d, <i>J</i> = 4.1 Hz, 1H), 8.36â8.33 (m, 1H), 8.01 (d, <i>J</i> = 2.9 Hz, 2H), 6.85 (s, 1H), 5.64 (s, 2H), 5.48 (d, <i>J</i> = 8.3 Hz, 2H), 3.61â3.48 (m, 4H), 0.94â0.76 (m, 4H), 0.01â0.00 (m, 18H).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 6-Bromo-1-isopropyl-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (<b>20b</b>)</h3><div class="NLM_p last">2-Iodopropane (0.4 mL, 4.0 mmol) was added to a mixture of 6-bromo-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (500 mg, 1.0 mmol) and cesium carbonate (1000 mg, 4.0 mmol) in DMF (4 mL). After stirring at 90 Â°C for 48 h, the mixture was diluted with EtOAc (80 mL) and washed with water. The organic layer was concentrated in vacuo and the residue was purified by silica gel chromatography (solvent gradient of 0â40% EtOAc in heptane) to afford the title compound (240 mg, 40%). LCMS (ESI): [M + H]<sup>+</sup> = 437.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.62 (s, 1H), 8.31 (s, 1H), 7.87 (d, <i>J</i> = 9.9 Hz, 2H), 6.65 (s, 1H), 5.79 (s, 1H), 5.52 (s, 2H), 4.84â4.71 (m, 1H), 3.72â3.59 (m, 2H), 1.58 (d, <i>J</i> = 6.9 Hz, 6H), 0.99â0.85 (m, 2H), 0.00 (s, 9H).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2-(4-Methoxypiperidin-1-yl)pyrimidin-4-ylamine (<b>22</b>)</h3><div class="NLM_p last">2-Chloropyrimidin-4-ylamine (3.5 g, 27.0 mmol), 4-methoxypiperidine hydrochloride (4.09 g, 27.0 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (26.4 g, 81.0 mmol) were suspended in DMF (60 mL) and heated at 120 Â°C for 18 h. The reaction mixture was partitioned between water and EtOAc. The aqueous phase was washed with EtOAc (2Ã), and the combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo affording the title compound as a solid (2.5 g). The aqueous phase was concentrated in vacuo and the slurry was extracted with EtOAc. The volatiles were removed in vacuo, and the resulting residue was purified by silica gel chromatography (solvent gradient of 0â100% EtOAc in cyclohexane) and then triturated with cyclohexane, affording a second batch of the title compound (2.38 g, 87% combining the two batches). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.94 (1H, d, <i>J</i> = 5.60 Hz), 5.74 (1H, d, <i>J</i> = 5.60 Hz), 4.53 (2H s), 4.33â4.24 (2H, m), 3.47â3.37 (4H, m), 3.33â3.24 (2H, m), 1.98â1.87 (2H, m), 1.60â1.47 (2H, m).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> [2-(4-Methoxypiperidin-1-yl)pyrimidin-4-yl]-[2-(1<i>H</i>-pyrazol-4-yl)-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-yl]amine (<b>4</b>)</h3><div class="NLM_p">A mixture of 6-bromo-3-(2-trimethylsilanylethoxymethyl)-2-[1-(2-trimethylsilanylethoxymethyl)-1<i>H</i>-pyrazol-4-yl]-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (120 mg, 0.23 mmol), <b>22</b> (53 mg, 0.25 mmol), Pd<sub>2</sub>dba<sub>3</sub> (10 mg, 0.01 mmol), XPhos (22 mg, 0.046 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (273 mg, 0.84 mmol) in dioxane (2 mL) was purged with argon (3Ã) and heated at 120 Â°C for 18 h. The cooled reaction mixture was diluted with DCM and filtered through Celite. The filtrate was concentrated in vacuo and the resulting residue was purified by chromatography on silica (solvent gradient of 0â10% MeOH in DCM, followed by 0â15% MeOH in EtOAc and by 0â10% 2 M NH<sub>3</sub>/MeOH in DCM) to afford [2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-[3-(2-trimethylsilanylethoxymethyl)-2-[1-(2-trimethylsilanylethoxymethyl)-1<i>H</i>-pyrazol-4-yl]-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-yl]amine (120 mg, 81%). LCMS (ESI): [M + H]<sup>+</sup> 652.4.</div><div class="NLM_p last">[2-(4-Methoxypiperidin-1-yl)pyrimidin-4-yl]-[3-(2-trimethylsilanylethoxymethyl)-2-[1-(2-trimethylsilanylethoxymethyl)-1<i>H</i>-pyrazol-4-yl]-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-yl]amine (120 mg, 0.18 mmol) was suspended in MeOH (5 mL) and HCl (6 M aqueous solution, 0.5 mL). The reaction mixture was stirred at room temperature for 3 h and then at 50 Â°C for a further 3 h. A solid precipitated on standing. The suspension thus obtained was dissolved in MeOH by the use of heat and sonication and the resulting solution was loaded onto an SCX cartridge. The cartridge was washed with MeOH while the product was eluted with 2 M NH<sub>3</sub> in MeOH. The product containing fractions were combined and concentrated in vacuo, and the resulting residue was purified by chromatography on silica (solvent gradient of 0â10% 2 M NH<sub>3</sub>/MeOH in DCM) to afford the title compound as a white solid (55 mg, 76%). LCMS (ESI): [M + H]<sup>+</sup> 391.9. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 13.29 (1H, s), 12.67 (1H, s), 9.61 (1H, s), 8.51 (1H, s), 8.43â8.09 (2H, br s), 8.03 (1H, s), 7.93 (1H, d, <i>J</i> = 5.9 Hz), 6.58â6.50 (1H, m), 4.25â4.14 (2H, m), 3.48â3.30 (3H, m), 3.28 (3H, s), 1.93â1.84 (2H, m), 1.47â1.35 (2H, m).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-(2-(4-Methoxypiperidin-1-yl)pyrimidin-4-yl)-2-(1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-amine (<b>5</b>)</h3><div class="NLM_p last">A mixture of 6-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (125 mg, 0.239 mmol), <b>22</b> (64.6 mg, 0.310 mmol), tris(dibenzylideneacetone)dipalladium(0) (10.9 mg, 0.012 mmol), Xantphos (14.2 mg, 0.024 mmol), and cesium carbonate (233 mg, 0.716 mmol) in 1,4-dioxane (1.5 mL) and 1,2-dimethoxyethane (1.5 mL) was added to a microwave tube. After purging with nitrogen for 5 min, the sealed tube was heated at 120 Â°C in a CEM microwave for 60 min. The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated in vacuo. The resulting residue was purified by silica gel chromatography (solvent gradient of 0â100% EtOAc in heptane) to afford <i>N</i>-(2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-amine (43 mg, 28%; LCMS (ESI): [M + H]<sup>+</sup> = 652.0) as an off-white solid which was dissolved in MeOH (1 mL) and 10% aqueous NaOH (0.1 mL) and stirred at room temperature for 30 min. The mixture was evaporated and the residue was purified by HPLC (C18 silica on a 20 min gradient of 5â50% acetonitrile/0.1% NH<sub>4</sub>OH in water) to afford the title compound (5.0 mg, 20%). LCMS (ESI): [M + H]<sup>+</sup> = 391.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.46 (s, 1H), 8.44 (s, 1H), 8.07 (s, 2H), 7.96â7.87 (m, 2H), 6.63â6.53 (m, 2H), 4.24 (dt, <i>J</i> = 13.0, 4.6 Hz, 2H), 3.52â3.35 (m, 2H), 3.30 (s, 3H), 1.97â1.85 (m, 2H), 1.51â1.36 (m, 2H).</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 1-Isopropyl-<i>N</i>-(2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl)-2-(1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-amine (<b>6</b>)</h3><div class="NLM_p last">6-Bromo-1-isopropyl-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (236 mg, 0.542 mmol), <b>22</b> (169 mg, 0.813 mmol), tris(dibenzylideneacetone)dipalladium(0) (24.8 mg, 0.0271 mmol), Xantphos (32.3 mg, 0.054 mmol), cesium carbonate (442 mg, 1.36 mmol), and 1,4-dioxane (4 mL) were added to a pressure tube. After purging with nitrogen for 5 min, the sealed tube was heated at 120 Â°C for 20 h. The reaction mixture was filtered through a pad of Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the residue was purified by silica gel chromatography (solvent gradient of 0â100% EtOAc in heptane) to afford 1-isopropyl-<i>N</i>-(2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-amine (110 mg, 36%; LCMS (ESI): [M + H]<sup>+</sup> = 563.6) as an off-white solid. This material was dissolved in 4 N HCl in 1,4-dioxane (4 mL) and stirred at room temperature for 1 h. The mixture was concentrated and the residue was purified by preparatory HPLC (C18 silica on a 20 min gradient of 5â50% acetonitrile/0.1% NH<sub>4</sub>OH in water) to afford the title compound (19 mg, 22%). LCMS (ESI): [M + H]<sup>+</sup> = 433.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 13.21 (s, 1H), 9.56 (s, 1H), 8.50 (s, 1H), 8.33 (s, 1H), 7.93 (d, <i>J</i> = 5.7 Hz, 1H), 6.45 (s, 2H), 4.72 (p, <i>J</i> = 7.1 Hz, 1H), 4.33â4.24 (m, 2H), 3.50â3.34 (m, 2H), 3.30 (s, 3H), 1.91 (d, <i>J</i> = 12.2 Hz, 2H), 1.57 (d, <i>J</i> = 7.0 Hz, 6H), 1.43 (dq, <i>J</i> = 8.2, 4.5, 3.9 Hz, 2H).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 6-Bromo-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (<b>23a</b>)</h3><div class="NLM_p last">A mixture of 6-bromo-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (250.4 mg, 1.271 mmol), 2-iodopropane (0.50 mL, 5.0 mmol), cesium carbonate (878 mg, 2.67 mmol), and DMF (5.0 mL, 64 mmol) was heated at 90 Â°C for 20 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with water (2Ã) and brine, dried over magnesium sulfate, filtered, and evaporated in vacuo. The crude product was purified via flash chromatography on silica gel (12 g silica, solvent gradient of 0â100% EtOAc in DCM) to yield 272.4 mg (90%) of the title compound. LCMS (ESI): [M + H]<sup>+</sup> = 239. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.59 (d, <i>J</i> = 1.3 Hz, 1H), 7.83 (s, 1H), 7.65 (d, <i>J</i> = 3.5 Hz, 1H), 6.65 (dd, <i>J</i> = 3.5, 0.8 Hz, 1H), 4.82 (p, <i>J</i> = 6.6 Hz, 1H), 1.44 (d, <i>J</i> = 6.7 Hz, 6H).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 6-Chloro-1-cyclopentyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (<b>23b</b>)</h3><div class="NLM_p last">A mixture of 6-chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (100 mg, 0.65 mmol), iodocyclopentane (254 mg, 1.3 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (422 mg, 1.3 mmol) in DMF (1 mL) was heated at 80 Â°C for 18 h. The cooled reaction mixture was partitioned between water and EtOAc. The aqueous phase was further extracted with EtOAc, and the combined organic phases were dried (MgSO<sub>4</sub>) and concentrated in vacuo. The resulting residue was purified by chromatography on silica (solvent gradient of 0â50% EtOAc in cyclohexane) to afford the title compound as a colorless oil (80 mg, 56%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 8.64 (1H, s), 7.31 (1H, s), 7.21 (1H, d, <i>J</i> = 3.3 Hz), 6.57 (1H, d, <i>J</i> = 3.2 Hz), 4.76â4.65 (1H, m), 2.30â2.17 (2H, m), 1.97â1.72 (6H, m).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (1-Isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]amine (<b>7</b>)</h3><div class="NLM_p last">A mixture of 6-bromo-1-isopropylpyrrolo[3,2-<i>c</i>]pyridine (95.7 mg, 0.400 mmol), <b>22</b> (112.4 mg, 0.5397 mmol), chloro[[BrettPhos][2-(2-aminoethylphenyl)palladium(II)]]/[BrettPhos] admixture (31.0 mg, 0.0232 mmol), sodium <i>tert</i>-butoxide (118.1 mg, 1.23 mmol), and <i>tert</i>-butanol (1.5 mL, 16 mmol) was heated under nitrogen at 90 Â°C for 5 h. The reaction mixture was filtered through Celite, rinsing with 2-propanol, and concentrated. The crude product was purified via flash chromatography on silica gel (4 g of silica, solvent gradient of 0â10% MeOH in DCM) followed by achiral SFC to yield 71.9 mg (49%) of the title compound. LCMS (ESI): [M + H]<sup>+</sup> = 361.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.60 (s, 1H), 8.52 (d, <i>J</i> = 1.2 Hz, 1H), 8.29 (s, 1H), 7.93 (d, <i>J</i> = 5.6 Hz, 1H), 7.45 (d, <i>J</i> = 3.3 Hz, 1H), 6.52 (dd, <i>J</i> = 3.3, 0.8 Hz, 1H), 6.36 (d, <i>J</i> = 5.7 Hz, 1H), 4.59 (p, <i>J</i> = 6.7 Hz, 1H), 4.31â4.17 (m, 2H), 3.51â3.42 (m, 1H), 3.42â3.33 (m, 2H), 1.98â1.84 (m, 2H), 1.49 (d, <i>J</i> = 6.7 Hz, 6H), 1.46â1.36 (m, 2H).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (1-Cyclopentyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-6-yl)-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]amine (<b>8</b>)</h3><div class="NLM_p last">A mixture of 6-bromo-1-cyclopentylpyrrolo[3,2-<i>c</i>]pyridine (98.5 mg, 0.371 mmol), <b>22</b> (105.4 mg, 0.5061 mmol), chloro[[BrettPhos][2-(2-aminoethylphenyl)palladium(II)]]/[BrettPhos] admixture (26.1 mg, 0.0195 mmol), sodium <i>tert</i>-butoxide (119.0 mg, 1.24 mmol), and <i>tert</i>-butanol (1.5 mL, 16 mmol) was heated under nitrogen at 90 Â°C for 5 h. The reaction mixture was filtered through Celite, rinsing with 2-propanol, and concentrated. The crude product was purified via flash chromatography on silica gel (4 g of silica, solvent gradient of 0â10% MeOH in DCM) followed by achiral SFC to yield 48.3 mg (33%) of the title compound. LCMS (ESI): [M + H]<sup>+</sup> = 393.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.60 (s, 1H), 8.52 (d, <i>J</i> = 0.9 Hz, 1H), 8.29 (s, 1H), 7.93 (d, <i>J</i> = 5.6 Hz, 1H), 7.43 (d, <i>J</i> = 3.3 Hz, 1H), 6.52 (dd, <i>J</i> = 3.4, 0.8 Hz, 1H), 6.36 (d, <i>J</i> = 5.7 Hz, 1H), 4.76â4.67 (m, 1H), 4.28â4.19 (m, 2H), 3.51â3.43 (m, 1H), 3.43â3.33 (m, 2H), 3.29 (s, 3H), 2.19â2.08 (m, 2H), 1.98â1.79 (m, 6H), 1.78â1.65 (m, 2H), 1.51â1.34 (m, 2H).</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (2-Chloro-5-nitropyridin-4-yl)isopropylamine (<b>24</b>)</h3><div class="NLM_p last">Isopropylamine (1.43 mL, 16.7 mmol) was added dropwise to a solution of 2,4-dichloro-5-nitropyridine (3 g, 13.9 mmol) and triethylamine (3.9 mL, 27.8 mmol) in THF (50 mL) at room temperature, resulting in a mild exotherm. The reaction mixture was stirred at room temperature for 3 h and then partitioned between water and EtOAc. The aqueous phase was washed with EtOAc, and the combined organic phases were washed with brine, dried (MgSO<sub>4</sub>), and concentrated in vacuo, affording the title compound as a yellow solid (quantitative). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 9.02 (1H, s), 8.08 (1H, s), 6.74 (1H, s), 3.88â3.72 (1H, m), 1.37 (6H, d, <i>J</i> = 6.4 Hz).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i><sup>4</sup>-Isopropyl-<i>N</i><sup>2</sup>-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]pyridine-2,4,5-triamine (<b>25</b>)</h3><div class="NLM_p">(2-Chloro-5-nitropyridin-4-yl)isopropylamine (517 mg, 2.4 mmol), <b>11</b> (500 mg, 2.4 mmol), XPhos (229 mg, 48 Î¼mol), Pd<sub>2</sub>(dba)<sub>3</sub> (109 mg, 12 Î¼mol), and Cs<sub>2</sub>CO<sub>3</sub> (1.56 g, 4.8 mmol) were suspended in 1,4-dioxane (10 mL). The reaction mixture was degassed with argon, sonicated, and then heated under reflux for 3 h. The cooled reaction mixture was partitioned between water and EtOAc. The aqueous phase was washed with EtOAc (2Ã), and the combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The resulting dark brown solid was triturated with diethyl ether, affording <i>N</i><sup>4</sup>-isopropyl-<i>N</i><sup>2</sup>-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-5-nitropyridine-2,4-diamine as a bright yellow solid (667 mg, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 9.02 (1H, s), 8.25 (1H, m), 8.11 (1H, d, <i>J</i> = 5.5 Hz), 7.66 (1H, s), 7.30 (1H, s), 6.06 (1H, d, <i>J</i> = 5.5 Hz), 4.33â4.20 (2H, m), 3.94â3.82 (1H, m), 3.56â3.44 (3H, m), 3.41 (3H, s), 2.00â1.89 (2H, m), 1.68â1.57 (2H, m), 1.37 (6H, d, <i>J</i> = 6.38 Hz).</div><div class="NLM_p last"><i>N</i><sup>4</sup>-Isopropyl-<i>N</i><sup>2</sup>-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-5-nitropyridine-2,4-diamine (2.18 g, 5.6 mmol) and Pd/C (10% by weight) (300 mg) were suspended in a mixture of EtOAc/MeOH (100 mL/10 mL) and stirred under a hydrogen atmosphere for 18 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The resulting residue was purified by silica gel chromatography (solvent gradient of 0â10% 2 M NH<sub>3</sub>/MeOH in DCM) to afford the title compound (1.84 g, 92%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.99 (1H, d, <i>J</i> = 5.7 Hz), 7.61 (1H, s), 7.27 (1H, s), 7.18 (1H, s), 6.14 (1H, d, <i>J</i> = 5.7 Hz), 4.37â4.2 (3H, m), 3.76â3.64 (1H, m), 3.50â3.33 (6H, m), 2.82 (2H, s), 1.99â1.89 (2H, m), 1.65â1.52 (2H, m), 1.28 (6H, d, <i>J</i> = 6.3 Hz).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (1-Isopropyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-yl)-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]amine (<b>9</b>)</h3><div class="NLM_p last">To a solution of <i>N</i><sup>4</sup>-isopropyl-<i>N</i><sup>2</sup>-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]pyridine-2,4,5-triamine (70 mg, 0.19 mmol) in trimethyl orthoformate (2 mL) was added formic acid (5 drops) and the reaction mixture was heated at 100 Â°C for 1 h. The volatiles were removed in vacuo and the resulting residue was purified by HPLC (C18 silica on a 20 min gradient of 20â60% acetonitrile/0.1% NH<sub>4</sub>OH in water followed by a 20 min gradient of 5â50% acetonitrile/0.1% HCO<sub>2</sub>H in water) to afford the title compound as a formate salt (19 mg, 27%). LCMS (ESI): [M + H]<sup>+</sup> 367.9. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.74 (1H, s), 8.60 (1H, d, <i>J</i> = 0.9 Hz), 8.35 (1H, s), 8.28 (1H, s), 8.14 (0.4H, s), 7.92 (1H,d, <i>J</i> = 5.7 Hz), 6.33 (1H, d, <i>J</i> = 5.7 Hz), 4.65â4.54 (1H, m), 4.24â4.12 (2H, m), 3.24 (3H, s), 2.46â2.25 (3H, m), 1.91â1.77 (2H, m), 1.51 (6H, d, <i>J</i> = 6.8 Hz), 1.44â1.31 (2H, m).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2-Bromo-4-chloro-5-iodopyridine (<b>26</b>)</h3><div class="NLM_p last">To a three-necked round-bottom flask containing acetonitrile (1.5 L), 2-bromo-5-iodopyridin-4-amine (125 g, 418 mmol), and copper(I) chloride (61.0 g, 622 mmol) was added <i>tert</i>-butyl nitrite (86.0 g, 835 mmol) dropwise with stirring at 50 Â°C. The resulting solution was heated to reflux for 1 h. The reaction mixture was cooled to room temperature and concentrated in vacuo. The crude product was purified via flash chromatography on silica gel (solvent gradient of 1â10% EtOAc in petroleum ether) to afford the title compound (96 g, 72%) as a yellow solid.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 6-Bromo-4-chloropyridine-3-carbaldehyde (<b>27</b>)</h3><div class="NLM_p">Into a 2 L pressure tank reactor were placed 2-bromo-4-chloro-5-iodopyridine (30.0 g, 94.2 mmol), MeOH (500 L), triethylamine (28.6 g, 282 mmol), and palladium(II) acetate (2.10 g, 9.35 mmol). The resulting solution was stirred at 60 Â°C under an atmosphere of CO (1â2 atm). After 18 h, the reaction was cooled to room temperature, filtered, and concentrated in vacuo. The crude product was purified via flash chromatography on silica gel (solvent gradient of 2â20% EtOAc in petroleum ether) to afford methyl 6-bromo-4-chloropyridine-3-carboxylate (11 g, 47%) as a white solid. LCMS (ESI): [M + H]<sup>+</sup> = 250. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.14 (s, 1H), 7.64 (s, 1H), 3.98 (s, 3H).</div><div class="NLM_p last">To a three-necked round-bottom flask under nitrogen containing methyl 6-bromo-4-chloropyridine-3-carboxylate (35.0 g, 139 mmol) in DCM (700 mL) was added diisobutylaluminum hydride (1 M in hexanes) (153 mL) dropwise with stirring at â78 Â°C. The resulting solution was maintained at â78 Â°C for 1 h and then warmed to room temperature. After 1 h, the reaction was quenched by addition of HCl (2 N in water, 100 mL) followed by water (500 mL). The resulting solution was extracted with DCM (3 Ã 500 mL), and the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified via flash chromatography on silica gel (solvent gradient of 1â10% EtOAc in petroleum ether) to afford the title compound (17 g, 55%) as a white solid. LCMS (ESI): [M + H]<sup>+</sup> = 220.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 6-Bromo-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (<b>28</b>)</h3><div class="NLM_p last">To a reaction vessel were added 6-bromo-4-chloropyridine-3-carbaldehyde (24.0 g, 109 mmol), 1,4-dioxane (600 mL), triethylamine (22.0 g, 217 mmol), and hydrazine hydrate (9.50 g, 131 mmol), and the reaction mixture was heated to reflux for 3 days. The reaction was cooled to room temperature and concentrated in vacuo. The crude product was purified via flash chromatography on silica gel (solvent gradient of 1â5% MeOH in DCM) to afford the title compound (7.4 g, 34%) as a yellow solid. LCMS (ESI): [M + H]<sup>+</sup> = 198. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 13.62 (br, 1H), 8.93 (s, 1H), 8.35 (s, 1H), 7.81 (s, 1H).</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 6-Bromo-3-iodo-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (<b>29</b>)</h3><div class="NLM_p last">To a reaction vessel were added a solution of 6-bromo-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (5.50 g, 27.8 mmol) in DMF (100 mL), potassium hydroxide (3.60 g, 64.2 mmol), and iodine (14.2 g, 55.9 mmol), and the resulting mixture was stirred for 16 h at 40 Â°C. The reaction was cooled to room temperature and diluted with water (500 mL). The resulting suspension was filtered, and the solids were collected and dried in an oven under reduced pressure to afford the title compound (10.5 g) as a yellow solid. LCMS (ESI): [M + H]<sup>+</sup> = 324. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 14.00 (s, 1H), 8.61 (s, 1H), 7.88 (s, 1H).</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 6-Bromo-3-iodo-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (<b>30</b>)</h3><div class="NLM_p last">To a solution of 6-bromo-3-iodo-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (10.4 g, 32.1 mmol) in DMF (100 mL) under nitrogen were added sodium hydride (2.10 g, 52.5 mmol) and 2-iodopropane (21.0 g, 123 mmol), and the reaction mixture was stirred at room temperature. After 16 h, the reaction was quenched with water (400 mL) and extracted with EtOAc (2 Ã 300 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified via flash chromatography on silica gel (eluent:of 10% EtOAc in petroleum ether) to afford the title compound (5.2 g, 44%) as a white solid. LCMS (ESI): [M + H]<sup>+</sup> = 366. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.57 (s, 1H), 8.13 (s, 1H), 5.07â5.00 (m, 1H), 1.46â1.45 (d, <i>J</i> = 6.8 Hz, 6 H).</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 6-Bromo-<i>N</i>-(diphenylmethylene)-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-amine (<b>31</b>)</h3><div class="NLM_p last">A mixture of 6-bromo-3-iodo-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (300 mg, 0.82 mmol), diphenylmethanimine (150 mg, 0.83 mmol), tris(dibenzylideneacetone)dipalladium(0) (75 mg, 0.08 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (36 mg, 0.08 mmol), and cesium carbonate (540 mg, 1.66 mmol) in 1,4-dioxane (6 mL) was stirred for 3 h at 90 Â°C in an inert atmosphere of nitrogen. The solution was cooled to room temperature, diluted with water (20 mL), and extracted with EtOAc (2Ã). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (solvent gradient of 0â60% EtOAc in petroleum ether) to afford the title compound (200 mg, 58%) as a yellow solid. LCMS (ESI): [M + H]<sup>+</sup> = 419.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 1-Isopropyl-<i>N</i><sup>6</sup>-(2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-3,6-diamine (<b>10</b>)</h3><div class="NLM_p">A mixture of 6-bromo-<i>N</i>-(diphenylmethylene)-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-amine (80 mg, 0.19 mmol), tris(dibenzylideneacetone)dipalladium(0) (17.5 mg, 0.02 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (9.1 mg, 0.02 mmol), <b>22</b> (48 mg, 0.23 mmol), and cesium carbonate (125 mg, 0.39 mmol) in 1,4-dioxane (2 mL) was stirred for 2 h at 100 Â°C in an inert atmosphere of nitrogen. The resulting mixture was cooled to room temperature and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (solvent gradient 0â65% EtOAc in petroleum) to afford <i>N</i><sup>3</sup>-(diphenylmethylene)-1-isopropyl-<i>N</i><sup>6</sup>-(2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-3,6-diamine (60 mg, 57%) as a yellow solid. LCMS (ESI): [M + H]<sup>+</sup> = 547.</div><div class="NLM_p last">To a reaction vessel were added <i>N</i><sup>3</sup>-(diphenylmethylene)-1-isopropyl-<i>N</i><sup>6</sup>-(2-(4-methoxypiperidin-1-yl) pyrimidin-4-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine-3,6-diamine (60 mg, 0.11 mmol) and HCl in 1,4-dioxane (4 M, 8 mL). The resulting solution was stirred for 0.5 h at room temperature. The pH value of the solution was adjusted to 8 with sodium bicarbonate (aq) and the mixture was extracted with of EtOAc (2Ã). The resulting mixture was concentrated in vacuo. The resulting residue was purified via reverse-phase HPLC and lyophilized to afford the title compound (25.3 mg, 60%) as a light yellow solid. LCMS (ESI): [M + H]<sup>+</sup> = 383.15. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.76 (s, 1H), 8.63 (s, 1H), 8.05 (s, 1H), 7.97 (d, <i>J</i> = 5.6 Hz, 1H), 6.35 (d, <i>J</i> = 5.6 Hz, 1H), 5.77 (s, 2H), 4.50â4.44 (m, 1H), 4.25â4.20 (m, 2H), 3.49â3.40 (m, 1H), 3.38â3.34 (m, 2H), 3.32 (s, 3H), 1.92â1.90 (m, 2H), 1.50â1.30 (m, 8H).</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Enzymatic assays</h3><div class="NLM_p last">Experiments were carried out as previously described.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> In Vitro Microsome Metabolic Stability</h3><div class="NLM_p last">Experiments were carried out as previously described.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43"><a href="/doi/suppl/10.1021/jm501578n">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Tabulated biochemical Jak family activity for compounds <b>1</b>â<b>3</b>; tabulated structures and data for amide modifications; PDB codes and measurements used for the generation of Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>b; experimental procedures for kinetic solubility experiments; preparation and characterization of compounds <b>1</b>â<b>3</b> and <b>11</b>â<b>14</b>; protein expression, purification, and crystallographic methods; data collection and refinement statistics; and HPLC methods used to determine chemical purity. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501578n/suppl_file/jm501578n_si_001.pdf">jm501578n_si_001.pdf (784.95 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB codes are as follows: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ7">4RJ7</a> for <b>1</b> complexed with TMLR, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ6">4RJ6</a> for <b>4</b> complexed with TMLR, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ5">4RJ5</a> for <b>5</b> complexed with TMLR, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ4">4RJ4</a> for <b>6</b> complexed with TMLR, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ8">4RJ8</a> for <b>8</b> complexed with TMLR, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ3">4RJ3</a> for <b>8</b> complexed with CDK2.</p><div class="testing" data-doi="10.1021/jm501578n" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84268" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84268" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily J. Hanan</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0169606f606f2f646c686d784166646f642f626e6c"><span class="__cf_email__" data-cfemail="395158575857175c54505540795e5c575c175a5654">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles Eigenbrot</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marian C. Bryan</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel J. Burdick</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryan K. Chan</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuan Chen</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennafer Dotson</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Heald</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip S. Jackson</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hank La</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Lainchbury</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shiva Malek</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hans E. Purkey</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gabriele Schaefer</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Schmidt</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eileen M. Seward</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Sideris</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Tam</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shumei Wang</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siew Kuen Yeap</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ivana Yen</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianping Yin</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Yu</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Inna Zilberleyb</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy P. Heffron</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Structural Biology, Â§Drug Metabolism and
Pharmacokinetics, â¥Biochemical and Cellular Pharmacology, â¥Molecular Oncology, and #Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Argenta, Early
Discovery Charles River, 7/8 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United
Kingdom</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d3397e3306-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60863" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60863" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Christopher Hamman, Michael Hayes, Yutao Jiang, Baiwei Lin, Deven Wang, and Mengling Wong for purification and analytical support, Baiwei Lin for conducting kinetic solubility and LogD experiments, and Ning Liu for conducting liver microsome stability experiments. We thank the CCDC<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> for their help in the use of Relibase to query the PDB and, in particular, Tjelvar Olsson, who provided scripts for the radial distribution plots. We thank Kristina Grabowski of the Chemical Computing Group<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> for her svl script to calculate the geometries specific to gatekeeper methionines. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231. The Berkeley Center for Structural Biology is supported in part by the National Institutes of Health, National Institute of General Medical Sciences, and the Howard Hughes Medical Institute. Use of the LS-CAT Sector 21 of the Advanced Photon Source (APS) was supported by the Michigan Economic Development Corp. and the Michigan Technology Tri-Corridor (Grant 085P1000817). APS, an Office of Science User Facility operated for the U.S. Department of Energy Office of Science by Argonne National Laboratory, was supported by the U.S. DOE under Contract No. DE-AC02-06CH11357.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i46" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i46"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> Abbreviations Used</h2><tr><td class="NLM_term">CSD</td><td class="NLM_def"><p class="first last">Cambridge Structural Database</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HOAc</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">Jak</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">NaOAc</td><td class="NLM_def"><p class="first last">sodium acetate</p></td></tr><tr><td class="NLM_term">NaOtBu</td><td class="NLM_def"><p class="first last">sodium <i>tert</i>-butoxide</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">2-(trimethylsilyl)ethoxymethyl</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">TMdel</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor (T790M/del746â750)</p></td></tr><tr><td class="NLM_term">TMLR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor (T790M/L858R)</p></td></tr><tr><td class="NLM_term">Tyk2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">wtEGFR</td><td class="NLM_def"><p class="first last">wild-type epidermal growth factor receptor.</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 57 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Oncogene addiction: Setting the stage for molecularly targeted cancer therapy</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3214</span><span class="NLM_x">â</span> <span class="NLM_lpage">3231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1101%2Fgad.1609907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=18079171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrsb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=3214-3231&author=S.+V.+Sharmaauthor=J.+Settleman&title=Oncogene+addiction%3A+Setting+the+stage+for+molecularly+targeted+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene addiction: setting the stage for molecularly targeted cancer therapy</span></div><div class="casAuthors">Sharma, Sreenath V.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3214-3231</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first punch setting the stage and the second delivering the knock-out.  This analogy can be extended to molecularly targeted cancer therapies, with oncogene addiction serving to set the stage for tumor cell killing by a targeted therapeutic agent.  While in vitro and in vivo examples abound documenting the existence of this phenomenon, the mechanistic underpinnings that govern oncogene addiction are just beginning to emerge.  Our current inability to fully exploit this weakness of cancer cells stems from an incomplete understanding of oncogene addiction, which nonetheless represents one of the rare chinks in the formidable armor of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk4ia5nlRCDbVg90H21EOLACvtfcHk0lh6LQvOKgKjmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrsb7J&md5=e367eb201f849ecac6c29ce7f80138fa</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1101%2Fgad.1609907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1609907%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DOncogene%2520addiction%253A%2520Setting%2520the%2520stage%2520for%2520molecularly%2520targeted%2520cancer%2520therapy%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D3214%26epage%3D3231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">â</span> <span class="NLM_lpage">1167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7241</span><span class="NLM_x">â</span> <span class="NLM_lpage">7244</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7241-7244&author=S.+Tracyauthor=T.+Mukoharaauthor=M.+Hansenauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=P.+A.+Janne&title=Gefitinib+induces+apoptosis+in+the+EGFRL858R+non-small-cell+lung+cancer+cell+line+H3255"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DMukohara%26aufirst%3DT.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DGefitinib%2520induces%2520apoptosis%2520in%2520the%2520EGFRL858R%2520non-small-cell%2520lung%2520cancer%2520cell%2520line%2520H3255%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7241%26epage%3D7244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Inhibition of EGFR signaling: All mutations are not created equal</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">e377</span><span class="NLM_x">) </span> <span class="NLM_fpage">1085</span><span class="NLM_x">â</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=1085-1087&issue=e377&author=A.+F.+Gazdarauthor=J.+D.+Minna&title=Inhibition+of+EGFR+signaling%3A+All+mutations+are+not+created+equal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DInhibition%2520of%2520EGFR%2520signaling%253A%2520All%2520mutations%2520are%2520not%2520created%2520equal%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26issue%3De377%26spage%3D1085%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lgFaU6sQog8Aw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">â</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lgFaU6sQog8Aw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">â</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+Correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lhIJ0FL8GemqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520Correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ânever smokersâ and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">â</span> <span class="NLM_lpage">13311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Jackman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cioffredi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5267</span><span class="NLM_x">â</span> <span class="NLM_lpage">5273</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1078-0432.CCR-09-0888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=19671843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFeitLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5267-5273&author=D.+M.+Jackmanauthor=V.+A.+Millerauthor=L.+A.+Cioffrediauthor=B.+Y.+Yeapauthor=P.+A.+Janneauthor=G.+J.+Rielyauthor=M.+G.+Ruizauthor=G.+Giacconeauthor=L.+V.+Sequistauthor=B.+E.+Johnson&title=Impact+of+epidermal+growth+factor+receptor+and+KRAS+mutations+on+clinical+outcomes+in+previously+untreated+non-small+cell+lung+cancer+patients%3A+Results+of+an+online+tumor+registry+of+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online Tumor registry of clinical trials</span></div><div class="casAuthors">Jackman, David M.; Miller, Vincent A.; Cioffredi, Leigh-Anne; Yeap, Beow Y.; Jaenne, Pasi A.; Riely, Gregory J.; Ruiz, Marielle Gallegos; Giaccone, Giuseppe; Sequist, Lecia V.; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5267-5273</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on outcomes with erlotinib or gefitinib therapy continues to be debated.  This study combines patient data from five trials in predominantly Western populations to assess the impact of EGFR and KRAS mutations on first-line therapy with an EGFR-tyrosine kinase inhibitor (TKI) and compare clin. vs. mol. predictors of sensitivity.  Chemotherapy-naive patients with advanced non-small cell lung cancer and known EGFR mutation status treated with erlotinib or gefitinib monotherapy as part of a clin. trial were eligible for inclusion.  Patients received daily erlotinib (150 mg) or gefitinib (250 mg) until disease progression or unacceptable toxicity.  Data were collected in a password-protected web database.  Clin. outcomes were analyzed to look for differences based on EGFR and KRAS genotypes, as well as clin. characteristics.  Patients (223) from five clin. trials were included.  Sensitizing EGFR mutations were assocd. with a 67% response rate, time to progression (TTP) of 11.8 mo, and overall survival of 23.9 mo.  Exon 19 deletions were assocd. with longer median TTP and overall survival compared with L858R mutations.  Wild-type EGFR was assocd. with poorer outcomes (response rate, 3%; TTP, 3.2 mo) irresp. of KRAS status.  No difference in outcome was seen between patients harboring KRAS transition vs. transversion mutations.  EGFR genotype was more effective than clin. characteristics at selecting appropriate patients for consideration of first-line therapy with an EGFR-TKI.  EGFR mutation status is assocd. with sensitivity to treatment with an EGFR-TKI in patients with advanced non-small cell lung cancer.  Patients harboring sensitizing EGFR mutations should be considered for first-line erlotinib or gefitinib. (Clin Cancer Res 2009;15(16):5267-73).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUmIDiCjeVvrVg90H21EOLACvtfcHk0lhIJ0FL8GemqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFeitLs%253D&md5=2d9669c6e4c396d632424c1c0190868c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0888%26sid%3Dliteratum%253Aachs%26aulast%3DJackman%26aufirst%3DD.%2BM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCioffredi%26aufirst%3DL.%2BA.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DRuiz%26aufirst%3DM.%2BG.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DImpact%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520KRAS%2520mutations%2520on%2520clinical%2520outcomes%2520in%2520previously%2520untreated%2520non-small%2520cell%2520lung%2520cancer%2520patients%253A%2520Results%2520of%2520an%2520online%2520tumor%2520registry%2520of%2520clinical%2520trials%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5267%26epage%3D5273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vivanco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Larriba, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertran-Alamillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span> </span><span class="NLM_article-title">Screening for epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">958</span><span class="NLM_x">â</span> <span class="NLM_lpage">967</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1056%2FNEJMoa0904554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=19692684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=958-967&author=R.+Rosellauthor=T.+Moranauthor=C.+Queraltauthor=R.+Portaauthor=F.+Cardenalauthor=C.+Campsauthor=M.+Majemauthor=G.+Lopez-Vivancoauthor=D.+Islaauthor=M.+Provencioauthor=A.+Insaauthor=B.+Massutiauthor=J.+L.+Gonzalez-Larribaauthor=L.+Paz-Aresauthor=I.+Boverauthor=R.+Garcia-Campeloauthor=M.+A.+Morenoauthor=S.+Catotauthor=C.+Rolfoauthor=N.+Reguartauthor=R.+Palmeroauthor=J.+M.+Sanchezauthor=R.+Bastusauthor=C.+Mayoauthor=J.+Bertran-Alamilloauthor=M.+A.+Molinaauthor=J.+J.+Sanchezauthor=M.+Taron&title=Screening+for+epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Screening for epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Rosell, Rafael; Moran, Teresa; Queralt, Cristina; Porta, Rut; Cardenal, Felipe; Camps, Carlos; Majem, Margarita; Lopez-Vivanco, Guillermo; Isla, Dolores; Provencio, Mariano; Insa, Amelia; Massuti, Bartomeu; Gonzalez-Larriba, Jose Luis; Paz-Ares, Luis; Bover, Isabel; Garcia-Campelo, Rosario; Moreno, Miguel Angel; Catot, Silvia; Rolfo, Christian; Reguart, Noemi; Palmero, Ramon; Sanchez, Jose Miguel; Bastus, Roman; Mayo, Clara; Bertran-Alamillo, Jordi; Molina, Miguel Angel; Sanchez, Jose Javier; Taron, Miquel; Cuello, M.; Pallares, C.; Lianes, P.; Remon, J.; Ibeas, R.; Martinez del Prado, P.; Angeles Sala, M.; Santander-Lobera, C.; Velez de Mendizabal, E.; Vinolas, N.; Terrasa, J.; Valdivia, J.; Diz, P.; Jimenez-Berlana, U.; Velasco-Ortiz de Taranco, A.; Ales Martinez, E.; Sanchez-Escribano, R.; Carrato, A.; Guillen-Ponce, C.; Mesia, C.; Antonio Macias, J.; Lopez-Brea, M.; Oramas, J.; Barneto, I.; Garrido, P.; Mayol, M. J.; Lopez, A.; Artal, A.; Saenz, A.; Hernando, S.; Cobo, M.; Blanco, R.; Bernabe, R.; Guillem, V.; Angel Munoz, M.; Maestu, I.; Salvatierra, A.; De Las Penas, R.; Alfaro, J.; Alberola, V.; Juan, O.; Martin, C.; Puertas, J.; Felip, E.; Gonzalez-Gonzalez, J. F.; Iglesias-Docampo, L.; Dorta, F. J.; Martinez-Aguillo, M.; Salgado, E.; Mesia, R.; Lastra-Aras, E.; Garcia-Munoz, J. P.; Lastra, R.; Alvarez, I.; Roig, J.; Oruezabal, J.; Poveda, A.; Lavernia, J.; Gutierrez, D.; Filipovich, E.; Aguiar, D.; Rodriguez, D.; Buxo, J.; Cardona, A. F.; Bes, P.; Paredes, A.; Tortorella, A. M.; Moreno, J. A.; Martinez-Garcia, J.; Alonso, J. L.; Lopez-Martin, A.; Echarri-Gonzalez, M. J.; Van Kooten, M.; Guerrero, A.; Domine, M.; Diaz, I.; Heras, L.; Garcia, R.; Anton, I.; Jarchum, G.; Bartolucci, R. E.; Lomas, M.; Rubiales, A.; Duque, J. L.; Escriva de Romani, S.; Barbeta, E.; Reina, J. J.; Castro, J.; Belda, C.; Vidal, J. M.; Trigo, J. M.; Vadell, C.; Zarba, J. J.; Esunza, P.; Garau, I.; Lopez-Pousa, A.; De la Gandara, I.; Widakowich, J.; Morales, S.; Martinez, M.; Luis, R.; de la Colina, M.; Calzas, J.; Garcia-Castro, I.; Ruiz, C.; Lopez-Criado, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">958-967</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer.  We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the assocn. between the mutations and the outcome of erlotinib treatment.  From Apr. 2005 through Nov. 2008, lung cancers from 2105 patients in 129 institutions in Spain were screened for EGFR mutations.  The anal. was performed in a central lab.  Patients with tumors carrying EGFR mutations were eligible for erlotinib treatment.  EGFR mutations were found in 350 of 2105 patients (16.6%).  Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%) (P < 0.001 for all comparisons).  The mutations were deletions in exon 19 (62.2%) and L858R (37.8%).  Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 mo and 27 mo, resp.  The adjusted hazard ratios for the duration of progression-free survival were 2.94 for men (P < 0.001); 1.92 for the presence of the L858R mutation, as compared with a deletion in exon 19 (P = 0.02); and 1.68 for the presence of the L858R mutation in paired serum DNA, as compared with the absence of the mutation (P = 0.02).  The most common adverse events were mild rashes and diarrhea; grade 3 cutaneous toxic effects were recorded in 16 patients (7.4%) and grade 3 diarrhea in 8 patients (3.7%).  Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvZWnSnU_ScbVg90H21EOLACvtfcHk0lh_SXUmowamgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M&md5=288ea35bd5201579d8c89ad6d7c4306a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904554%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCardenal%26aufirst%3DF.%26aulast%3DCamps%26aufirst%3DC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DGonzalez-Larriba%26aufirst%3DJ.%2BL.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DCatot%26aufirst%3DS.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DBastus%26aufirst%3DR.%26aulast%3DMayo%26aufirst%3DC.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DTaron%26aufirst%3DM.%26atitle%3DScreening%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D958%26epage%3D967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">â</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+biologically+based+treatment+of+EGFR-mutant+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0lh_SXUmowamgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520biologically%2520based%2520treatment%2520of%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">â</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lh_SXUmowamgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">e73</span><span class="NLM_x">) </span> <span class="NLM_fpage">225</span><span class="NLM_x">â</span> <span class="NLM_lpage">235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=225-235&issue=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26issue%3De73%26spage%3D225%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Balak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouerfelli, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6494</span><span class="NLM_x">â</span> <span class="NLM_lpage">6501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1078-0432.CCR-06-1570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17085664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6494-6501&author=M.+N.+Balakauthor=Y.+Gongauthor=G.+J.+Rielyauthor=R.+Somwarauthor=A.+R.+Liauthor=M.+F.+Zakowskiauthor=A.+Chiangauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=Novel+D761Y+and+common+secondary+T790M+mutations+in+epidermal+growth+factor+receptor-mutant+lung+adenocarcinomas+with+acquired+resistance+to+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors</span></div><div class="casAuthors">Balak, Marissa N.; Gong, Yixuan; Riely, Gregory J.; Somwar, Romel; Li, Allan R.; Zakowski, Maureen F.; Chiang, Anne; Yang, Guangli; Ouerfelli, Ouathek; Kris, Mark G.; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6494-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been assocd. with a second-site EGFR mutation, which leads to substitution of methionine for threonine at position 790 (T790M).  We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy.  Exptl. Design: Tumor cells from patients with acquired resistance were examd. for secondary EGFR kinase domain mutations by mol. analyses.  RESULTS: Eight of 16 patients (50% obsd. rate; 95% confidence interval, 25-75%) had tumor cells with second-site EGFR mutations.  Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.  When combined with a drug-sensitive L858R mutation, the D761Y mutation modestly reduced the sensitivity of mutant EGFR to TKIs in both surrogate kinase and cell viability assays.  In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.  CONCLUSIONS: The T790M mutation is common in patients with acquired resistance.  The limited spectrum of TKI-resistant mutations in EGFR, which binds to erlotinib in the active conformation, contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib, which binds to ABL and KIT, resp., in closed conformations.  Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anat. site and mode of binding to the kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeHDQldYeDLVg90H21EOLACvtfcHk0lhfrVkh52L4sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI&md5=e817eb717673081d89ec3d58a04a7d4d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBalak%26aufirst%3DM.%2BN.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNovel%2520D761Y%2520and%2520common%2520secondary%2520T790M%2520mutations%2520in%2520epidermal%2520growth%2520factor%2520receptor-mutant%2520lung%2520adenocarcinomas%2520with%2520acquired%2520resistance%2520to%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6494%26epage%3D6501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuboi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span> </span><span class="NLM_article-title">Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">5764</span><span class="NLM_x">â</span> <span class="NLM_lpage">5769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1078-0432.CCR-06-0714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17020982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVartbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5764-5769&author=T.+Kosakaauthor=Y.+Yatabeauthor=H.+Endohauthor=K.+Yoshidaauthor=T.+Hidaauthor=M.+Tsuboiauthor=H.+Tadaauthor=H.+Kuwanoauthor=T.+Mitsudomi&title=Analysis+of+epidermal+growth+factor+receptor+gene+mutation+in+patients+with+non-small+cell+lung+cancer+and+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib</span></div><div class="casAuthors">Kosaka, Takayuki; Yatabe, Yasushi; Endoh, Hideki; Yoshida, Kimihide; Hida, Toyoaki; Tsuboi, Masahiro; Tada, Hirohito; Kuwano, Hiroyuki; Mitsudomi, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5764-5769</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Non-small cell lung cancers carrying activating mutations in the gene for the epidermal growth factor receptor (EGFR) are highly sensitive to EGFR-specific tyrosine kinase inhibitors.  However, most patients who initially respond subsequently experience disease progression while still on treatment.  Part of this "acquired resistance" is attributable to a secondary mutation resulting in threonine to methionine at codon 790 (T790M) of EGFR.  Exptl. Design: We sequenced exons 18 to 21 of the EGFR gene to look for secondary mutations in tumors with acquired resistance to gefitinib in 14 patients with adenocarcinomas.  Subcloning or cycleave PCR was used in addn. to normal sequencing to increase the sensitivity of the assay.  We also looked for T790M in pretreatment samples from 52 patients who were treated with gefitinib.  We also looked for secondary KRAS gene mutations because tumors with KRAS mutations are generally resistant to tyrosine kinase inhibitors.  RESULTS: Seven of 14 tumors had a secondary T790M mutation.  There were no other novel secondary mutations.  We detected no T790M mutations in pretreatment specimens from available five tumors among these seven tumors.  Patients with T790M tended to be women, never smokers, and carrying deletion mutations, but the T790M was not assocd. with the duration of gefitinib administration.  None of the tumors had an acquired mutation in the KRAS gene.  CONCLUSIONS: A secondary T790M mutation of EGFR accounted for half the tumors with acquired resistance to gefitinib in Japanese patients.  Other drug-resistant secondary mutations are uncommon in the EGFR gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZou5KHFws9bVg90H21EOLACvtfcHk0lhfrVkh52L4sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVartbvL&md5=331c3e60cb4470484b418ee1b9a80674</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0714%26sid%3Dliteratum%253Aachs%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DEndoh%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DTsuboi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DKuwano%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DAnalysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520gene%2520mutation%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5764%26epage%3D5769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">â</span> <span class="NLM_lpage">2247</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lhgdqQwofeu1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">â</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0lhgdqQwofeu1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">â</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: The new wave of BCR-ABL inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrd2324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17853901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Flying+under+the+radar%3A+The+new+wave+of+BCR-ABL+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Flying under the radar: the new wave of BCR-ABL inhibitors</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">834-848</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia caused by the mutant BCR-ABL kinase has been successfully treated with inhibitors of this kinase, such as imatinib, but mutations within the kinase can result in resistance to these drugs.  Quintas-Cardama and colleagues discuss novel BCR-ABL inhibitors that have the potential to overcome such resistance.  The introduction of the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis) revolutionized the treatment of chronic myeloid leukemia (CML).  However, most patients with CML receiving imatinib still harbor mol. residual disease and some develop resistance assocd. with ABL kinase domain mutations.  The second-generation BCR-ABL inhibitors nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) have shown significant activity after imatinib failure in clin. trials, but still face similar obstacles to imatinib, including negligible activity against the frequent BCR-ABL T315I mutation and modest effects in advanced phases of CML.  Various medicinal chem. efforts, in part aided by structural studies of the ABL kinase-imatinib complex have resulted in the synthesis of a new generation of BCR-ABL inhibitors, some of which have shown encouraging preliminary activity in clin. trials, including against T315I mutants.  Here, we discuss these emerging therapies, which have the potential to improve the outcome of patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2DBi1E-INLVg90H21EOLACvtfcHk0lhgdqQwofeu1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ&md5=6a8692cd0405f77256df82ae7de21e18</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd2324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2324%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520The%2520new%2520wave%2520of%2520BCR-ABL%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D834%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="note"><p class="first last">Erlotinib activity in biochemical assays: wtEGFR <i>K</i><sub>i</sub> = 0.1 nM, EGFR(L858R) <i>K</i><sub>i</sub> = 0.3 nM, EGFR(d746â750) <i>K</i><sub>i</sub> = 0.1 nM, EGFR(T790M/L858R) <i>K</i><sub>i</sub> = 123 nM, and EGFR(T790M/d746â750) <i>K</i><sub>i</sub> = 95 nM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">â</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lhlLDnClovX4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Janne, P. A.; Schellens, J. H.; Engelman, J. A.; Eckhardt, S. G.; Millham, R.; Denis, L. J.; Britten, C. D.; Wong, S. G.; Boss, D. S.; Camidge, D. R.</span><span> </span><span class="NLM_article-title">Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span>, (May 20 suppl; abstr 8027).</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1200%2FJCO.2007.14.7611" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&author=P.+A.+Janne&author=J.+H.+Schellens&author=J.+A.+Engelman&author=S.+G.+Eckhardt&author=R.+Millham&author=L.+J.+Denis&author=C.+D.+Britten&author=S.+G.+Wong&author=D.+S.+Boss&author=D.+R.+Camidge&title=Preliminary+activity+and+safety+results+from+a+phase+I+clinical+trial+of+PF-00299804%2C+an+irreversible+pan-HER+inhibitor%2C+in+patients+%28pts%29+with+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.7611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.7611%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DPreliminary%2520activity%2520and%2520safety%2520results%2520from%2520a%2520phase%2520I%2520clinical%2520trial%2520of%2520PF-00299804%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">â</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+irreversible+pan-ErbB+receptor+tyrosine+kinase+inhibitor%3A+Results+of+a+phase+II+trial+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with â¥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (â¤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0lhlLDnClovX4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520irreversible%2520pan-ErbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%253A%2520Results%2520of%2520a%2520phase%2520II%2520trial%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">â</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kluterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+Inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0lgdan4TAqcdtw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520Inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">â</span> <span class="NLM_lpage">791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&author=Y.+Kimauthor=J.+Koauthor=Z.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.+H.+Ouauthor=M.+J.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0lgdan4TAqcdtw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D784%26epage%3D791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Preliminary results from a phase I study with AZD9291: An irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations in non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S15</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S15&issue=Suppl+3&author=M.+Ransonauthor=W.+Paoauthor=D.+W.+Kimauthor=S.+W.+Kimauthor=Y.+Oheauthor=E.+Felipauthor=D.+Planchardauthor=S.+Ghiorghiuauthor=M.+Cantariniauthor=P.+A.+Janne&title=Preliminary+results+from+a+phase+I+study+with+AZD9291%3A+An+irreversible+inhibitor+of+epidermal+growth+factor+receptor+%28EGFR%29+activating+and+resistance+mutations+in+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DPreliminary%2520results%2520from%2520a%2520phase%2520I%2520study%2520with%2520AZD9291%253A%2520An%2520irreversible%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520activating%2520and%2520resistance%2520mutations%2520in%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26issue%3DSuppl%25203%26spage%3DS15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span> </span><span class="NLM_article-title">First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1200%2FJCO.2012.44.2806" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2524&author=L.+V.+Sequistauthor=J.-C.+Soriaauthor=S.+Gadgeelauthor=H.+Wakeleeauthor=D.+R.+Camidgeauthor=A.+Vargaauthor=P.+Fidiasauthor=A.+J.+Wozniakauthor=J.+W.+Nealauthor=R.+C.+Doebeleauthor=E.+B.+Garonauthor=S.+Jaw-Tsaiauthor=J.+C.+Sternauthor=A.+Allenauthor=J.+W.+Goldman&title=First-in-human+evaluation+of+CO-1686%2C+an+irreversible%2C+selective%2C+and+potent+tyrosine+kinase+inhibitor+of+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.44.2806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.44.2806%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DWakelee%26aufirst%3DH.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DStern%26aufirst%3DJ.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26atitle%3DFirst-in-human%2520evaluation%2520of%2520CO-1686%252C%2520an%2520irreversible%252C%2520selective%252C%2520and%2520potent%2520tyrosine%2520kinase%2520inhibitor%2520of%2520EGFR%2520T790M%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D2524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Red Brewer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">â</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lje-qVpHsU9Pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medikonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">In vitro and In vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">â</span> <span class="NLM_lpage">1479</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1535-7163.MCT-13-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=24723450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1468-1479&author=R.+Tjin+Tham+Sjinauthor=K.+Leeauthor=A.+O.+Walterauthor=A.+Dubrovskiyauthor=M.+Sheetsauthor=T.+S.+Martinauthor=M.+T.+Labenskiauthor=Z.+Zhuauthor=R.+Testerauthor=R.+Karpauthor=A.+Medikondaauthor=P.+Chaturvediauthor=Y.+Renauthor=H.+Haringsmaauthor=J.+Etterauthor=M.+Raponiauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=D.+Niuauthor=M.+Nachtauthor=W.+F.+Westlinauthor=R.+C.+Petterauthor=A.+Allenauthor=J.+Singh&title=In+vitro+and+In+vivo+characterization+of+irreversible+mutant-selective+EGFR+inhibitors+that+are+wild-type+sparing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span></div><div class="casAuthors">Tjin Tham Sjin Robert; Lee Kwangho; Walter Annette O; Dubrovskiy Aleksandr; Sheets Michael; Martin Thia St; Labenski Matthew T; Zhu Zhendong; Tester Richland; Karp Russell; Medikonda Aravind; Chaturvedi Prasoon; Ren Yixuan; Haringsma Henry; Etter Jeff; Raponi Mitch; Simmons Andrew D; Harding Thomas C; Niu Deqiang; Nacht Mariana; Westlin William F; Petter Russell C; Allen Andrew; Singh Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with non-small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib.  However, all patients relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approximately 60% of all resistance.  Second-generation irreversible EGFR inhibitors are effective against T790M mutations in vitro, but retain affinity for wild-type EGFR (EGFR(WT)).  These inhibitors have not provided compelling clinical benefit in T790M-positive patients, apparently because of dose-limiting toxicities associated with inhibition of EGFR(WT).  Thus, there is an urgent clinical need for therapeutics that overcome T790M drug resistance while sparing EGFR(WT).  Here, we describe a lead optimization program that led to the discovery of four potent irreversible 2,4-diaminopyrimidine compounds that are EGFR mutant (EGFR(mut)) selective and have been designed to have low affinity for EGFR(WT).  Pharmacokinetic and pharmacodynamic studies in H1975 tumor-bearing mice showed that exposure was dose proportional resulting in dose-dependent EGFR modulation.  Importantly, evaluation of normal lung tissue from the same animals showed no inhibition of EGFR(WT).  Of all the compounds tested, compound 3 displayed the best efficacy in EGFR(L858R/T790M)-driven tumors.  Compound 3, now renamed CO-1686, is currently in a phase I/II clinical trial in patients with EGFR(mut)-advanced NSCLC that have received prior EGFR-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdUiOZStIjAqx48Rj5GnGofW6udTcc2eb40Bm3waxjy7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D&md5=b42556f3737b33c07511a77ab63ed1d1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0966%26sid%3Dliteratum%253Aachs%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DMedikonda%26aufirst%3DA.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DHaringsma%26aufirst%3DH.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520and%2520In%2520vivo%2520characterization%2520of%2520irreversible%2520mutant-selective%2520EGFR%2520inhibitors%2520that%2520are%2520wild-type%2520sparing%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1468%26epage%3D1479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaligam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 5</span><span class="NLM_x">) </span> <span class="NLM_fpage">8009</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8009&issue=Suppl.+5&author=P.+A.+Janneauthor=S.+S.+Ramaligamauthor=J.+C.+H.+Yangauthor=M.-J.+Ahnauthor=D.-W.+Kimauthor=S.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=E.+Felipauthor=C.+Watkinsauthor=M.+Cantariniauthor=S.+Ghiorghiuauthor=M.+Ranson&title=Clinical+activity+of+the+mutant-selective+EGFR+inhibitor+AZD9291+in+patients+%28pts%29+with+EGFR+inhibitor-resistant+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRamaligam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DClinical%2520activity%2520of%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520AZD9291%2520in%2520patients%2520%2528pts%2529%2520with%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3DSuppl.%25205%26spage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirazzoli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Noncovalent wild-type-sparing inhibitors of EGFR T790M</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=168-181&author=H.+J.+Leeauthor=G.+Schaeferauthor=T.+P.+Heffronauthor=L.+Shaoauthor=X.+Yeauthor=S.+Siderisauthor=S.+Malekauthor=E.+Chanauthor=M.+Merchantauthor=H.+Laauthor=S.+Ubhayakarauthor=R.+L.+Yauchauthor=V.+Pirazzoliauthor=K.+Politiauthor=J.+Settleman&title=Noncovalent+wild-type-sparing+inhibitors+of+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DPirazzoli%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DNoncovalent%2520wild-type-sparing%2520inhibitors%2520of%2520EGFR%2520T790M%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D168%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="note"><p class="first last">Preliminary phase I data suggest that irreversible inhibitors AZD9291 and CO-1686 do not appear to have the toxicities seen with previous irreversible inhibitors of EGFR.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Evans, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">â</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug-protein+adducts%3A+An+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development</span></div><div class="casAuthors">Evans, David C.; Watt, Alan P.; Nicoll-Griffith, Deborah A.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity.  Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Labs. has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage.  This requires a flexible approach to defining bioactivation issues in a variety of metab. vectors and typically involves the initial use of small mol. trapping agents to define the potential for bioactivation.  At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) prepns. from preclin. species and human, and also in vivo, typically in the rat.  This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Labs.  The availability of a dedicated Labeled Compd. Synthesis group, coupled to a close working relationship between Drug Metab. and Medicinal Chem., represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsPmSgJDD8rVg90H21EOLACvtfcHk0liNl3djZ2GcZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D&md5=9ab130c5462b2245e2f4c783afb01d1d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug-protein%2520adducts%253A%2520An%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: An orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">â</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+An+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0liNl3djZ2GcZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520An%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span> </span><span class="NLM_article-title">Drug discovery for a new generation of covalent drugs</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">â</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1517%2F17460441.2012.688744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=22607458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFWmt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=561-581&author=A.+S.+Kalgutkarauthor=D.+K.+Dalvie&title=Drug+discovery+for+a+new+generation+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery for a new generation of covalent drugs</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">561-581</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The design of target-specific covalent inhibitors is conceptually attractive because of increased biochem. efficiency through covalency and increased duration of action that outlasts the pharmacokinetics of the agent.  Although many covalent inhibitors have been approved or are in advanced clin. trials to treat indications such as cancer and hepatitis C, there is a general tendency to avoid them as drug candidates because of concerns regarding immune-mediated toxicity that can arise from indiscriminate reactivity with off-target proteins.Areas covered: The review examines potential reason(s) for the excellent safety record of marketed covalent agents and advanced clin. candidates for emerging therapeutic targets.  A significant emphasis is placed on proteomic techniques and chem./biochem. reactivity assays that aim to provide a systematic rank ordering of pharmacol. selectivity relative to off-target protein reactivity of covalent inhibitors.Expert opinion: While tactics to examine selective covalent modification of the pharmacol. target are broadly applicable in drug discovery, it is unclear whether the output from such studies can prospectively predict idiosyncratic immune-mediated drug toxicity.  Opinions regarding an acceptable threshold of protein reactivity/body burden for a toxic electrophile and a non-toxic electrophilic covalent drug have not been defined.  Increasing confidence in proteomic and chem./biochem. reactivity screens will require a retrospective side-by-side profiling of marketed covalent drugs and electrophiles known to cause deleterious toxic effects via non-selective covalent binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmXy20mDTPbVg90H21EOLACvtfcHk0liNl3djZ2GcZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFWmt7k%253D&md5=b7fc8e60b263dda5765dd8380f52df17</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.688744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.688744%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26atitle%3DDrug%2520discovery%2520for%2520a%2520new%2520generation%2520of%2520covalent%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D561%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezhkovskiy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantik, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menghrajani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambrone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Lead identification of novel and selective TYK2 inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">â</span> <span class="NLM_lpage">187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1016%2Fj.ejmech.2013.03.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=23867602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVejtL%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=175-187&author=J.+Liangauthor=V.+Tsuiauthor=A.+Van+Abbemaauthor=L.+Baoauthor=K.+Barrettauthor=M.+Beresiniauthor=L.+Berezhkovskiyauthor=W.+S.+Blairauthor=C.+Changauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=M.+Liimattaauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=A.+Sambroneauthor=Y.+Xiaoauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=M.+Stanleyauthor=M.+Ultschauthor=B.+Zhangauthor=L.+C.+Wuauthor=S.+Magnuson&title=Lead+identification+of+novel+and+selective+TYK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Lead identification of novel and selective TYK2 inhibitors</span></div><div class="casAuthors">Liang, Jun; Tsui, Vickie; Van Abbema, Anne; Bao, Liang; Barrett, Kathy; Beresini, Maureen; Berezhkovskiy, Leo; Blair, Wade S.; Chang, Christine; Driscoll, James; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liimatta, Marya; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Sambrone, Amy; Xiao, Yisong; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Stanley, Mark; Ultsch, Mark; Zhang, Birong; Wu, Lawren C.; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-187</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2.  Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine (I) as a promising starting point for lead identification.  Initial expansion of 3 sep. regions of the mol. led to eventual identification of cyclopropyl amide (II), a potent lead analog with good kinase selectivity, physicochem. properties, and pharmacokinetic profile.  Anal. of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXEWbuB0597rVg90H21EOLACvtfcHk0liNl3djZ2GcZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVejtL%252FL&md5=4271738e73a0b680a4441b9231762ef0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.070%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DStanley%26aufirst%3DM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520identification%2520of%2520novel%2520and%2520selective%2520TYK2%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D67%26spage%3D175%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="note"><p class="first last">Percent inhibition of 296 kinases determined at Invitrogen for compound <b>3</b>; inhibition of >80% at 1 Î¼M observed for EGFR(T790M/L858R), EGFR(T790M), Jak2, Jak2 JH1/JH2, MAP4K4, Mink1, and Tyk2.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">â</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljNOpZ1HrJwbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Shultz, M. D.</span><span> </span><span class="NLM_article-title">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5980</span><span class="NLM_x">â</span> <span class="NLM_lpage">5991</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1016%2Fj.bmcl.2013.08.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=24018190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5980-5991&author=M.+D.+Shultz&title=Setting+expectations+in+molecular+optimizations%3A+Strengths+and+limitations+of+commonly+used+composite+parameters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5980-5991</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over the past 15 years there have been extensive efforts to understand and reduce the high attrition rates of drug candidates with an increased focus on physicochem. properties.  The fruits of this labor have been the generation of numerous efficiency indexes, metric-based rules and visualization tools to help guide medicinal chemists in the design of new compds. with more favorable properties.  This deluge of information may have had the unintended consequence of further obfuscating mol. optimizations by the inability of these scoring functions, rules and guides to reach a consensus on when a particular transformation is identified as beneficial.  In this manuscript, several composite parameters, or efficiency indexes, are examd. utilizing theor. and exptl. matched mol. pair analyses in order to understand the basis for how each will perform under varying scenarios of mol. optimizations.  In contrast to empirically derived composite parameters based on heavy atom count, lipophilic efficiency (LipE) sets consistent expectations regardless of mol. wt. or relative potency and can be used to generate consistent expectations for any matched mol. pair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJeTISXSJyLbVg90H21EOLACvtfcHk0ljNOpZ1HrJwbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI&md5=3b766e26254f482b75b8973888c13aec</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.029%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520expectations%2520in%2520molecular%2520optimizations%253A%2520Strengths%2520and%2520limitations%2520of%2520commonly%2520used%2520composite%2520parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5980%26epage%3D5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. H.</span><span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">â</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0ljNOpZ1HrJwbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="note"><p class="first last">PBD accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="note"><p class="first last">When compound <b>1</b> is modeled into the 1M17 wtEGFR structure, if the water molecule adjacent to the gatekeeper side chain is allowed to rotate, the carbonyl oxygen of compound <b>1</b> is within hydrogen-bonding distance (<3.0 Ã) of that water.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">â</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Ã resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0lgbPkRWoyXE8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="note"><p class="first last">Conformational searches were carried out in MacroModel 10.0, using the OPLS_2005 forcefield and mixed torsional/low-mode sampling for 1000 steps. Low-energy conformations within 1 kcal/mol of the global minimum for each molecule were compared, and the number of conformers around the amide bond was used as a proxy for the degrees of freedom.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="note"><p class="first last">A structure of compound <b>6</b> complexed with wtEGFR was not obtained. Neither of the two binding modes offers a hydrogen-bonding partner for Thr790; if recapitulated in wtEGFR, the binding mode for <b>6</b> observed in TMLR would displace the water molecule typically observed to solvate Thr854, while failing to provide a compensating interaction.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">A medicinal chemistâs guide to molecular interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5061</span><span class="NLM_x">â</span> <span class="NLM_lpage">5084</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100112j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5061-5084&author=C.+Bissantzauthor=B.+Kuhnauthor=M.+Stahl&title=A+medicinal+chemist%E2%80%99s+guide+to+molecular+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm100112j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100112j%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DA%2520medicinal%2520chemist%25E2%2580%2599s%2520guide%2520to%2520molecular%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5061%26epage%3D5084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="note"><p class="first last">See Table S3 of the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for PDB codes and measurements.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="note"><p class="first last">A total of 34 out of 531 (6%) kinases have equivalent Met + Thr residues and 27 out of 531 (5%) kinases have equivalent Met + Ser residues.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="note"><p class="first last">Electron density suggests that the catalytic Lys of CDK2 is acetylated in the complex with compound <b>8</b>; however, we believe that this artifact of the crystallization system should not impact the binding mode of this compound.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="note"><p class="first last">Percent inhibition of 219 kinases at 1 Î¼M determined at Invitrogen; kinases inhibited at > 80%: MAP4K4, MELK, Mink1, MST1, Rse.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><div class="note"><p class="first last">While pyrrolopyridine-based inhibitors have been reported to inhibit MPS1, compounds <b>9</b> and <b>10</b> inhibit MPS1 at only 24â27% when tested at 1 Î¼M (Invitrogen).</p></div><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAndrew, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijssen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span> </span><span class="NLM_article-title">Structure-based design of orally bioavailable 1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">10045</span><span class="NLM_x">â</span> <span class="NLM_lpage">10065</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401395s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=10045-10065&author=S.+Naudauthor=I.+M.+Westwoodauthor=A.+Faisalauthor=P.+Sheldrakeauthor=V.+Bavetsiasauthor=B.+Atrashauthor=K.+M.+Cheungauthor=M.+Liuauthor=A.+Hayesauthor=J.+Schmittauthor=A.+Woodauthor=V.+Choiauthor=K.+Boxallauthor=G.+Makauthor=M.+Gurdenauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=A.+Henleyauthor=R.+Bakerauthor=C.+McAndrewauthor=B.+Matijssenauthor=R.+Burkeauthor=S.+Hoelderauthor=S.+A.+Ecclesauthor=F.+I.+Raynaudauthor=S.+Linardopoulosauthor=R.+L.+van+Montfortauthor=J.+Blagg&title=Structure-based+design+of+orally+bioavailable+1H-pyrrolo%5B3%2C2-c%5Dpyridine+inhibitors+of+mitotic+kinase+monopolar+spindle+1+%28MPS1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm401395s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401395s%26sid%3Dliteratum%253Aachs%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DSheldrake%26aufirst%3DP.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DChoi%26aufirst%3DV.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DGurden%26aufirst%3DM.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DMcAndrew%26aufirst%3DC.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3DHoelder%26aufirst%3DS.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DStructure-based%2520design%2520of%2520orally%2520bioavailable%25201H-pyrrolo%255B3%252C2-c%255Dpyridine%2520inhibitors%2520of%2520mitotic%2520kinase%2520monopolar%2520spindle%25201%2520%2528MPS1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D10045%26epage%3D10065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="note"><p class="first last">Percent inhibition of 219 kinases at 1 Î¼M determined at Invitrogen; kinases inhibited at >80%: MAP4K4, Mink1, MST1, MST2, Rse.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">â</span> <span class="NLM_lpage">4785</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="note"><p class="first last">See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for experimental procedures.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinhababu, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh-Bakht, S. C.</span><span> </span><span class="NLM_article-title">Metabolic stability screen for drug discovery using cassette analysis and column switching</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">â</span> <span class="NLM_lpage">72</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.2174%2F187231207779814364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=19356021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=67-72&author=J.+S.+Halladayauthor=S.+Wongauthor=S.+M.+Jafferauthor=A.+K.+Sinhababuauthor=S.+C.+Khojasteh-Bakht&title=Metabolic+stability+screen+for+drug+discovery+using+cassette+analysis+and+column+switching"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic stability screen for drug discovery using cassette analysis and column switching</span></div><div class="casAuthors">Halladay, Jason S.; Wong, Susan; Jaffer, Sharmin M.; Sinhababu, Achintya K.; Khojasteh-Bakht, S. Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In vitro metabolic stability assays are used to screen compds. for stability in the presence of various drug metabolizing enzymes, usually cytochrome P 450 in liver prepns. (e.g., liver microsomes).  High-throughput metabolic stability assays using pooling methods have been developed to keep pace with screening requirements at the lead ADME optimization stage.  In our lab., we have improved the metabolic stability assay using the cassette anal. method, column switching, and incorporated time saving techniques in method development to yield a robust method which reduces data turnaround time, increases compd. throughput, and maximizes mass spectrometer usage.  This method can det. metabolic stability using microsomes or hepatocytes from any species.  We describe our findings following incubation of 40 different compds. with human liver microsomes and anal. by the cassette and discrete anal. methods.  Similar metabolic stability results were obtained using the cassette anal. and discrete anal. method.  An overall 70% time savings was achieved by pooling four new compds. into one sample for method development/MS optimization, cassetting four samples into one sample to minimize the no. of injections on LC/MS/MS anal., and using a column switching system to analyze the samples, which results in a two-fold decrease in the LC/MS/MS anal. time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKzVSm6sBe1bVg90H21EOLACvtfcHk0linOfbo70Ln3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D&md5=e00c66b3ca6a1eaee107c4eb81e07bf5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F187231207779814364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231207779814364%26sid%3Dliteratum%253Aachs%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DJaffer%26aufirst%3DS.%2BM.%26aulast%3DSinhababu%26aufirst%3DA.%2BK.%26aulast%3DKhojasteh-Bakht%26aufirst%3DS.%2BC.%26atitle%3DMetabolic%2520stability%2520screen%2520for%2520drug%2520discovery%2520using%2520cassette%2520analysis%2520and%2520column%2520switching%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2007%26volume%3D1%26spage%3D67%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span>Cambridge Crystallographic Database, Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, United Kingdom.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cambridge+Crystallographic+Database%2C+Cambridge+Crystallographic+Data+Centre%2C+12+Union+Road%2C+Cambridge+CB2+1EZ%2C+United+Kingdom."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span>Chemical Computing Group, Kaiser-Wilhelm-Ring 11, 50672 Koln, Germany.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chemical+Computing+Group%2C+Kaiser-Wilhelm-Ring+11%2C+50672+Koln%2C+Germany."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':[],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':[],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':[],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':[],'ref42':[],'ref43':['cit43'],'ref44':[],'ref45':[],'ref46':['cit46'],'ref47':[],'ref48':[],'ref49':[],'ref50':[],'ref51':['cit51'],'ref52':[],'ref53':['cit53'],'ref54':[],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 35 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Flocâh, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiao-E Yan, Pelin Ayaz, Su-Jie Zhu, Peng Zhao, Ling Liang, Casey H. Zhang, Ya-Chuang Wu, Je-Luen Li, Hwan Geun Choi, Xin Huang, Yibing Shan, David E. Shaw, <span class="NLM_string-name hlFld-ContribAuthor">Cai-Hong Yun</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis of AZD9291 Selectivity for EGFR T790M. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8502-8511. <a href="https://doi.org/10.1021/acs.jmedchem.0c00891" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00891</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00891%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bof%252BAZD9291%252BSelectivity%252Bfor%252BEGFR%252BT790M%26aulast%3DYan%26aufirst%3DXiao-E%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26052020%26date%3D03082020%26date%3D16072020%26volume%3D63%26issue%3D15%26spage%3D8502%26epage%3D8511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Harald Engelhardt, Dietrich BÃ¶se, Mark Petronczki, Dirk Scharn, Gerd Bader, Anke Baum, Andreas Bergner, Eugene Chong, Sandra DÃ¶bel, Georg Egger, Christian Engelhardt, Peter Ettmayer, Julian E. Fuchs, Thomas Gerstberger, Nina Gonnella, Andreas Grimm, Elisabeth Grondal, Nizar Haddad, Barbara Hopfgartner, Roland Kousek, Mariusz Krawiec, Monika Kriz, Lyne Lamarre, Joyce Leung, Moriz Mayer, Nitinchandra D. Patel, Biljana Peric Simov, Jonathan T. Reeves, Renate Schnitzer, Andreas Schrenk, Bernadette Sharps, Flavio Solca, Heinz StadtmÃ¼ller, Zhulin Tan, Tobias Wunberg, Andreas Zoephel, <span class="NLM_string-name hlFld-ContribAuthor">Darryl B. McConnell</span>. </span><span class="cited-content_cbyCitation_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10272-10293. <a href="https://doi.org/10.1021/acs.jmedchem.9b01169" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStart%252BSelective%252Band%252BRigidify%25253A%252BThe%252BDiscovery%252BPath%252Btoward%252Ba%252BNext%252BGeneration%252Bof%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DEngelhardt%26aufirst%3DHarald%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14082019%26date%3D13112019%26date%3D05112019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pirama
Nayagam Arunachalam, Prakasam Kuppusamy, Sivakumar Ganesan, Suresh Krishnamoorthy, Roshan Y. Nimje, Lokesh Babu Jarugu, Nanjundaswamy Kanikahalli Chikkananjaiah, China Anki Reddy, Prakash Anjanappa, Murali Botlagunta, Sridhar Vanteru, Nageswararao Maddala, Muniyappa Shankar, Satheesh Nair, John Hynes, Jr., Joseph B. Santella, III, Percy H. Carter, Richard Rampulla, Muthalagu Vetrichelvan, Anuradha Gupta, Arun Kumar Gupta, <span class="NLM_string-name hlFld-ContribAuthor">Arvind Mathur</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Scalable Synthesis for the Potent Kinase Inhibitor BMS-986236; 1-(5-(4-(3-Hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-4-(isopropylamino)pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (5)
                                     , 912-918. <a href="https://doi.org/10.1021/acs.oprd.9b00023" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00023%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BScalable%252BSynthesis%252Bfor%252Bthe%252BPotent%252BKinase%252BInhibitor%252BBMS-986236%25253B%252B1-%2525285-%2525284-%2525283-Hydroxy-3-methylbutyl%252529-1H-1%25252C2%25252C3-triazol-1-yl%252529-4-%252528isopropylamino%252529pyridin-2-yl%252529-1H-pyrazolo%25255B3%25252C4-b%25255Dpyridine-5-carbonitrile%26aulast%3DArunachalam%26aufirst%3DPirama%2BNayagam%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D16012019%26date%3D09042019%26date%3D27032019%26volume%3D23%26issue%3D5%26spage%3D912%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew T. Parsons, Michele Kubryk, Simon J. Hedley, Oliver R. Thiel, David Bauer, Matthew S. Potter-Racine, <span class="NLM_string-name hlFld-ContribAuthor">Zhenxin Lin</span>. </span><span class="cited-content_cbyCitation_article-title">An Improved Process for the Preparation of a Covalent Kinase Inhibitor through a CâN Bond-Forming SNAr Reaction. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (7)
                                     , 898-902. <a href="https://doi.org/10.1021/acs.oprd.8b00080" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00080%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DAn%252BImproved%252BProcess%252Bfor%252Bthe%252BPreparation%252Bof%252Ba%252BCovalent%252BKinase%252BInhibitor%252Bthrough%252Ba%252BC%2525E2%252580%252593N%252BBond-Forming%252BSNAr%252BReaction%26aulast%3DParsons%26aufirst%3DAndrew%2BT.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D20032018%26date%3D12062018%26volume%3D22%26issue%3D7%26spage%3D898%26epage%3D902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bryan K.  Chan</span>, <span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Krista K.  Bowman</span>, <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>, <span class="hlFld-ContribAuthor ">Daniel  Burdick</span>, <span class="hlFld-ContribAuthor ">Emily  Chan</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Saundra  Clausen</span>, <span class="hlFld-ContribAuthor ">Trisha  Dela Vega</span>, <span class="hlFld-ContribAuthor ">Jennafer  Dotson</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Richard L.  Elliott</span>, <span class="hlFld-ContribAuthor ">Robert A.  Heald</span>, <span class="hlFld-ContribAuthor ">Philip S.  Jackson</span>, <span class="hlFld-ContribAuthor ">Jamie D.  Knight</span>, <span class="hlFld-ContribAuthor ">Hank  La</span>, <span class="hlFld-ContribAuthor ">Michael D.  Lainchbury</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Hans E.  Purkey</span>, <span class="hlFld-ContribAuthor ">Gabriele  Schaefer</span>, <span class="hlFld-ContribAuthor ">Stephen  Schmidt</span>, <span class="hlFld-ContribAuthor ">Eileen M.  Seward</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Lily  Shao</span>, <span class="hlFld-ContribAuthor ">Shumei  Wang</span>, <span class="hlFld-ContribAuthor ">Siew Kuen  Yeap</span>, <span class="hlFld-ContribAuthor ">Ivana  Yen</span>, <span class="hlFld-ContribAuthor ">Christine  Yu</span>, and <span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (19)
                                     , 9080-9093. <a href="https://doi.org/10.1021/acs.jmedchem.6b00995" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00995%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BNoncovalent%25252C%252BMutant-Selective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%26aulast%3DChan%26aufirst%3DBryan%2BK.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D06072016%26date%3D12092016%26date%3D13102016%26date%3D26082016%26volume%3D59%26issue%3D19%26spage%3D9080%26epage%3D9093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Ruiz-Castillo</span> and <span class="hlFld-ContribAuthor ">Stephen L.  Buchwald</span>  . </span><span class="cited-content_cbyCitation_article-title">Applications of Palladium-Catalyzed CâN Cross-Coupling Reactions. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (19)
                                     , 12564-12649. <a href="https://doi.org/10.1021/acs.chemrev.6b00512" title="DOI URL">https://doi.org/10.1021/acs.chemrev.6b00512</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.6b00512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.6b00512%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DApplications%252Bof%252BPalladium-Catalyzed%252BC%2525E2%252580%252593N%252BCross-Coupling%252BReactions%26aulast%3DRuiz-Castillo%26aufirst%3DPaula%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03082016%26date%3D30092016%26date%3D12102016%26volume%3D116%26issue%3D19%26spage%3D12564%26epage%3D12649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6580-6594. <a href="https://doi.org/10.1021/acs.jmedchem.5b00840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChallenges%252Band%252BPerspectives%252Bon%252Bthe%252BDevelopment%252Bof%252BSmall-Molecule%252BEGFR%252BInhibitors%252Bagainst%252BT790M-Mediated%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D02062015%26date%3D26022016%26date%3D28072016%26date%3D16022016%26volume%3D59%26issue%3D14%26spage%3D6580%26epage%3D6594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James F.  Blake</span>, <span class="hlFld-ContribAuthor ">Michael  Burkard</span>, <span class="hlFld-ContribAuthor ">Jocelyn  Chan</span>, <span class="hlFld-ContribAuthor ">Huifen  Chen</span>, <span class="hlFld-ContribAuthor ">Kang-Jye  Chou</span>, <span class="hlFld-ContribAuthor ">Dolores  Diaz</span>, <span class="hlFld-ContribAuthor ">Danette A.  Dudley</span>, <span class="hlFld-ContribAuthor ">John J.  Gaudino</span>, <span class="hlFld-ContribAuthor ">Stephen E.  Gould</span>, <span class="hlFld-ContribAuthor ">Jonas  Grina</span>, <span class="hlFld-ContribAuthor ">Thomas  Hunsaker</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Matthew  Martinson</span>, <span class="hlFld-ContribAuthor ">David  Moreno</span>, <span class="hlFld-ContribAuthor ">Lars  Mueller</span>, <span class="hlFld-ContribAuthor ">Christine  Orr</span>, <span class="hlFld-ContribAuthor ">Patricia  Pacheco</span>, <span class="hlFld-ContribAuthor ">Ann  Qin</span>, <span class="hlFld-ContribAuthor ">Kevin  Rasor</span>, <span class="hlFld-ContribAuthor ">Li  Ren</span>, <span class="hlFld-ContribAuthor ">Kirk  Robarge</span>, <span class="hlFld-ContribAuthor ">Sheerin  Shahidi-Latham</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Stults</span>, <span class="hlFld-ContribAuthor ">Francis  Sullivan</span>, <span class="hlFld-ContribAuthor ">Weiru  Wang</span>, <span class="hlFld-ContribAuthor ">Jianping  Yin</span>, <span class="hlFld-ContribAuthor ">Aihe  Zhou</span>, <span class="hlFld-ContribAuthor ">Marcia  Belvin</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">John  Moffat</span>, and <span class="hlFld-ContribAuthor ">Jacob B.  Schwarz</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (12)
                                     , 5650-5660. <a href="https://doi.org/10.1021/acs.jmedchem.6b00389" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00389%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528S%252529-1-%2525281-%2525284-Chloro-3-fluorophenyl%252529-2-hydroxyethyl%252529-4-%2525282-%252528%2525281-methyl-1H-pyrazol-5-yl%252529amino%252529pyrimidin-4-yl%252529pyridin-2%2525281H%252529-one%252B%252528GDC-0994%252529%25252C%252Ban%252BExtracellular%252BSignal-Regulated%252BKinase%252B1%25252F2%252B%252528ERK1%25252F2%252529%252BInhibitor%252Bin%252BEarly%252BClinical%252BDevelopment%26aulast%3DBlake%26aufirst%3DJames%2BF.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D15032016%26date%3D07062016%26date%3D23062016%26date%3D26052016%26volume%3D59%26issue%3D12%26spage%3D5650%26epage%3D5660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Burdick</span>, <span class="hlFld-ContribAuthor ">Bryan K.  Chan</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Saundra  Clausen</span>, <span class="hlFld-ContribAuthor ">Jennafer  Dotson</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Richard  Elliott</span>, <span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Robert  Heald</span>, <span class="hlFld-ContribAuthor ">Philip  Jackson</span>, <span class="hlFld-ContribAuthor ">Hank  La</span>, <span class="hlFld-ContribAuthor ">Michael  Lainchbury</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Sam E.  Mann</span>, <span class="hlFld-ContribAuthor ">Hans E.  Purkey</span>, <span class="hlFld-ContribAuthor ">Gabriele  Schaefer</span>, <span class="hlFld-ContribAuthor ">Stephen  Schmidt</span>, <span class="hlFld-ContribAuthor ">Eileen  Seward</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Shumei  Wang</span>, <span class="hlFld-ContribAuthor ">Ivana  Yen</span>, <span class="hlFld-ContribAuthor ">Christine  Yu</span>, and <span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (1)
                                     , 100-104. <a href="https://doi.org/10.1021/acsmedchemlett.5b00428" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00428</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00428%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPyridones%252Bas%252BHighly%252BSelective%25252C%252BNoncovalent%252BInhibitors%252Bof%252BT790M%252BDouble%252BMutants%252Bof%252BEGFR%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D06112015%26date%3D17122015%26date%3D21122015%26date%3D14012016%26date%3D17122015%26volume%3D7%26issue%3D1%26spage%3D100%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Heald</span>, <span class="hlFld-ContribAuthor ">Krista K.  Bowman</span>, <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>, <span class="hlFld-ContribAuthor ">Daniel  Burdick</span>, <span class="hlFld-ContribAuthor ">Bryan  Chan</span>, <span class="hlFld-ContribAuthor ">Emily  Chan</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Saundra  Clausen</span>, <span class="hlFld-ContribAuthor ">Belen  Dominguez-Fernandez</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Richard  Elliott</span>, <span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Philip  Jackson</span>, <span class="hlFld-ContribAuthor ">Jamie  Knight</span>, <span class="hlFld-ContribAuthor ">Hank  La</span>, <span class="hlFld-ContribAuthor ">Michael  Lainchbury</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Sam  Mann</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">Kyle  Mortara</span>, <span class="hlFld-ContribAuthor ">Hans  Purkey</span>, <span class="hlFld-ContribAuthor ">Gabriele  Schaefer</span>, <span class="hlFld-ContribAuthor ">Stephen  Schmidt</span>, <span class="hlFld-ContribAuthor ">Eileen  Seward</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Lily  Shao</span>, <span class="hlFld-ContribAuthor ">Shumei  Wang</span>, <span class="hlFld-ContribAuthor ">Kuen  Yeap</span>, <span class="hlFld-ContribAuthor ">Ivana  Yen</span>, <span class="hlFld-ContribAuthor ">Christine  Yu</span>, and <span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (22)
                                     , 8877-8895. <a href="https://doi.org/10.1021/acs.jmedchem.5b01412" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01412</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01412%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNoncovalent%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%25253A%252BA%252BLead%252BOptimization%252BCase%252BStudy%26aulast%3DHeald%26aufirst%3DRobert%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D30062015%26date%3D12112015%26date%3D25112015%26date%3D10102015%26volume%3D58%26issue%3D22%26spage%3D8877%26epage%3D8895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>, <span class="hlFld-ContribAuthor ">Liping H.  Pettus</span>, <span class="hlFld-ContribAuthor ">Kate  Ashton</span>, <span class="hlFld-ContribAuthor ">James  Brown</span>, <span class="hlFld-ContribAuthor ">Jian Jeffrey  Chen</span>, <span class="hlFld-ContribAuthor ">Brad  Herberich</span>, <span class="hlFld-ContribAuthor ">Fang-Tsao  Hong</span>, <span class="hlFld-ContribAuthor ">Essa  Hu-Harrington</span>, <span class="hlFld-ContribAuthor ">Tom  Nguyen</span>, <span class="hlFld-ContribAuthor ">David J.  St. Jean, Jr.</span>, <span class="hlFld-ContribAuthor ">Seifu  Tadesse</span>, <span class="hlFld-ContribAuthor ">David  Bauer</span>, <span class="hlFld-ContribAuthor ">Michele  Kubryk</span>, <span class="hlFld-ContribAuthor ">Jinghui  Zhan</span>, <span class="hlFld-ContribAuthor ">Keegan  Cooke</span>, <span class="hlFld-ContribAuthor ">Petia  Mitchell</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Faye  Hsieh</span>, <span class="hlFld-ContribAuthor ">Dean  Hickman</span>, <span class="hlFld-ContribAuthor ">Nataraj  Kalyanaraman</span>, <span class="hlFld-ContribAuthor ">Tian  Wu</span>, <span class="hlFld-ContribAuthor ">Darren L.  Reid</span>, <span class="hlFld-ContribAuthor ">Edward K.  Lobenhofer</span>, <span class="hlFld-ContribAuthor ">Dina A.  Andrews</span>, <span class="hlFld-ContribAuthor ">Nancy  Everds</span>, <span class="hlFld-ContribAuthor ">Roberto  Guzman</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Parsons</span>, <span class="hlFld-ContribAuthor ">Simon J.  Hedley</span>, <span class="hlFld-ContribAuthor ">Jason  Tedrow</span>, <span class="hlFld-ContribAuthor ">Oliver R.  Thiel</span>, <span class="hlFld-ContribAuthor ">Matthew  Potter</span>, <span class="hlFld-ContribAuthor ">Robert  Radinsky</span>, <span class="hlFld-ContribAuthor ">Pedro J.  Beltran</span>, and <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>  . </span><span class="cited-content_cbyCitation_article-title">Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (9)
                                     , 987-992. <a href="https://doi.org/10.1021/acsmedchemlett.5b00193" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00193%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOxopyrido%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252BCovalent%252BL858R%25252FT790M%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%26aulast%3DWurz%26aufirst%3DRyan%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D08052015%26date%3D27072015%26date%3D31072015%26date%3D10092015%26date%3D27072015%26volume%3D6%26issue%3D9%26spage%3D987%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Athanasios  Papastathopoulos</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Lougiakis</span>, <span class="hlFld-ContribAuthor ">Ioannis K.  Kostakis</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Marakos</span>, <span class="hlFld-ContribAuthor ">Nicole  Pouli</span>, <span class="hlFld-ContribAuthor ">Harris  Pratsinis</span>, <span class="hlFld-ContribAuthor ">Dimitris  Kletsas</span>. </span><span class="cited-content_cbyCitation_article-title">New bioactive 5-arylcarboximidamidopyrazolo[3,4-c]pyridines: Synthesis, cytotoxic activity, mechanistic investigation and structure-activity relationships. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113387. <a href="https://doi.org/10.1016/j.ejmech.2021.113387" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113387</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113387%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bbioactive%252B5-arylcarboximidamidopyrazolo%25255B3%25252C4-c%25255Dpyridines%25253A%252BSynthesis%25252C%252Bcytotoxic%252Bactivity%25252C%252Bmechanistic%252Binvestigation%252Band%252Bstructure-activity%252Brelationships%26aulast%3DPapastathopoulos%26aufirst%3DAthanasios%26date%3D2021%26volume%3D218%26spage%3D113387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ravi  Saini</span>, <span class="hlFld-ContribAuthor ">Shehnaz  Fatima</span>, <span class="hlFld-ContribAuthor ">Subhash Mohan  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">TMLRpred: A machine learning classification model to distinguish reversible EGFR double mutant inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2020,</strong> <em>96 </em>
                                    (3)
                                     , 921-930. <a href="https://doi.org/10.1111/cbdd.13697" title="DOI URL">https://doi.org/10.1111/cbdd.13697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13697%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DTMLRpred%25253A%252BA%252Bmachine%252Blearning%252Bclassification%252Bmodel%252Bto%252Bdistinguish%252Breversible%252BEGFR%252Bdouble%252Bmutant%252Binhibitors%26aulast%3DSaini%26aufirst%3DRavi%26date%3D2020%26date%3D2020%26volume%3D96%26issue%3D3%26spage%3D921%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Laixue  Pang</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Lifei  Wang</span>, <span class="hlFld-ContribAuthor ">John Z. H.  Zhang</span>, <span class="hlFld-ContribAuthor ">Tong  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>38 </em>
                                    (4)
                                     , 985-996. <a href="https://doi.org/10.1080/07391102.2019.1591304" title="DOI URL">https://doi.org/10.1080/07391102.2019.1591304</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1591304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1591304%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DDecoding%252Bmolecular%252Bmechanism%252Bof%252Binhibitor%252Bbindings%252Bto%252BCDK2%252Busing%252Bmolecular%252Bdynamics%252Bsimulations%252Band%252Bbinding%252Bfree%252Benergy%252Bcalculations%26aulast%3DChen%26aufirst%3DJianzhong%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D4%26spage%3D985%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">LÃ­dia Moreira  Lima</span>, <span class="hlFld-ContribAuthor ">Maria LetÃ­cia  de Castro Barbosa</span>, <span class="hlFld-ContribAuthor ">Daniel Nascimento  do Amaral</span>, <span class="hlFld-ContribAuthor ">Eliezer J.  Barreiro</span>. </span><span class="cited-content_cbyCitation_article-title">Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 155-201. <a href="https://doi.org/10.1007/7355_2020_95" title="DOI URL">https://doi.org/10.1007/7355_2020_95</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_95%26sid%3Dliteratum%253Aachs%26atitle%3DCase%252BStudy%252Bon%252BReceptor%252BTyrosine%252BKinases%252BEGFR%25252C%252BVEGFR%25252C%252Band%252BPDGFR%26aulast%3DLima%26aufirst%3DL%25C3%25ADdia%2BMoreira%26date%3D2020%26date%3D2020%26spage%3D155%26epage%3D201%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Reversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 129-161. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00004-4" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00004-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00004-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00004-4%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BReversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D129%26epage%3D161%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yingjie  Jiao</span>, <span class="hlFld-ContribAuthor ">Fengzhe  Sun</span>, <span class="hlFld-ContribAuthor ">Xudong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Revisiting the molecular mechanism of acquired resistance to reversible tyrosine kinase inhibitors caused by EGFR gatekeeper T790M mutation in non-small-cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2018,</strong> <em>27 </em>
                                    (9)
                                     , 2160-2170. <a href="https://doi.org/10.1007/s00044-018-2224-7" title="DOI URL">https://doi.org/10.1007/s00044-018-2224-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-018-2224-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-018-2224-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DRevisiting%252Bthe%252Bmolecular%252Bmechanism%252Bof%252Bacquired%252Bresistance%252Bto%252Breversible%252Btyrosine%252Bkinase%252Binhibitors%252Bcaused%252Bby%252BEGFR%252Bgatekeeper%252BT790M%252Bmutation%252Bin%252Bnon-small-cell%252Blung%252Bcancer%26aulast%3DZhao%26aufirst%3DYan%26date%3D2018%26date%3D2018%26volume%3D27%26issue%3D9%26spage%3D2160%26epage%3D2170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuwei  Wang</span>, <span class="hlFld-ContribAuthor ">Huanling  Lai</span>, <span class="hlFld-ContribAuthor ">Xingxing  Fan</span>, <span class="hlFld-ContribAuthor ">Lianxiang  Luo</span>, <span class="hlFld-ContribAuthor ">Fugang  Duan</span>, <span class="hlFld-ContribAuthor ">Zebo  Jiang</span>, <span class="hlFld-ContribAuthor ">Qianqian  Wang</span>, <span class="hlFld-ContribAuthor ">Elaine Lai Han  Leung</span>, <span class="hlFld-ContribAuthor ">Liang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fphar.2018.00728" title="DOI URL">https://doi.org/10.3389/fphar.2018.00728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2018.00728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2018.00728%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DGossypol%252BInhibits%252BNon-small%252BCell%252BLung%252BCancer%252BCells%252BProliferation%252Bby%252BTargeting%252BEGFRL858R%25252FT790M%26aulast%3DWang%26aufirst%3DYuwei%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shehnaz  Fatima</span>, <span class="hlFld-ContribAuthor ">Subhash Mohan  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2018,</strong> <em>38 </em>
                                    (4)
                                     , 299-306. <a href="https://doi.org/10.1080/10799893.2018.1494740" title="DOI URL">https://doi.org/10.1080/10799893.2018.1494740</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2018.1494740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2018.1494740%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DUnraveling%252Bstructural%252Brequirements%252Bof%252Bamino-pyrimidine%252BT790M%25252FL858R%252Bdouble%252Bmutant%252BEGFR%252Binhibitors%25253A%252B2D%252Band%252B3D%252BQSAR%252Bstudy%26aulast%3DFatima%26aufirst%3DShehnaz%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D4%26spage%3D299%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaling  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Hongjiang  Xu</span>, <span class="hlFld-ContribAuthor ">Xiabing  Li</span>, <span class="hlFld-ContribAuthor ">Lijun  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Baolin  Li</span>, <span class="hlFld-ContribAuthor ">Xiquan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>147 </em>, 77-89. <a href="https://doi.org/10.1016/j.ejmech.2018.01.090" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.090%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D6%25252C7-Dimorpholinoalkoxy%252Bquinazoline%252Bderivatives%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bwith%252Benhanced%252Bantiproliferative%252Bactivities%252Bagainst%252Btumor%252Bcells%26aulast%3DZhang%26aufirst%3DYaling%26date%3D2018%26volume%3D147%26spage%3D77%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuting  Zhan</span>, <span class="hlFld-ContribAuthor ">Hongjing  Zang</span>, <span class="hlFld-ContribAuthor ">Juan  Feng</span>, <span class="hlFld-ContribAuthor ">Junmi  Lu</span>, <span class="hlFld-ContribAuthor ">Lingjiao  Chen</span>, <span class="hlFld-ContribAuthor ">Songqing  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Long non-coding RNAs associated with non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (40)
                                     , 69174-69184. <a href="https://doi.org/10.18632/oncotarget.20088" title="DOI URL">https://doi.org/10.18632/oncotarget.20088</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.20088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.20088%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DLong%252Bnon-coding%252BRNAs%252Bassociated%252Bwith%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DZhan%26aufirst%3DYuting%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D40%26spage%3D69174%26epage%3D69184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Golnaz  Bahramali</span>, <span class="hlFld-ContribAuthor ">Bahram  Goliaei</span>, <span class="hlFld-ContribAuthor ">Zarrin  Minuchehr</span>, <span class="hlFld-ContribAuthor ">Sayed-Amir  Marashi</span>. </span><span class="cited-content_cbyCitation_article-title">A network biology approach to understanding the importance of chameleon proteins in human physiology and pathology. </span><span class="cited-content_cbyCitation_journal-name">Amino Acids</span><span> <strong>2017,</strong> <em>49 </em>
                                    (2)
                                     , 303-315. <a href="https://doi.org/10.1007/s00726-016-2361-6" title="DOI URL">https://doi.org/10.1007/s00726-016-2361-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00726-016-2361-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00726-016-2361-6%26sid%3Dliteratum%253Aachs%26jtitle%3DAmino%2520Acids%26atitle%3DA%252Bnetwork%252Bbiology%252Bapproach%252Bto%252Bunderstanding%252Bthe%252Bimportance%252Bof%252Bchameleon%252Bproteins%252Bin%252Bhuman%252Bphysiology%252Band%252Bpathology%26aulast%3DBahramali%26aufirst%3DGolnaz%26date%3D2017%26date%3D2016%26volume%3D49%26issue%3D2%26spage%3D303%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zygmunt S.  Derewenda</span>, <span class="hlFld-ContribAuthor ">Adam  Godzik</span>. </span><span class="cited-content_cbyCitation_article-title">The âSticky Patchâ Model of Crystallization and Modification of Proteins for Enhanced Crystallizability. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 77-115. <a href="https://doi.org/10.1007/978-1-4939-7000-1_4" title="DOI URL">https://doi.org/10.1007/978-1-4939-7000-1_4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-7000-1_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-7000-1_4%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252B%2525E2%252580%25259CSticky%252BPatch%2525E2%252580%25259D%252BModel%252Bof%252BCrystallization%252Band%252BModification%252Bof%252BProteins%252Bfor%252BEnhanced%252BCrystallizability%26aulast%3DDerewenda%26aufirst%3DZygmunt%2BS.%26date%3D2017%26date%3D2017%26spage%3D77%26epage%3D115%26pub%3DSpringer%2520New%2520York%26atitle%3DProtein%252BCrystallography%26aulast%3DWlodawer%26aufirst%3DAlexander%26date%3D2017%26volume%3D1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">D.M.  Wilson</span>, <span class="hlFld-ContribAuthor ">J.G.  Kettle</span>, <span class="hlFld-ContribAuthor ">F.W.  Goldberg</span>, <span class="hlFld-ContribAuthor ">K.M.  Foote</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 39-75. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12391-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12391-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12391-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12391-1%26sid%3Dliteratum%253Aachs%26atitle%3DSelective%252BKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.A.%26date%3D2017%26spage%3D39%26epage%3D75%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R.A.  Ward</span>, <span class="hlFld-ContribAuthor ">M.R.V  Finlay</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Case History: Osimertinib (AZD9291). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-32. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12448-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12448-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12448-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12448-5%26sid%3Dliteratum%253Aachs%26atitle%3DMedicinal%252BChemistry%252BCase%252BHistory%25253A%252BOsimertinib%252B%252528AZD9291%252529%26aulast%3DWard%26aufirst%3DR.A.%26date%3D2017%26spage%3D1%26epage%3D32%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vassiliki  Giannouli</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Lougiakis</span>, <span class="hlFld-ContribAuthor ">Ioannis K.  Kostakis</span>, <span class="hlFld-ContribAuthor ">Nicole  Pouli</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Marakos</span>, <span class="hlFld-ContribAuthor ">Alexios-Leandros  Skaltsounis</span>, <span class="hlFld-ContribAuthor ">Sangkil  Nam</span>, <span class="hlFld-ContribAuthor ">Richard  Jove</span>, <span class="hlFld-ContribAuthor ">David  Horne</span>, <span class="hlFld-ContribAuthor ">Roxane  Tenta</span>, <span class="hlFld-ContribAuthor ">Harris  Pratsinis</span>, <span class="hlFld-ContribAuthor ">Dimitris  Kletsas</span>. </span><span class="cited-content_cbyCitation_article-title">The discovery of new cytotoxic pyrazolopyridine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (21)
                                     , 5229-5233. <a href="https://doi.org/10.1016/j.bmcl.2016.09.056" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.09.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.09.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.09.056%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DThe%252Bdiscovery%252Bof%252Bnew%252Bcytotoxic%252Bpyrazolopyridine%252Bderivatives%26aulast%3DGiannouli%26aufirst%3DVassiliki%26date%3D2016%26volume%3D26%26issue%3D21%26spage%3D5229%26epage%3D5233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Michailidou</span>, <span class="hlFld-ContribAuthor ">Vassiliki  Giannouli</span>, <span class="hlFld-ContribAuthor ">Vasilios  Kotsikoris</span>, <span class="hlFld-ContribAuthor ">Olga  Papadodima</span>, <span class="hlFld-ContribAuthor ">Georgia  Kontogianni</span>, <span class="hlFld-ContribAuthor ">Ioannis K.  Kostakis</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Lougiakis</span>, <span class="hlFld-ContribAuthor ">Aristotelis  Chatziioannou</span>, <span class="hlFld-ContribAuthor ">Fragiskos N.  Kolisis</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Marakos</span>, <span class="hlFld-ContribAuthor ">Nicole  Pouli</span>, <span class="hlFld-ContribAuthor ">Heleni  Loutrari</span>. </span><span class="cited-content_cbyCitation_article-title">Novel pyrazolopyridine derivatives as potential angiogenesis inhibitors: Synthesis, biological evaluation and transcriptome-based mechanistic analysis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>121 </em>, 143-157. <a href="https://doi.org/10.1016/j.ejmech.2016.05.035" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.05.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.05.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.05.035%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bpyrazolopyridine%252Bderivatives%252Bas%252Bpotential%252Bangiogenesis%252Binhibitors%25253A%252BSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Btranscriptome-based%252Bmechanistic%252Banalysis%26aulast%3DMichailidou%26aufirst%3DMaria%26date%3D2016%26volume%3D121%26spage%3D143%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pei-Liang  Zhao</span>, <span class="hlFld-ContribAuthor ">Yan-Hong  Li</span>, <span class="hlFld-ContribAuthor ">Hai-Kui  Yang</span>, <span class="hlFld-ContribAuthor ">Peng  Chen</span>, <span class="hlFld-ContribAuthor ">Bei  Zhang</span>, <span class="hlFld-ContribAuthor ">Qi  Sun</span>, <span class="hlFld-ContribAuthor ">Qiu  Li</span>, <span class="hlFld-ContribAuthor ">Wen-Wei  You</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antiproliferative activity of novel 5-nitropyrimidine-2,4-diamine derivatives bearing alkyl acetate moiety. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>118 </em>, 161-169. <a href="https://doi.org/10.1016/j.ejmech.2016.04.038" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.038%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantiproliferative%252Bactivity%252Bof%252Bnovel%252B5-nitropyrimidine-2%25252C4-diamine%252Bderivatives%252Bbearing%252Balkyl%252Bacetate%252Bmoiety%26aulast%3DZhao%26aufirst%3DPei-Liang%26date%3D2016%26volume%3D118%26spage%3D161%26epage%3D169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sang Min  Lim</span>, <span class="hlFld-ContribAuthor ">Yujeong  Jeong</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (8)
                                     , 853-878. <a href="https://doi.org/10.4155/fmc-2016-0019" title="DOI URL">https://doi.org/10.4155/fmc-2016-0019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0019%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DStrategies%252Bto%252Bovercome%252Bacquired%252Bresistances%252Bconferred%252Bby%252Bmutations%252Bin%252Bthe%252Bkinase%252Bdomain%252Bof%252BEGFR%26aulast%3DLim%26aufirst%3DSang%2BMin%26date%3D2016%26volume%3D8%26issue%3D8%26spage%3D853%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepak  Bararia</span>, <span class="hlFld-ContribAuthor ">Hui Si  Kwok</span>, <span class="hlFld-ContribAuthor ">Robert S.  Welner</span>, <span class="hlFld-ContribAuthor ">Akihiko  Numata</span>, <span class="hlFld-ContribAuthor ">MenyhÃ¡rt B.  SÃ¡rosi</span>, <span class="hlFld-ContribAuthor ">Henry  Yang</span>, <span class="hlFld-ContribAuthor ">Sheena  Wee</span>, <span class="hlFld-ContribAuthor ">Sebastian  Tschuri</span>, <span class="hlFld-ContribAuthor ">Debleena  Ray</span>, <span class="hlFld-ContribAuthor ">Oliver  Weigert</span>, <span class="hlFld-ContribAuthor ">Elena  Levantini</span>, <span class="hlFld-ContribAuthor ">Alexander K.  Ebralidze</span>, <span class="hlFld-ContribAuthor ">Jayantha  Gunaratne</span>, <span class="hlFld-ContribAuthor ">Daniel G.  Tenen</span>. </span><span class="cited-content_cbyCitation_article-title">Acetylation of C/EBPÎ± inhibits its granulopoietic function. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2016,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/ncomms10968" title="DOI URL">https://doi.org/10.1038/ncomms10968</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/ncomms10968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fncomms10968%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DAcetylation%252Bof%252BC%25252FEBP%2525CE%2525B1%252Binhibits%252Bits%252Bgranulopoietic%252Bfunction%26aulast%3DBararia%26aufirst%3DDeepak%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Matt  Baumgardner</span>, <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Peter  Fan</span>, <span class="hlFld-ContribAuthor ">Xiao-Hui  Gu</span>, <span class="hlFld-ContribAuthor ">Hank  La</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Hans E.  Purkey</span>, <span class="hlFld-ContribAuthor ">Gabriele  Schaefer</span>, <span class="hlFld-ContribAuthor ">Stephen  Schmidt</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Ivana  Yen</span>, <span class="hlFld-ContribAuthor ">Christine  Yu</span>, <span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>. </span><span class="cited-content_cbyCitation_article-title">4-Aminoindazolyl-dihydrofuro[3,4- d ]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (2)
                                     , 534-539. <a href="https://doi.org/10.1016/j.bmcl.2015.11.078" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.11.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.11.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.11.078%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D4-Aminoindazolyl-dihydrofuro%25255B3%25252C4-%252Bd%252B%25255Dpyrimidines%252Bas%252Bnon-covalent%252Binhibitors%252Bof%252Bmutant%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Btyrosine%252Bkinase%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D534%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mindy I.  Davis</span>, <span class="hlFld-ContribAuthor ">Anton  Simeonov</span>, <span class="hlFld-ContribAuthor ">Wendy  Lea</span>, <span class="hlFld-ContribAuthor ">Doug  Auld</span>. </span><span class="cited-content_cbyCitation_article-title">Literature Search and Review. </span><span class="cited-content_cbyCitation_journal-name">ASSAY and Drug Development Technologies</span><span> <strong>2015,</strong> <em>13 </em>
                                    (3)
                                     , 147-154. <a href="https://doi.org/10.1089/adt.2015.1303.lr" title="DOI URL">https://doi.org/10.1089/adt.2015.1303.lr</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/adt.2015.1303.lr&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fadt.2015.1303.lr%26sid%3Dliteratum%253Aachs%26jtitle%3DASSAY%2520and%2520Drug%2520Development%2520Technologies%26atitle%3DLiterature%252BSearch%252Band%252BReview%26aulast%3DDavis%26aufirst%3DMindy%2BI.%26date%3D2015%26volume%3D13%26issue%3D3%26spage%3D147%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0015.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) X-ray structure of compound <b>1</b> complexed with TMLR and (b) overlay of <b>1</b> (green) and erlotinib (magenta) complexed with wtEGFR (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>)<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0016.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of the bicyclic motif.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0017.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structures of <b>4</b> (green) and <b>5</b> (magenta) complexed with TMLR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0018.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. a) X-ray structure of <b>6</b> complexed with TMLR and (b) overlay of ligands <b>5</b> (magenta) and <b>6</b> (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0019.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. The centroid shift describes the distance within the plane of a sulfur atom from the center of the aromatic ring. (a) PyrimidineÂ·Â·Â·Met790 geometry observed in the <b>6</b>/TMLR complex: centroid shift â 1.375 Ã, height â 3.34 Ã measured roughly perpendicular to the plane at 92.9Â°. (b) Distribution of gatekeeper methionine sulfur in the proximity of a ligand aromatic ring for methionine-gatekeeper kinases in the PDB.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0001.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Models of <b>4</b> (a, green), <b>5</b> (b, magenta) and <b>6</b> (b, blue) in the Jak2 active site (PBD ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4hge">4hge</a>), with the protein surface colored according to lipophilicity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0002.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of <b>8</b> complexed with (a) TMLR and (b) CDK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>4</b>â<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) polyphosphoric acid, 200 Â°C, 18 h, quant.; (b) sodium hydride, SEM-Cl, THF, DMF, rt, 2 h, 81%; (c) iodine monochloride, NaOAc, HOAc, 70 Â°C, 18 h, 34%; (d) methanesulfonyl chloride, triethylamine, DCM, 0 Â°C to rt, 2 h, 46%; (e) 4-ethynyl-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, triethylamine, DMF, 50â100 Â°C, 33%; (f) 4-ethynyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, triethylamine, DMF, 50â100 Â°C, 34%; (g) NaH, SEM-Cl, THF, 0 Â°C to rt, 5 h, 36%; (h) 2-iodopropane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 Â°C, 48 h, 40%; (i) 4-methoxypiperidine hydrochloride, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 120 Â°C, 18 h, 87%; (j) <b>16</b>, <b>20a</b>, or <b>20b</b>, Pd<sub>2</sub>dba<sub>3</sub>, X-Phos or Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 120 Â°C, 28â81%; (k) HCl, MeOH, rt to 50 Â°C, 22â76%.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>7</b> and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-iodopropane or iodocyclopentane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 Â°C, 18â20 h, 56â90%; (b) <b>22</b>, chloro[[BrettPhos][2-(2-aminoethylphenyl)palladium(II)]]/[BrettPhos], NaOtBu, tBuOH, 90 Â°C, 5 h, 33â49%.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compound <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) isopropylamine, triethylamine, THF, rt, 3 h, quant.; (b) <b>22</b>, Pd<sub>2</sub>dba<sub>3</sub>, X-Phos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, reflux, 3 h, 72%; (c) Pd/C, EtOAc, MeOH, H<sub>2</sub>, rt, 18 h, 92%; (d) trimethyl orthoformate, formic acid, 100 Â°C, 1 h, 27%.</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/medium/jm-2014-01578n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501578n/20151110/images/large/jm-2014-01578n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501578n&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CuCl, <i>tert</i>-butyl nitrite, acetonitrile, 50 Â°C to reflux, 1 h, 72%; (b) palladium(II) acetate, triethylamine, MeOH, CO, 60 Â°C, 18 h, 47%; (c) diisobutylaluminum hydride, DCM, â78 Â°C, 1 h, 55%; (d) hydrazine hydrate, triethylamine, dioxane, reflux, 3 d, 34%; (e) iodine, potassium hydroxide, DMF, 40 C, 16 h; (f) 2-iodopropane, sodium hydride, DMF, rt, 16 h, 44% over two steps; (g) diphenylmethanimine, Pd<sub>2</sub>dba<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 90 Â°C, 3 h, 58%; (h) <b>22</b>, Pd<sub>2</sub>dba<sub>3</sub>, X-Phos or Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 Â°C, 2 h, 57%; (i) HCl, dioxane, rt, 0.5 h, 60%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 57 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Oncogene addiction: Setting the stage for molecularly targeted cancer therapy</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3214</span><span class="NLM_x">â</span> <span class="NLM_lpage">3231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1101%2Fgad.1609907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=18079171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrsb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=3214-3231&author=S.+V.+Sharmaauthor=J.+Settleman&title=Oncogene+addiction%3A+Setting+the+stage+for+molecularly+targeted+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene addiction: setting the stage for molecularly targeted cancer therapy</span></div><div class="casAuthors">Sharma, Sreenath V.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3214-3231</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first punch setting the stage and the second delivering the knock-out.  This analogy can be extended to molecularly targeted cancer therapies, with oncogene addiction serving to set the stage for tumor cell killing by a targeted therapeutic agent.  While in vitro and in vivo examples abound documenting the existence of this phenomenon, the mechanistic underpinnings that govern oncogene addiction are just beginning to emerge.  Our current inability to fully exploit this weakness of cancer cells stems from an incomplete understanding of oncogene addiction, which nonetheless represents one of the rare chinks in the formidable armor of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk4ia5nlRCDbVg90H21EOLACvtfcHk0lg9hTqBlMnl7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrsb7J&md5=e367eb201f849ecac6c29ce7f80138fa</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1101%2Fgad.1609907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1609907%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DOncogene%2520addiction%253A%2520Setting%2520the%2520stage%2520for%2520molecularly%2520targeted%2520cancer%2520therapy%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D3214%26epage%3D3231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">â</span> <span class="NLM_lpage">1167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7241</span><span class="NLM_x">â</span> <span class="NLM_lpage">7244</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7241-7244&author=S.+Tracyauthor=T.+Mukoharaauthor=M.+Hansenauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=P.+A.+Janne&title=Gefitinib+induces+apoptosis+in+the+EGFRL858R+non-small-cell+lung+cancer+cell+line+H3255"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DMukohara%26aufirst%3DT.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DGefitinib%2520induces%2520apoptosis%2520in%2520the%2520EGFRL858R%2520non-small-cell%2520lung%2520cancer%2520cell%2520line%2520H3255%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7241%26epage%3D7244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Inhibition of EGFR signaling: All mutations are not created equal</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">e377</span><span class="NLM_x">) </span> <span class="NLM_fpage">1085</span><span class="NLM_x">â</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=1085-1087&issue=e377&author=A.+F.+Gazdarauthor=J.+D.+Minna&title=Inhibition+of+EGFR+signaling%3A+All+mutations+are+not+created+equal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DInhibition%2520of%2520EGFR%2520signaling%253A%2520All%2520mutations%2520are%2520not%2520created%2520equal%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26issue%3De377%26spage%3D1085%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lh_eoDrbXKQiA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">â</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lhmWnPxIrVSyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">â</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+Correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lhmWnPxIrVSyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520Correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ânever smokersâ and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">â</span> <span class="NLM_lpage">13311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Jackman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cioffredi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5267</span><span class="NLM_x">â</span> <span class="NLM_lpage">5273</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1078-0432.CCR-09-0888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=19671843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFeitLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5267-5273&author=D.+M.+Jackmanauthor=V.+A.+Millerauthor=L.+A.+Cioffrediauthor=B.+Y.+Yeapauthor=P.+A.+Janneauthor=G.+J.+Rielyauthor=M.+G.+Ruizauthor=G.+Giacconeauthor=L.+V.+Sequistauthor=B.+E.+Johnson&title=Impact+of+epidermal+growth+factor+receptor+and+KRAS+mutations+on+clinical+outcomes+in+previously+untreated+non-small+cell+lung+cancer+patients%3A+Results+of+an+online+tumor+registry+of+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online Tumor registry of clinical trials</span></div><div class="casAuthors">Jackman, David M.; Miller, Vincent A.; Cioffredi, Leigh-Anne; Yeap, Beow Y.; Jaenne, Pasi A.; Riely, Gregory J.; Ruiz, Marielle Gallegos; Giaccone, Giuseppe; Sequist, Lecia V.; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5267-5273</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on outcomes with erlotinib or gefitinib therapy continues to be debated.  This study combines patient data from five trials in predominantly Western populations to assess the impact of EGFR and KRAS mutations on first-line therapy with an EGFR-tyrosine kinase inhibitor (TKI) and compare clin. vs. mol. predictors of sensitivity.  Chemotherapy-naive patients with advanced non-small cell lung cancer and known EGFR mutation status treated with erlotinib or gefitinib monotherapy as part of a clin. trial were eligible for inclusion.  Patients received daily erlotinib (150 mg) or gefitinib (250 mg) until disease progression or unacceptable toxicity.  Data were collected in a password-protected web database.  Clin. outcomes were analyzed to look for differences based on EGFR and KRAS genotypes, as well as clin. characteristics.  Patients (223) from five clin. trials were included.  Sensitizing EGFR mutations were assocd. with a 67% response rate, time to progression (TTP) of 11.8 mo, and overall survival of 23.9 mo.  Exon 19 deletions were assocd. with longer median TTP and overall survival compared with L858R mutations.  Wild-type EGFR was assocd. with poorer outcomes (response rate, 3%; TTP, 3.2 mo) irresp. of KRAS status.  No difference in outcome was seen between patients harboring KRAS transition vs. transversion mutations.  EGFR genotype was more effective than clin. characteristics at selecting appropriate patients for consideration of first-line therapy with an EGFR-TKI.  EGFR mutation status is assocd. with sensitivity to treatment with an EGFR-TKI in patients with advanced non-small cell lung cancer.  Patients harboring sensitizing EGFR mutations should be considered for first-line erlotinib or gefitinib. (Clin Cancer Res 2009;15(16):5267-73).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUmIDiCjeVvrVg90H21EOLACvtfcHk0lgfXdelGi6iwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFeitLs%253D&md5=2d9669c6e4c396d632424c1c0190868c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0888%26sid%3Dliteratum%253Aachs%26aulast%3DJackman%26aufirst%3DD.%2BM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCioffredi%26aufirst%3DL.%2BA.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DRuiz%26aufirst%3DM.%2BG.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DImpact%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520KRAS%2520mutations%2520on%2520clinical%2520outcomes%2520in%2520previously%2520untreated%2520non-small%2520cell%2520lung%2520cancer%2520patients%253A%2520Results%2520of%2520an%2520online%2520tumor%2520registry%2520of%2520clinical%2520trials%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5267%26epage%3D5273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vivanco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Larriba, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertran-Alamillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span> </span><span class="NLM_article-title">Screening for epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">958</span><span class="NLM_x">â</span> <span class="NLM_lpage">967</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1056%2FNEJMoa0904554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=19692684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=958-967&author=R.+Rosellauthor=T.+Moranauthor=C.+Queraltauthor=R.+Portaauthor=F.+Cardenalauthor=C.+Campsauthor=M.+Majemauthor=G.+Lopez-Vivancoauthor=D.+Islaauthor=M.+Provencioauthor=A.+Insaauthor=B.+Massutiauthor=J.+L.+Gonzalez-Larribaauthor=L.+Paz-Aresauthor=I.+Boverauthor=R.+Garcia-Campeloauthor=M.+A.+Morenoauthor=S.+Catotauthor=C.+Rolfoauthor=N.+Reguartauthor=R.+Palmeroauthor=J.+M.+Sanchezauthor=R.+Bastusauthor=C.+Mayoauthor=J.+Bertran-Alamilloauthor=M.+A.+Molinaauthor=J.+J.+Sanchezauthor=M.+Taron&title=Screening+for+epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Screening for epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Rosell, Rafael; Moran, Teresa; Queralt, Cristina; Porta, Rut; Cardenal, Felipe; Camps, Carlos; Majem, Margarita; Lopez-Vivanco, Guillermo; Isla, Dolores; Provencio, Mariano; Insa, Amelia; Massuti, Bartomeu; Gonzalez-Larriba, Jose Luis; Paz-Ares, Luis; Bover, Isabel; Garcia-Campelo, Rosario; Moreno, Miguel Angel; Catot, Silvia; Rolfo, Christian; Reguart, Noemi; Palmero, Ramon; Sanchez, Jose Miguel; Bastus, Roman; Mayo, Clara; Bertran-Alamillo, Jordi; Molina, Miguel Angel; Sanchez, Jose Javier; Taron, Miquel; Cuello, M.; Pallares, C.; Lianes, P.; Remon, J.; Ibeas, R.; Martinez del Prado, P.; Angeles Sala, M.; Santander-Lobera, C.; Velez de Mendizabal, E.; Vinolas, N.; Terrasa, J.; Valdivia, J.; Diz, P.; Jimenez-Berlana, U.; Velasco-Ortiz de Taranco, A.; Ales Martinez, E.; Sanchez-Escribano, R.; Carrato, A.; Guillen-Ponce, C.; Mesia, C.; Antonio Macias, J.; Lopez-Brea, M.; Oramas, J.; Barneto, I.; Garrido, P.; Mayol, M. J.; Lopez, A.; Artal, A.; Saenz, A.; Hernando, S.; Cobo, M.; Blanco, R.; Bernabe, R.; Guillem, V.; Angel Munoz, M.; Maestu, I.; Salvatierra, A.; De Las Penas, R.; Alfaro, J.; Alberola, V.; Juan, O.; Martin, C.; Puertas, J.; Felip, E.; Gonzalez-Gonzalez, J. F.; Iglesias-Docampo, L.; Dorta, F. J.; Martinez-Aguillo, M.; Salgado, E.; Mesia, R.; Lastra-Aras, E.; Garcia-Munoz, J. P.; Lastra, R.; Alvarez, I.; Roig, J.; Oruezabal, J.; Poveda, A.; Lavernia, J.; Gutierrez, D.; Filipovich, E.; Aguiar, D.; Rodriguez, D.; Buxo, J.; Cardona, A. F.; Bes, P.; Paredes, A.; Tortorella, A. M.; Moreno, J. A.; Martinez-Garcia, J.; Alonso, J. L.; Lopez-Martin, A.; Echarri-Gonzalez, M. J.; Van Kooten, M.; Guerrero, A.; Domine, M.; Diaz, I.; Heras, L.; Garcia, R.; Anton, I.; Jarchum, G.; Bartolucci, R. E.; Lomas, M.; Rubiales, A.; Duque, J. L.; Escriva de Romani, S.; Barbeta, E.; Reina, J. J.; Castro, J.; Belda, C.; Vidal, J. M.; Trigo, J. M.; Vadell, C.; Zarba, J. J.; Esunza, P.; Garau, I.; Lopez-Pousa, A.; De la Gandara, I.; Widakowich, J.; Morales, S.; Martinez, M.; Luis, R.; de la Colina, M.; Calzas, J.; Garcia-Castro, I.; Ruiz, C.; Lopez-Criado, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">958-967</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer.  We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the assocn. between the mutations and the outcome of erlotinib treatment.  From Apr. 2005 through Nov. 2008, lung cancers from 2105 patients in 129 institutions in Spain were screened for EGFR mutations.  The anal. was performed in a central lab.  Patients with tumors carrying EGFR mutations were eligible for erlotinib treatment.  EGFR mutations were found in 350 of 2105 patients (16.6%).  Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%) (P < 0.001 for all comparisons).  The mutations were deletions in exon 19 (62.2%) and L858R (37.8%).  Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 mo and 27 mo, resp.  The adjusted hazard ratios for the duration of progression-free survival were 2.94 for men (P < 0.001); 1.92 for the presence of the L858R mutation, as compared with a deletion in exon 19 (P = 0.02); and 1.68 for the presence of the L858R mutation in paired serum DNA, as compared with the absence of the mutation (P = 0.02).  The most common adverse events were mild rashes and diarrhea; grade 3 cutaneous toxic effects were recorded in 16 patients (7.4%) and grade 3 diarrhea in 8 patients (3.7%).  Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvZWnSnU_ScbVg90H21EOLACvtfcHk0lgfXdelGi6iwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M&md5=288ea35bd5201579d8c89ad6d7c4306a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904554%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCardenal%26aufirst%3DF.%26aulast%3DCamps%26aufirst%3DC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DGonzalez-Larriba%26aufirst%3DJ.%2BL.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DCatot%26aufirst%3DS.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DBastus%26aufirst%3DR.%26aulast%3DMayo%26aufirst%3DC.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DTaron%26aufirst%3DM.%26atitle%3DScreening%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D958%26epage%3D967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">â</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+biologically+based+treatment+of+EGFR-mutant+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0ljiMO8FvybHLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520biologically%2520based%2520treatment%2520of%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">â</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljiMO8FvybHLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">e73</span><span class="NLM_x">) </span> <span class="NLM_fpage">225</span><span class="NLM_x">â</span> <span class="NLM_lpage">235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=225-235&issue=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26issue%3De73%26spage%3D225%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Balak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouerfelli, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6494</span><span class="NLM_x">â</span> <span class="NLM_lpage">6501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1078-0432.CCR-06-1570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17085664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6494-6501&author=M.+N.+Balakauthor=Y.+Gongauthor=G.+J.+Rielyauthor=R.+Somwarauthor=A.+R.+Liauthor=M.+F.+Zakowskiauthor=A.+Chiangauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=Novel+D761Y+and+common+secondary+T790M+mutations+in+epidermal+growth+factor+receptor-mutant+lung+adenocarcinomas+with+acquired+resistance+to+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors</span></div><div class="casAuthors">Balak, Marissa N.; Gong, Yixuan; Riely, Gregory J.; Somwar, Romel; Li, Allan R.; Zakowski, Maureen F.; Chiang, Anne; Yang, Guangli; Ouerfelli, Ouathek; Kris, Mark G.; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6494-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been assocd. with a second-site EGFR mutation, which leads to substitution of methionine for threonine at position 790 (T790M).  We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy.  Exptl. Design: Tumor cells from patients with acquired resistance were examd. for secondary EGFR kinase domain mutations by mol. analyses.  RESULTS: Eight of 16 patients (50% obsd. rate; 95% confidence interval, 25-75%) had tumor cells with second-site EGFR mutations.  Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.  When combined with a drug-sensitive L858R mutation, the D761Y mutation modestly reduced the sensitivity of mutant EGFR to TKIs in both surrogate kinase and cell viability assays.  In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.  CONCLUSIONS: The T790M mutation is common in patients with acquired resistance.  The limited spectrum of TKI-resistant mutations in EGFR, which binds to erlotinib in the active conformation, contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib, which binds to ABL and KIT, resp., in closed conformations.  Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anat. site and mode of binding to the kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeHDQldYeDLVg90H21EOLACvtfcHk0lhR39CYAJ9o5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI&md5=e817eb717673081d89ec3d58a04a7d4d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBalak%26aufirst%3DM.%2BN.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNovel%2520D761Y%2520and%2520common%2520secondary%2520T790M%2520mutations%2520in%2520epidermal%2520growth%2520factor%2520receptor-mutant%2520lung%2520adenocarcinomas%2520with%2520acquired%2520resistance%2520to%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6494%26epage%3D6501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuboi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span> </span><span class="NLM_article-title">Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">5764</span><span class="NLM_x">â</span> <span class="NLM_lpage">5769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1078-0432.CCR-06-0714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17020982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVartbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5764-5769&author=T.+Kosakaauthor=Y.+Yatabeauthor=H.+Endohauthor=K.+Yoshidaauthor=T.+Hidaauthor=M.+Tsuboiauthor=H.+Tadaauthor=H.+Kuwanoauthor=T.+Mitsudomi&title=Analysis+of+epidermal+growth+factor+receptor+gene+mutation+in+patients+with+non-small+cell+lung+cancer+and+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib</span></div><div class="casAuthors">Kosaka, Takayuki; Yatabe, Yasushi; Endoh, Hideki; Yoshida, Kimihide; Hida, Toyoaki; Tsuboi, Masahiro; Tada, Hirohito; Kuwano, Hiroyuki; Mitsudomi, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5764-5769</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Non-small cell lung cancers carrying activating mutations in the gene for the epidermal growth factor receptor (EGFR) are highly sensitive to EGFR-specific tyrosine kinase inhibitors.  However, most patients who initially respond subsequently experience disease progression while still on treatment.  Part of this "acquired resistance" is attributable to a secondary mutation resulting in threonine to methionine at codon 790 (T790M) of EGFR.  Exptl. Design: We sequenced exons 18 to 21 of the EGFR gene to look for secondary mutations in tumors with acquired resistance to gefitinib in 14 patients with adenocarcinomas.  Subcloning or cycleave PCR was used in addn. to normal sequencing to increase the sensitivity of the assay.  We also looked for T790M in pretreatment samples from 52 patients who were treated with gefitinib.  We also looked for secondary KRAS gene mutations because tumors with KRAS mutations are generally resistant to tyrosine kinase inhibitors.  RESULTS: Seven of 14 tumors had a secondary T790M mutation.  There were no other novel secondary mutations.  We detected no T790M mutations in pretreatment specimens from available five tumors among these seven tumors.  Patients with T790M tended to be women, never smokers, and carrying deletion mutations, but the T790M was not assocd. with the duration of gefitinib administration.  None of the tumors had an acquired mutation in the KRAS gene.  CONCLUSIONS: A secondary T790M mutation of EGFR accounted for half the tumors with acquired resistance to gefitinib in Japanese patients.  Other drug-resistant secondary mutations are uncommon in the EGFR gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZou5KHFws9bVg90H21EOLACvtfcHk0lieJsinGD8UVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVartbvL&md5=331c3e60cb4470484b418ee1b9a80674</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0714%26sid%3Dliteratum%253Aachs%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DEndoh%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DTsuboi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DKuwano%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DAnalysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520gene%2520mutation%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5764%26epage%3D5769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">â</span> <span class="NLM_lpage">2247</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lieJsinGD8UVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">â</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0lieJsinGD8UVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">â</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: The new wave of BCR-ABL inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrd2324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17853901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Flying+under+the+radar%3A+The+new+wave+of+BCR-ABL+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Flying under the radar: the new wave of BCR-ABL inhibitors</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">834-848</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia caused by the mutant BCR-ABL kinase has been successfully treated with inhibitors of this kinase, such as imatinib, but mutations within the kinase can result in resistance to these drugs.  Quintas-Cardama and colleagues discuss novel BCR-ABL inhibitors that have the potential to overcome such resistance.  The introduction of the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis) revolutionized the treatment of chronic myeloid leukemia (CML).  However, most patients with CML receiving imatinib still harbor mol. residual disease and some develop resistance assocd. with ABL kinase domain mutations.  The second-generation BCR-ABL inhibitors nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) have shown significant activity after imatinib failure in clin. trials, but still face similar obstacles to imatinib, including negligible activity against the frequent BCR-ABL T315I mutation and modest effects in advanced phases of CML.  Various medicinal chem. efforts, in part aided by structural studies of the ABL kinase-imatinib complex have resulted in the synthesis of a new generation of BCR-ABL inhibitors, some of which have shown encouraging preliminary activity in clin. trials, including against T315I mutants.  Here, we discuss these emerging therapies, which have the potential to improve the outcome of patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2DBi1E-INLVg90H21EOLACvtfcHk0lg-fp63WjPLUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ&md5=6a8692cd0405f77256df82ae7de21e18</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd2324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2324%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520The%2520new%2520wave%2520of%2520BCR-ABL%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D834%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="note"><p class="first last">Erlotinib activity in biochemical assays: wtEGFR <i>K</i><sub>i</sub> = 0.1 nM, EGFR(L858R) <i>K</i><sub>i</sub> = 0.3 nM, EGFR(d746â750) <i>K</i><sub>i</sub> = 0.1 nM, EGFR(T790M/L858R) <i>K</i><sub>i</sub> = 123 nM, and EGFR(T790M/d746â750) <i>K</i><sub>i</sub> = 95 nM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">â</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lg-fp63WjPLUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Janne, P. A.; Schellens, J. H.; Engelman, J. A.; Eckhardt, S. G.; Millham, R.; Denis, L. J.; Britten, C. D.; Wong, S. G.; Boss, D. S.; Camidge, D. R.</span><span> </span><span class="NLM_article-title">Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span>, (May 20 suppl; abstr 8027).</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1200%2FJCO.2007.14.7611" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&author=P.+A.+Janne&author=J.+H.+Schellens&author=J.+A.+Engelman&author=S.+G.+Eckhardt&author=R.+Millham&author=L.+J.+Denis&author=C.+D.+Britten&author=S.+G.+Wong&author=D.+S.+Boss&author=D.+R.+Camidge&title=Preliminary+activity+and+safety+results+from+a+phase+I+clinical+trial+of+PF-00299804%2C+an+irreversible+pan-HER+inhibitor%2C+in+patients+%28pts%29+with+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.7611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.7611%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DPreliminary%2520activity%2520and%2520safety%2520results%2520from%2520a%2520phase%2520I%2520clinical%2520trial%2520of%2520PF-00299804%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">â</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+irreversible+pan-ErbB+receptor+tyrosine+kinase+inhibitor%3A+Results+of+a+phase+II+trial+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with â¥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (â¤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0ljlllLbybimnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520irreversible%2520pan-ErbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%253A%2520Results%2520of%2520a%2520phase%2520II%2520trial%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">â</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kluterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+Inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0ljlllLbybimnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520Inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">â</span> <span class="NLM_lpage">791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&author=Y.+Kimauthor=J.+Koauthor=Z.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.+H.+Ouauthor=M.+J.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0lgiCOPIqdB0xA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D784%26epage%3D791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Preliminary results from a phase I study with AZD9291: An irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations in non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S15</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S15&issue=Suppl+3&author=M.+Ransonauthor=W.+Paoauthor=D.+W.+Kimauthor=S.+W.+Kimauthor=Y.+Oheauthor=E.+Felipauthor=D.+Planchardauthor=S.+Ghiorghiuauthor=M.+Cantariniauthor=P.+A.+Janne&title=Preliminary+results+from+a+phase+I+study+with+AZD9291%3A+An+irreversible+inhibitor+of+epidermal+growth+factor+receptor+%28EGFR%29+activating+and+resistance+mutations+in+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DPreliminary%2520results%2520from%2520a%2520phase%2520I%2520study%2520with%2520AZD9291%253A%2520An%2520irreversible%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520activating%2520and%2520resistance%2520mutations%2520in%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26issue%3DSuppl%25203%26spage%3DS15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span> </span><span class="NLM_article-title">First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1200%2FJCO.2012.44.2806" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2524&author=L.+V.+Sequistauthor=J.-C.+Soriaauthor=S.+Gadgeelauthor=H.+Wakeleeauthor=D.+R.+Camidgeauthor=A.+Vargaauthor=P.+Fidiasauthor=A.+J.+Wozniakauthor=J.+W.+Nealauthor=R.+C.+Doebeleauthor=E.+B.+Garonauthor=S.+Jaw-Tsaiauthor=J.+C.+Sternauthor=A.+Allenauthor=J.+W.+Goldman&title=First-in-human+evaluation+of+CO-1686%2C+an+irreversible%2C+selective%2C+and+potent+tyrosine+kinase+inhibitor+of+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.44.2806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.44.2806%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DWakelee%26aufirst%3DH.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DStern%26aufirst%3DJ.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26atitle%3DFirst-in-human%2520evaluation%2520of%2520CO-1686%252C%2520an%2520irreversible%252C%2520selective%252C%2520and%2520potent%2520tyrosine%2520kinase%2520inhibitor%2520of%2520EGFR%2520T790M%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D2524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Red Brewer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">â</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgiCOPIqdB0xA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medikonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">In vitro and In vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">â</span> <span class="NLM_lpage">1479</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1158%2F1535-7163.MCT-13-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=24723450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1468-1479&author=R.+Tjin+Tham+Sjinauthor=K.+Leeauthor=A.+O.+Walterauthor=A.+Dubrovskiyauthor=M.+Sheetsauthor=T.+S.+Martinauthor=M.+T.+Labenskiauthor=Z.+Zhuauthor=R.+Testerauthor=R.+Karpauthor=A.+Medikondaauthor=P.+Chaturvediauthor=Y.+Renauthor=H.+Haringsmaauthor=J.+Etterauthor=M.+Raponiauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=D.+Niuauthor=M.+Nachtauthor=W.+F.+Westlinauthor=R.+C.+Petterauthor=A.+Allenauthor=J.+Singh&title=In+vitro+and+In+vivo+characterization+of+irreversible+mutant-selective+EGFR+inhibitors+that+are+wild-type+sparing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span></div><div class="casAuthors">Tjin Tham Sjin Robert; Lee Kwangho; Walter Annette O; Dubrovskiy Aleksandr; Sheets Michael; Martin Thia St; Labenski Matthew T; Zhu Zhendong; Tester Richland; Karp Russell; Medikonda Aravind; Chaturvedi Prasoon; Ren Yixuan; Haringsma Henry; Etter Jeff; Raponi Mitch; Simmons Andrew D; Harding Thomas C; Niu Deqiang; Nacht Mariana; Westlin William F; Petter Russell C; Allen Andrew; Singh Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with non-small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib.  However, all patients relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approximately 60% of all resistance.  Second-generation irreversible EGFR inhibitors are effective against T790M mutations in vitro, but retain affinity for wild-type EGFR (EGFR(WT)).  These inhibitors have not provided compelling clinical benefit in T790M-positive patients, apparently because of dose-limiting toxicities associated with inhibition of EGFR(WT).  Thus, there is an urgent clinical need for therapeutics that overcome T790M drug resistance while sparing EGFR(WT).  Here, we describe a lead optimization program that led to the discovery of four potent irreversible 2,4-diaminopyrimidine compounds that are EGFR mutant (EGFR(mut)) selective and have been designed to have low affinity for EGFR(WT).  Pharmacokinetic and pharmacodynamic studies in H1975 tumor-bearing mice showed that exposure was dose proportional resulting in dose-dependent EGFR modulation.  Importantly, evaluation of normal lung tissue from the same animals showed no inhibition of EGFR(WT).  Of all the compounds tested, compound 3 displayed the best efficacy in EGFR(L858R/T790M)-driven tumors.  Compound 3, now renamed CO-1686, is currently in a phase I/II clinical trial in patients with EGFR(mut)-advanced NSCLC that have received prior EGFR-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdUiOZStIjAqx48Rj5GnGofW6udTcc2eb2qxMh5iv9trntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D&md5=b42556f3737b33c07511a77ab63ed1d1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0966%26sid%3Dliteratum%253Aachs%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DMedikonda%26aufirst%3DA.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DHaringsma%26aufirst%3DH.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520and%2520In%2520vivo%2520characterization%2520of%2520irreversible%2520mutant-selective%2520EGFR%2520inhibitors%2520that%2520are%2520wild-type%2520sparing%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1468%26epage%3D1479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaligam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 5</span><span class="NLM_x">) </span> <span class="NLM_fpage">8009</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8009&issue=Suppl.+5&author=P.+A.+Janneauthor=S.+S.+Ramaligamauthor=J.+C.+H.+Yangauthor=M.-J.+Ahnauthor=D.-W.+Kimauthor=S.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=E.+Felipauthor=C.+Watkinsauthor=M.+Cantariniauthor=S.+Ghiorghiuauthor=M.+Ranson&title=Clinical+activity+of+the+mutant-selective+EGFR+inhibitor+AZD9291+in+patients+%28pts%29+with+EGFR+inhibitor-resistant+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRamaligam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DClinical%2520activity%2520of%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520AZD9291%2520in%2520patients%2520%2528pts%2529%2520with%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3DSuppl.%25205%26spage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirazzoli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Noncovalent wild-type-sparing inhibitors of EGFR T790M</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=168-181&author=H.+J.+Leeauthor=G.+Schaeferauthor=T.+P.+Heffronauthor=L.+Shaoauthor=X.+Yeauthor=S.+Siderisauthor=S.+Malekauthor=E.+Chanauthor=M.+Merchantauthor=H.+Laauthor=S.+Ubhayakarauthor=R.+L.+Yauchauthor=V.+Pirazzoliauthor=K.+Politiauthor=J.+Settleman&title=Noncovalent+wild-type-sparing+inhibitors+of+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DPirazzoli%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DNoncovalent%2520wild-type-sparing%2520inhibitors%2520of%2520EGFR%2520T790M%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D168%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="note"><p class="first last">Preliminary phase I data suggest that irreversible inhibitors AZD9291 and CO-1686 do not appear to have the toxicities seen with previous irreversible inhibitors of EGFR.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Evans, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">â</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug-protein+adducts%3A+An+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development</span></div><div class="casAuthors">Evans, David C.; Watt, Alan P.; Nicoll-Griffith, Deborah A.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity.  Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Labs. has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage.  This requires a flexible approach to defining bioactivation issues in a variety of metab. vectors and typically involves the initial use of small mol. trapping agents to define the potential for bioactivation.  At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) prepns. from preclin. species and human, and also in vivo, typically in the rat.  This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Labs.  The availability of a dedicated Labeled Compd. Synthesis group, coupled to a close working relationship between Drug Metab. and Medicinal Chem., represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsPmSgJDD8rVg90H21EOLACvtfcHk0lj-AtkzD5dSJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D&md5=9ab130c5462b2245e2f4c783afb01d1d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug-protein%2520adducts%253A%2520An%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: An orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">â</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+An+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0lj-AtkzD5dSJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520An%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span> </span><span class="NLM_article-title">Drug discovery for a new generation of covalent drugs</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">â</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1517%2F17460441.2012.688744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=22607458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFWmt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=561-581&author=A.+S.+Kalgutkarauthor=D.+K.+Dalvie&title=Drug+discovery+for+a+new+generation+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery for a new generation of covalent drugs</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">561-581</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The design of target-specific covalent inhibitors is conceptually attractive because of increased biochem. efficiency through covalency and increased duration of action that outlasts the pharmacokinetics of the agent.  Although many covalent inhibitors have been approved or are in advanced clin. trials to treat indications such as cancer and hepatitis C, there is a general tendency to avoid them as drug candidates because of concerns regarding immune-mediated toxicity that can arise from indiscriminate reactivity with off-target proteins.Areas covered: The review examines potential reason(s) for the excellent safety record of marketed covalent agents and advanced clin. candidates for emerging therapeutic targets.  A significant emphasis is placed on proteomic techniques and chem./biochem. reactivity assays that aim to provide a systematic rank ordering of pharmacol. selectivity relative to off-target protein reactivity of covalent inhibitors.Expert opinion: While tactics to examine selective covalent modification of the pharmacol. target are broadly applicable in drug discovery, it is unclear whether the output from such studies can prospectively predict idiosyncratic immune-mediated drug toxicity.  Opinions regarding an acceptable threshold of protein reactivity/body burden for a toxic electrophile and a non-toxic electrophilic covalent drug have not been defined.  Increasing confidence in proteomic and chem./biochem. reactivity screens will require a retrospective side-by-side profiling of marketed covalent drugs and electrophiles known to cause deleterious toxic effects via non-selective covalent binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmXy20mDTPbVg90H21EOLACvtfcHk0lj-AtkzD5dSJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFWmt7k%253D&md5=b7fc8e60b263dda5765dd8380f52df17</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.688744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.688744%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26atitle%3DDrug%2520discovery%2520for%2520a%2520new%2520generation%2520of%2520covalent%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D561%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezhkovskiy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantik, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menghrajani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambrone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Lead identification of novel and selective TYK2 inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">â</span> <span class="NLM_lpage">187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1016%2Fj.ejmech.2013.03.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=23867602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVejtL%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=175-187&author=J.+Liangauthor=V.+Tsuiauthor=A.+Van+Abbemaauthor=L.+Baoauthor=K.+Barrettauthor=M.+Beresiniauthor=L.+Berezhkovskiyauthor=W.+S.+Blairauthor=C.+Changauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=M.+Liimattaauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=A.+Sambroneauthor=Y.+Xiaoauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=M.+Stanleyauthor=M.+Ultschauthor=B.+Zhangauthor=L.+C.+Wuauthor=S.+Magnuson&title=Lead+identification+of+novel+and+selective+TYK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Lead identification of novel and selective TYK2 inhibitors</span></div><div class="casAuthors">Liang, Jun; Tsui, Vickie; Van Abbema, Anne; Bao, Liang; Barrett, Kathy; Beresini, Maureen; Berezhkovskiy, Leo; Blair, Wade S.; Chang, Christine; Driscoll, James; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liimatta, Marya; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Sambrone, Amy; Xiao, Yisong; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Stanley, Mark; Ultsch, Mark; Zhang, Birong; Wu, Lawren C.; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-187</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2.  Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine (I) as a promising starting point for lead identification.  Initial expansion of 3 sep. regions of the mol. led to eventual identification of cyclopropyl amide (II), a potent lead analog with good kinase selectivity, physicochem. properties, and pharmacokinetic profile.  Anal. of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXEWbuB0597rVg90H21EOLACvtfcHk0lj-AtkzD5dSJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVejtL%252FL&md5=4271738e73a0b680a4441b9231762ef0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.070%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DStanley%26aufirst%3DM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520identification%2520of%2520novel%2520and%2520selective%2520TYK2%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D67%26spage%3D175%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="note"><p class="first last">Percent inhibition of 296 kinases determined at Invitrogen for compound <b>3</b>; inhibition of >80% at 1 Î¼M observed for EGFR(T790M/L858R), EGFR(T790M), Jak2, Jak2 JH1/JH2, MAP4K4, Mink1, and Tyk2.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">â</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljy9qikA9zaDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Shultz, M. D.</span><span> </span><span class="NLM_article-title">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5980</span><span class="NLM_x">â</span> <span class="NLM_lpage">5991</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1016%2Fj.bmcl.2013.08.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=24018190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5980-5991&author=M.+D.+Shultz&title=Setting+expectations+in+molecular+optimizations%3A+Strengths+and+limitations+of+commonly+used+composite+parameters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5980-5991</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over the past 15 years there have been extensive efforts to understand and reduce the high attrition rates of drug candidates with an increased focus on physicochem. properties.  The fruits of this labor have been the generation of numerous efficiency indexes, metric-based rules and visualization tools to help guide medicinal chemists in the design of new compds. with more favorable properties.  This deluge of information may have had the unintended consequence of further obfuscating mol. optimizations by the inability of these scoring functions, rules and guides to reach a consensus on when a particular transformation is identified as beneficial.  In this manuscript, several composite parameters, or efficiency indexes, are examd. utilizing theor. and exptl. matched mol. pair analyses in order to understand the basis for how each will perform under varying scenarios of mol. optimizations.  In contrast to empirically derived composite parameters based on heavy atom count, lipophilic efficiency (LipE) sets consistent expectations regardless of mol. wt. or relative potency and can be used to generate consistent expectations for any matched mol. pair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJeTISXSJyLbVg90H21EOLACvtfcHk0ljy9qikA9zaDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI&md5=3b766e26254f482b75b8973888c13aec</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.029%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520expectations%2520in%2520molecular%2520optimizations%253A%2520Strengths%2520and%2520limitations%2520of%2520commonly%2520used%2520composite%2520parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5980%26epage%3D5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. H.</span><span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">â</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0ljy9qikA9zaDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="note"><p class="first last">PBD accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="note"><p class="first last">When compound <b>1</b> is modeled into the 1M17 wtEGFR structure, if the water molecule adjacent to the gatekeeper side chain is allowed to rotate, the carbonyl oxygen of compound <b>1</b> is within hydrogen-bonding distance (<3.0 Ã) of that water.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">â</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Ã resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0lhDp-kzLCIQdQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="note"><p class="first last">Conformational searches were carried out in MacroModel 10.0, using the OPLS_2005 forcefield and mixed torsional/low-mode sampling for 1000 steps. Low-energy conformations within 1 kcal/mol of the global minimum for each molecule were compared, and the number of conformers around the amide bond was used as a proxy for the degrees of freedom.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="note"><p class="first last">A structure of compound <b>6</b> complexed with wtEGFR was not obtained. Neither of the two binding modes offers a hydrogen-bonding partner for Thr790; if recapitulated in wtEGFR, the binding mode for <b>6</b> observed in TMLR would displace the water molecule typically observed to solvate Thr854, while failing to provide a compensating interaction.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">A medicinal chemistâs guide to molecular interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5061</span><span class="NLM_x">â</span> <span class="NLM_lpage">5084</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100112j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5061-5084&author=C.+Bissantzauthor=B.+Kuhnauthor=M.+Stahl&title=A+medicinal+chemist%E2%80%99s+guide+to+molecular+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm100112j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100112j%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DA%2520medicinal%2520chemist%25E2%2580%2599s%2520guide%2520to%2520molecular%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5061%26epage%3D5084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="note"><p class="first last">See Table S3 of the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for PDB codes and measurements.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="note"><p class="first last">A total of 34 out of 531 (6%) kinases have equivalent Met + Thr residues and 27 out of 531 (5%) kinases have equivalent Met + Ser residues.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="note"><p class="first last">Electron density suggests that the catalytic Lys of CDK2 is acetylated in the complex with compound <b>8</b>; however, we believe that this artifact of the crystallization system should not impact the binding mode of this compound.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="note"><p class="first last">Percent inhibition of 219 kinases at 1 Î¼M determined at Invitrogen; kinases inhibited at > 80%: MAP4K4, MELK, Mink1, MST1, Rse.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><div class="note"><p class="first last">While pyrrolopyridine-based inhibitors have been reported to inhibit MPS1, compounds <b>9</b> and <b>10</b> inhibit MPS1 at only 24â27% when tested at 1 Î¼M (Invitrogen).</p></div><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAndrew, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijssen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span> </span><span class="NLM_article-title">Structure-based design of orally bioavailable 1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">10045</span><span class="NLM_x">â</span> <span class="NLM_lpage">10065</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401395s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=10045-10065&author=S.+Naudauthor=I.+M.+Westwoodauthor=A.+Faisalauthor=P.+Sheldrakeauthor=V.+Bavetsiasauthor=B.+Atrashauthor=K.+M.+Cheungauthor=M.+Liuauthor=A.+Hayesauthor=J.+Schmittauthor=A.+Woodauthor=V.+Choiauthor=K.+Boxallauthor=G.+Makauthor=M.+Gurdenauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=A.+Henleyauthor=R.+Bakerauthor=C.+McAndrewauthor=B.+Matijssenauthor=R.+Burkeauthor=S.+Hoelderauthor=S.+A.+Ecclesauthor=F.+I.+Raynaudauthor=S.+Linardopoulosauthor=R.+L.+van+Montfortauthor=J.+Blagg&title=Structure-based+design+of+orally+bioavailable+1H-pyrrolo%5B3%2C2-c%5Dpyridine+inhibitors+of+mitotic+kinase+monopolar+spindle+1+%28MPS1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm401395s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401395s%26sid%3Dliteratum%253Aachs%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DSheldrake%26aufirst%3DP.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DChoi%26aufirst%3DV.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DGurden%26aufirst%3DM.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DMcAndrew%26aufirst%3DC.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3DHoelder%26aufirst%3DS.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DStructure-based%2520design%2520of%2520orally%2520bioavailable%25201H-pyrrolo%255B3%252C2-c%255Dpyridine%2520inhibitors%2520of%2520mitotic%2520kinase%2520monopolar%2520spindle%25201%2520%2528MPS1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D10045%26epage%3D10065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="note"><p class="first last">Percent inhibition of 219 kinases at 1 Î¼M determined at Invitrogen; kinases inhibited at >80%: MAP4K4, Mink1, MST1, MST2, Rse.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">â</span> <span class="NLM_lpage">4785</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="note"><p class="first last">See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for experimental procedures.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinhababu, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh-Bakht, S. C.</span><span> </span><span class="NLM_article-title">Metabolic stability screen for drug discovery using cassette analysis and column switching</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">â</span> <span class="NLM_lpage">72</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm501578n&amp;key=10.2174%2F187231207779814364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm501578n&amp;key=19356021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm501578n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=67-72&author=J.+S.+Halladayauthor=S.+Wongauthor=S.+M.+Jafferauthor=A.+K.+Sinhababuauthor=S.+C.+Khojasteh-Bakht&title=Metabolic+stability+screen+for+drug+discovery+using+cassette+analysis+and+column+switching"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic stability screen for drug discovery using cassette analysis and column switching</span></div><div class="casAuthors">Halladay, Jason S.; Wong, Susan; Jaffer, Sharmin M.; Sinhababu, Achintya K.; Khojasteh-Bakht, S. Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In vitro metabolic stability assays are used to screen compds. for stability in the presence of various drug metabolizing enzymes, usually cytochrome P 450 in liver prepns. (e.g., liver microsomes).  High-throughput metabolic stability assays using pooling methods have been developed to keep pace with screening requirements at the lead ADME optimization stage.  In our lab., we have improved the metabolic stability assay using the cassette anal. method, column switching, and incorporated time saving techniques in method development to yield a robust method which reduces data turnaround time, increases compd. throughput, and maximizes mass spectrometer usage.  This method can det. metabolic stability using microsomes or hepatocytes from any species.  We describe our findings following incubation of 40 different compds. with human liver microsomes and anal. by the cassette and discrete anal. methods.  Similar metabolic stability results were obtained using the cassette anal. and discrete anal. method.  An overall 70% time savings was achieved by pooling four new compds. into one sample for method development/MS optimization, cassetting four samples into one sample to minimize the no. of injections on LC/MS/MS anal., and using a column switching system to analyze the samples, which results in a two-fold decrease in the LC/MS/MS anal. time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKzVSm6sBe1bVg90H21EOLACvtfcHk0lg5aFg4t6EDSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D&md5=e00c66b3ca6a1eaee107c4eb81e07bf5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F187231207779814364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231207779814364%26sid%3Dliteratum%253Aachs%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DJaffer%26aufirst%3DS.%2BM.%26aulast%3DSinhababu%26aufirst%3DA.%2BK.%26aulast%3DKhojasteh-Bakht%26aufirst%3DS.%2BC.%26atitle%3DMetabolic%2520stability%2520screen%2520for%2520drug%2520discovery%2520using%2520cassette%2520analysis%2520and%2520column%2520switching%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2007%26volume%3D1%26spage%3D67%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span>Cambridge Crystallographic Database, Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, United Kingdom.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cambridge+Crystallographic+Database%2C+Cambridge+Crystallographic+Data+Centre%2C+12+Union+Road%2C+Cambridge+CB2+1EZ%2C+United+Kingdom."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span>Chemical Computing Group, Kaiser-Wilhelm-Ring 11, 50672 Koln, Germany.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chemical+Computing+Group%2C+Kaiser-Wilhelm-Ring+11%2C+50672+Koln%2C+Germany."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17','PDB','1M17'); return false;">PDB: 1M17</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4hge" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4hge','PDB','4hge'); return false;">PDB: 4hge</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ7','PDB','4RJ7'); return false;">PDB: 4RJ7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ6','PDB','4RJ6'); return false;">PDB: 4RJ6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ5','PDB','4RJ5'); return false;">PDB: 4RJ5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ4','PDB','4RJ4'); return false;">PDB: 4RJ4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ8','PDB','4RJ8'); return false;">PDB: 4RJ8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ3','PDB','4RJ3'); return false;">PDB: 4RJ3</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i43"><a href="/doi/suppl/10.1021/jm501578n">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_62632"></div></div></div></div></div><hr /></hr><p class="last">Tabulated biochemical Jak family activity for compounds <b>1</b>â<b>3</b>; tabulated structures and data for amide modifications; PDB codes and measurements used for the generation of Figure <a id="rightTab-" class=" internalNav" href="#fig5">5</a>b; experimental procedures for kinetic solubility experiments; preparation and characterization of compounds <b>1</b>â<b>3</b> and <b>11</b>â<b>14</b>; protein expression, purification, and crystallographic methods; data collection and refinement statistics; and HPLC methods used to determine chemical purity. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501578n/suppl_file/jm501578n_si_001.pdf">jm501578n_si_001.pdf (784.95 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB codes are as follows: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ7">4RJ7</a> for <b>1</b> complexed with TMLR, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ6">4RJ6</a> for <b>4</b> complexed with TMLR, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ5">4RJ5</a> for <b>5</b> complexed with TMLR, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ4">4RJ4</a> for <b>6</b> complexed with TMLR, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ8">4RJ8</a> for <b>8</b> complexed with TMLR, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RJ3">4RJ3</a> for <b>8</b> complexed with CDK2.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm501578n&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-23%3Barticle%3Aarticle%3A10.1021%2Fjm501578n%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm501578n" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6960fd751949","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
